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1. INTRUDUCTION
1.1 Adipose tissue and obesity 
Adipose tissue is an important organ, always present in the human body. Adipose 
tissue (AT) is quantitatively the most variable body component as it can make up from a 
few percent to more than 50% of body mass in obese persons. AT sites are also highly 
variable, ranging from subcutaneous areas and the abdominal cavity to retroperitoneal, 
mesenteric and muscle depots. There are more than 15 discrete AT depots such as 
perirenal, orbital, epididymal, omental, popliteal, etc. Approximately 90% of adipose 
tissue consists of adipocytes (fat cells), which are embedded in stromal connective, 
endothelial (vascular) and mesenchymal adipocyte precursor cells. 
Apart from storing lipids and energy, adipocytes are very active in the secretion of 
hormones and adipokines used in endocrine and paracrine activities. When energy 
cannot be supplied directly from the circulation or stored carbohydrates, lipids are 
mobilised from AT by lipolysis. In adipocytes, triglycerides are broken down into glycerol 
and free fatty acids, which produces an energy stimulus for organs, as well as the 
glucogenic substrates in the liver. Metabolic control of AT is regulated by hormones and 
catecholamines (the sympathicus and insulin). Insulin is the most potent antilipolytic 
hormone in adipose tissue that controls the anabolic activities of adipocytes (1,2). 
Adipose tissue is the main energy store in vertebrata and an endocrine controller of 
energy balance. White adipose tissue maintains energy homeostasis, while brown 
adipose tissue controls thermoregulation. 
The main form of adipose tissue is white adipose tissue that makes up 80-90% of that 
organ. White adipose tissue performs most of the metabolic and endocrine functions of 
AT and is richly vascularized and innervated. AT is mostly composed of adipocytes, 
which contain up to 90% of triglycerides, the most concentrated form of energy. Fat 
cells are incorporated into loose connective tissue that is richly vascularized and 
innervated. Under normal circumstances, women have more adipose tissue than men 
(25% vs. 15% of total body mass) due to energy preparations for pregnancy. 
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Obesity is a multifactorial chronic disease characterized by excessive storage of energy 
in excess adipose tissue (AT) that is closely related to insulin resistance. Abnormal fat 
accumulation has become a major global health problem due to increased risks of 
several chronic diseases and premature mortality. Nurses' Health Study and other major 
studies have established a correlation between obesity and the risk of metabolic 
syndrome, cardiovascular disease and mortality.  
 
Worldwide obesity has almost tripled since 1975, reaching 1.9 billion overweight adults 
in 2016. Out of this number, more than 650 million are obese (2,3). Categories of adult 
obesity are based upon body mass index (BMI), which correlates with percent body fat. 
This relatiioship varies among individulas by sex, age and race. 
The prevalence of obesity has increased in last 3 decades, so that prevalence of 
overweight added obese women in numerous europian and western countries is around 
60%. The obesity is increasing in women of reproductive age. 
 
Body Mass Index (BMI) is the most common measure to express body fat content in 
the body of a normal or overweight person. BMI is the ratio of body weight divided by 
the square of height (kg/m2) that expresses the area of the body. Such a calculation 
correlates well with the mass of fat tissue in the body and enables a reliable 
classification into the following categories: 
Table 1. Classification of BMI index by WHO 
• BMI < 18.5 kg/m2  underweight 
• BMI 18.5–24.9 kg/m2 normal 
• BMI 25–29.9 kg/m2 overweight 
• BMI ≥ 30 kg/m2  obesity 
- 30–34.9 kg/m2  class 1 
- 35–39.9 kg/m2  class 2 (severe obesity) 
- ≥ 40 kg/m2  class 3 (morbid obesity). 
 
For BMI in children, the difference is expressed by both gender and age. Most of the 
world's population lives in countries where obesity is a more common cause of death 
than malnutrition. In such an obesity pandemic, indicators in children are particularly 
worrisome. Excessive bodyweight and obesity occur in 41 million children under the age 
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of 5, and 340 million children and adolescents aged 5–19 (WHO 2016). The prevalence 
of overweight and obesity in children and adolescents has increased from 4% in 1975 to 
18% in 2016, while obesity rates increased from 1% to 8%. 
 
Globally, the average BMI in women increased from 22.1 kg/m2 to 24.4 kg/m2, and the 
incidence of obesity increased from 6.4% in 1975 to 14.9% today. The number of obese 
women increased 5 times in the last 40 years, with 20% of women being morbidly 
obese. Interestingly, a rapid increase in the prevalence of obesity has been registered in 
developed countries, but also in developing countries and many poor populations.  
The etiology is seemingly simple, arising from an imbalance between energy intake and 
energy expenditure. The causes are inadequate nutrition, reduced physical activity, 
accompanied by genetic and epigenetic effects(2,3,4). Shown below is the prevalence 
of overweight and obesity in women in selected countries. 
 
Table 2. Differences in obesity prevalence in selected countries 
Country 
Overweight   
BMI 25–29.9 kg/m2 
Obesity 
≥ 30 kg/m2 
USA 28.5 % 35.7 % 
Spain 26.5 % 22.9 % 
Albania 27.5 % 9.3 % 
Macedonia 33.9 % 21.1 % 
Europe 28 % 23 % 
Italy 21.9 % 8.2 % 
Kosovo () 27.7 % 23.5 % 
   
 
 
 
A recent report on the prevalence of obesity in 16 European countries provides 
somwhat different numbers (5): 
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Figure 1. Prevalence of obesity (according to BMI) in some European countries 
 
1.1.1 Anthropometric obesity measurement 
 
Depending on the location of accumulated adipose tissue, we differentiate between 
subcutaneous and visceral (central) AT. Gluteofemoral fat typically occurs in women 
(gynecoid fat distribution), while android obesity is characterized by accumulation of 
abdominal fat. Visceral (abdominal) obesity carries numerous health risks - metabolic 
syndrome, cardiovascular diseases and some types of cancer. Anthropometric 
measures for an assessment of general and central obesity include: 
a) body mass index (BMI) for general obesity assessment 
b) waist circumference (WC) 
c) waist to hip ratio (WHR) 
d) waist to stature ratio (WSR) - ratio of WC to height 
e) hip circumference (HC) 
f) body adiposity index (BAI) - ratio of HC to height. 
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The anthropometric measures listed in b) to f) are indicators of central obesity and thus 
of cardiovascular risk. The relationship of visceral AT to subcutaneous AT, skinfold 
measurement, and sagittal abdominal diameter are also used to assess the health risk.  
Measures of visceral obesity are more precise – dual energy x-ray absorptionometry 
(DEXA), CT and MRI.  
However, in standard clinical practice it is considered enough to measure WC, WHR, 
HC and possibly WSR. Anthropometric measurement of central obesity is characterized 
by a higher specificity and sensitivity for the determination of cardiovascular risk (CVD 
risk) than general obesity measurement (BMI) (2,6,7,8). The cut-off values for central 
obesity are (1,3,9,10): 
Table 3:  Normal value of WC and WHR 
Measure Men     Women 
WC 
Waist circumference 
102 cm 
94 cm 
88 cm 
80 cm 
WHO 
DM Society 
WHR 
Waist to hip ratio 
0.90         0.85 
WSR 
Waist to stature ratio 
                            0.5 
WHO – World Health Organization; DM – diabetes mellitus 
Approximately half of the women in developed countries have WC > 88 cm (54% of 
women and 37% of men), which correlates with a high incidence of metabolic syndrome 
in these populations (> 30%).The degree of cardio-vascular risk (CV) in case of central 
obesity can be expressed with 3 classes of WHR: 
 
Table 4. Classes of WHR related to CV risk 
Risk Men Woman 
Low 
Moderate 
High 
0.95 or lower 
0.96–1.0 
1.0 or higher 
0.80 or lower 
0.81–0.85 
0.86 or higher 
 
Numerous studies (Framingham Heart Study, Nurses' Health Study, Buffalo Health 
Study) have confirmed that obesity increases the risk of CVD (1,7,8). An Australian 
study conducted on 4487 women aged 20 to 69 has confirmed that anthropometric 
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measures of central obesity are strongly associated with 10-year CVD risk (1,7). 
Measures of abdominal obesity are better predictors of CVD risk compared with BMI. 
Shown below are ORs only for the prediction of 10-year CVD risk(1,9,11). 
 
Table 5. Cardiovascular risk according to anthropometric obesity measurments 
 
 BMI WC HC WHR WSR 
OR 
(CI) 
1.71 
(1.59–1.85) 
2.12 
(1.95–2.29) 
1.55 
(1.44–1.68) 
2.27 
(2.08–2.47) 
2.35 
(2.17–2.56) 
 
All central obesity measurements had a comparable predictive value (9).  In several 
meta-analyses it has been pointed out that WC and WHR are the most acceptable 
surrogate measures for CVD risk. Women with WHR≥0.88 are 3.25 times more at risk 
of cardiovascular disease than those with WHR <0.72. BMI only appears to be 
inadequate for accurate risk prediction. 
The composition of the body changes with age. Adipose tissue increases and muscle 
mass decreases. The increase in AT with aging leads to its distribution towards the 
abdominal region. These changes are more pronounced in women due to lower basal 
metabolism (basal metabolic rate). After the age of 20 the resting metabolic rate (RMR) 
falls by 2–3% every 10 years (total decrease up to 20%). Oxidation of fat, RMR, and 
energy imbalance alter the body composition with age (12). By comparing 
anthropometric and advanced (CT, DEXA) determination of AT accumulation, 
considerable differences were found according to gender, race and age (11). 
Today’s lifestyle implies a different relationship between energy intake and expenditure. 
The basal metabolism requires 1500–1600 kcal/day, while physical activities (which are 
reduced) use up only 500–1000 kcal/day. This means that the total daily need 
(depending on age) ranges between 2000 and 2500 kcal (1,14). 
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1.1.2 Distribution of adipose tissue and obesity phenotypes 
 
Adipose tissue is deposited in 5 different regions – depots (12,16,17): 
 
1. Subcutaneous adipose tissue, in obesity it can be distributed from head to toe. 
It has superficial and deep AT regions in the body and gluteofemorally. Their 
control and functions differ. 
2. Visceral, intraperitoneal AT affects the omentum and mesentery, and the 
epiploic appendices. It is drained by lymph and the portal vein, which points to 
possible pathophysiology. 
3. Retroperitoneal and pelvic AT is topographically specific but is often 
categorized as visceral AT. 
4. Pericardial AT is located around the heart. 
5. Intramuscular AT is found in the muscles. 
 
It has been pointed out that visceral adipose tissue involves cardiometabolic risk, while 
other AT sites may have a neutral or even protective metabolic effect. 
Regardless of BMI, women mostly exhibit a subcutaneous, gluteofemoral phenotype 
AT called gynecoid AT, which is responsible for the female pear-shaped body shape. 
Male, android obesity dominated by visceral and subcutaneous abdominal fat is less 
common. The android phenotype gives the body the shape of an apple. The 
gynecoid phenotype occurs in female puberty, where enough energy reserves trigger 
the hypothalamic-pituitary regulation of the ovarian function, menarche and subsequent 
cyclicality. In this way, the brain is informed of the readiness for pregnancy. 
 
The uptake of free fatty acids (FFA) and synthesis of triacylglycerides are greater in 
female gluteofemoral subcutaneous AT compared to abdominal AT. A young woman 
with a BMI of 22.5 kg/m2 has about 18 kg of adipose tissue, which amounts to almost 
30% of body mass. Only 5% of this mass is visceral AT (). In contrast, men have 12 kg 
of fat (15% of body mass), of which 10-12% is visceral AT. Different distribution of fat in 
the gluteofemoral region is induced by the expression of 280 genes that are largely 
different from those that stimulate abdominal accumulation of fat.  
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Fat distribution in women is also controlled by ovarian hormones. Estrogens inhibit 
visceral and abdominal (subcutaneous) adipose tissue and stimulate gluteofemoral AT. 
Androgens have the opposite effect. Generally, AT distribution depends on androgen 
and estrogen balance (1,7). 
 
The adipose tissue phenotype also depends on vascularization and innervation. White 
and brown adipose tissue can produce vascular endothelial growth factor (VEGF), 
which is a stimulus for neoangiogenesis. 
 
Aging leads to ectopic accumulation of fat in the bone marrow, muscles, liver, which 
can lead to the dysfunction of these tissues. Also, subcutaneous AT is lost, while the 
preservation of the visceral depot leads to metabolic disorders. Aging causes reduced 
capacity to convert preadipocytes into adipocytes, which may increase lipotoxicity. BAT 
(brown adipose tissue) functionality decreases with age, compromising 
thermoregulation. BAT atrophy is accompanied by a loss of BAT activity, decrease in 
adrenergic signalling, and a decline in the mitochondrial function. The consequences 
are reduced cold tolerance and disturbances in the control of body weight. BAT activity 
is five times lower at the age of 60 than at the age of 20, promoting age-related weight 
gain (12). As alcohol affects the oxidation of AT and promotes its storage, excessive 
consumption is in correlation with obesity. 
 
Regional distribution and redistribution of fat as well as lipolysis are also influenced by 
adrenaline and cortisol. These hormones support mobilization of abdominal visceral fat. 
Weight loss and exercise sometimes result in negative regional mobilization of fat, with 
the loss of AT from deeper depots.  
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1.1.3 Physiology and pathophysiology of adipose tissue 
 
Adipose tissue (AT) is not a passive storage of fat and energy, but a very active organ 
with many physiological functions: 
• energy storage 
• maintenance of energy homeostasis 
• regulation of body temperature 
• control of the hypothalamic-pituitary axis 
• control of gonadal function 
• control of reproduction 
• endocrine and paracrine functions 
• protection of the body from trauma. 
 
In women, AT dictates pubertal changes in the hypothalamus, informing the central 
nervous system (CNS) about the adequate energy reserve for pregnancy. The 
composition of the body, with too little or too much AT, reduces the reproductive 
potential and disrupts the menstrual cycle (1,7,14). 
 
AT is mostly made up of white adipose tissue (WAT), from which adipocytes are 
partially transformed into brown adipose tissue (BAT). There are major functional 
differences between WAT and BAT. It has been established that both types of tissue 
are metabolically active, with antagonistic functions: 
 
• WAT is the primary energy storage site 
• BAT regulates energy expenditure (by generating heat)– adaptive thermogenesis 
 
1.1.4  Differentiation of adipocytes – adipogenesis 
 
The accumulation of adipose tissue is a remnant of evolutionary physiology in terms of 
adaptation to survival conditions. Endothelial cells of vascular stroma are an unlimited 
source of adipocyte precursors. Increased caloric intake combined with inadequate 
expenditure promotes the hyperplasia of adipocytes.  
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The number of adipocytes grows as a result of stimuli for the conversion of pluripotent 
mesenchymal stem cells into preadipocytes, which are then differentiated into 
adipocytes. Fat cells have a high storage capacity for lipids, which significantly changes 
their volume. Such fibroblast transformation produces a mature (white) fat cell, a lipid 
droplet surrounded by a thin cytoplasm (with organelles) and a nucleus pressed towards 
the surface of the cell. The mesenchymal progenitors of adipocytes are distributed in 
the connective tissue under the skin and in the abdominal mesentery (13,14,15). 
 
Preadipocyte differentiation into fat cells depends on the nutritional status and is 
possible throughout the whole life. The amount of adipose tissue is therefore 
determined by the balance between lipolysis and lipogenesis (adipogenesis). 
Adipogenesis is stimulated by insulin and FFA, while leptin and VEGF participate in 
angiogenesis. 
 
Excessive intake of calories without adequate energy expenditure promotes adipocyte 
hyperplasia and adipogenesis, resulting in obesity. Under the influence of numerous 
signals, pluripotent mesenchymal stem cells are transformed. Since adipocyte precursor 
reserves are unlimited, the capacity for adipogenesis is high. CNS signals, the 
sympathicus (adrenergic hormones), insulin, cyclic AMP, and adipokines participate in 
the mobilization of progenitor cells. Only a balanced stimulus of differentiation activators 
steers the conversion of stem cells into adipocytes, myocytes, hondrocytes or 
osteocytes. There are also many genetic and epigenetic factors stimulating 
adipogenesis (14,15,18).Developmental genes of the homeobox family (HOX), T-box 
genes and other genes that regulate transcription have a major influence on the 
occurrence of obesity and distribution of fat. Genes for abdominal fat control are HOX 
3/5/6 TBX 5 and for the gluteofemoral phenotype HOXA 10 and SHOX 2. These 
transcription regulators have an important developmental role in the heterogeneity of 
adipogenesis and diversity of depots and AT distribution (7,17). 
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Activation of selective preadipocyte phenotype is triggered by bone morphogenetic 
proteins 2 and 4 (BMP 2/4) and Wnt protein, which primarily acts a stimulator, but 
may also inhibit differentiation. Wnt proteins primarily use the canonical pathway in the 
presence of β - catenin, but the use of noncanonical pathways is also possible. 
Deviation from differentiation towards adipocytes can ultimately be stimulated by Wnt 
and β-catenin. Phosphorylation of transcriptional gene factors for peroxiome proliferator 
activated receptor gamma (PPARγ) type 2 and C/EPB-β activates many adipogenic 
genes, leading to the generation of mature adipocytes. These transcription factors have 
multiple functions in adipose tissue (Fig. 2). The variety of their expression also affects 
the occurrence of different AT phenotypes (15,16,18,19,20). 
 
 
 
 
 
 
 
 
Figure 2. Adipogenesis - differentiation from stem cell to adipocyte (15,20). 
BMP - bone morphogenetic protein; PPAR gamma - peroxisome proliferator-activated 
receptor γ; C/EPBβ - CCATT enhancer - binding protein β 
Adipocyte hyperplasia and hypertrophy display significant functional differences. 
Hyperplasia increases the number of adipocytes, and hypertrophy increases cell size by 
accumulating triglycerides (Fig.3)  
Hyperplastic adipocytes release fewer FFAs and increase insulin sensitivity (20). 
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HYPERPLASIA HYPERTROPHY 
ADIPOCYTE 
●cell number ↑ 
● FFA release ↓ 
● adiponectin ↑ 
● cytokines ↓ 
● insulin sensitive 
 
● cell size ↑ 
● FFA release ↑ 
● adiponectin ↓ 
● cytokines ↑ 
● insulin sensitive ↓ 
dead cell 
 
 
      
 
 
 
 
Figure 3. Differences between adipocytes hyperplasia and hypertrophyFFA free fatty 
acids 
 
A disruption in the signals for adipocyte recruitment and differentiation (adipogenesis) 
produces dysfunctional hypertrophic adipocytes that are insulin resistant. This can 
disturb lipolysis inhibition. 
WAT plays a major role in the energy homeostasis of the whole body. It regulates lipid 
metabolism in other organs through its endocrine function. Adipokines, adiponectin and 
leptin in the liver stimulate the oxidation of FFAs (13,16,18). 
 
WAT contains adipocytes with a large lipid droplet that makes up 90% of the cell 
volume. Mitochondria are small and few. WAT is an important endocrine/immunological 
organ because it secretes adipokines and pro-inflammatory cytokines. This allows WAT 
to have a range of effects, including regulation of appetite, energy and lipid metabolism, 
control of sensitivity to insulin, etc. (22,23). 
 
Depending on the location, white adipose tissue has several specialized functions. By 
storing excess energy (in the form of TG), it controls the metabolism of glucose, lipids 
and overall energy homeostasis. Through endocrine functions, WAT regulates appetite 
and the reproductive function, while visceral fat plays a role in local and systemic 
inflammatory processes.  
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Disturbed adipocyte function, low-grade inflammation and lipotoxicity cause insulin 
resistance and a disposition to atherosclerosis and hypertension. 
 
The subcutaneous abdominal AT depot and upper body obesity strongly contribute to 
increased FFA levels (released by adrenergic stimulation), lipolysis and dyslipidemia. 
The gluteofemoral depot in women and lower body AT remove fat from the circulation 
and form a long-term energy reserve for all physiological potentialities. 
 
Complex AT functions in metabolism control are responsible for controlling the activities 
of the autonomic nervous system, endocrine system, feedback mechanisms of 
autocrine and paracrine secretion of adipokines, leptin function and control of AT 
vascularization. Diverse AT functions also manage the transfer of pulsations from GH 
through leptin to FFAs and glycerol. 
 
Triglycerides, esters derived from glycerol, are the main source of energy for all cells. 
Triglycerides are hydrolyzed via lipolysis into glycerol and free fatty acids, and FFAs 
participate as an energy substrate, precursors for the lipid cell membrane synthesis and 
mediators in cell signalling. FFA oxidation in mitochondria liberates ATP and provides 
energy. 
 
The sympathetic nervous system controls lipid catabolism, and the parasympathicus 
controls anabolic processes. WAT and BAT differ in terms of function, morphology and 
molecular structure, but both types are dynamic, pluripotent organs. Environmental 
conditions may trigger hypothalamic control of white adipocyte conversion into brown 
adipocytes. This is supported by the existence of BAT islets in the otherwise dominant 
WAT. Exposure to chronic cold and prolonged β-adrenergic stimulation significantly 
stimulate the development of such thermogenically competent cells. A transitional form 
of white to brown adipocytes is beige adipocytes. Beige adipocytes are a subtype of 
BAT dispersed within white adipose tissue (subcutaneous). These UCP1 cells are 
generated by transdifferentiation of WAT, or from another cell line (13,18). 
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Thiazolidinedions (insulin sensitizers) stimulate WAT "browning", which gave rise to the 
idea of obesity therapy. It is undeniable that BAT, apart from the physiological function 
of adaptive thermogenesis, has an effect towards the leaner phenotype and resistance 
to obesity (18,19,20,22). 
 
Brown adipose tissue (BAT) exists in newborns, but also in adults, where it helps in 
adaptation to cold. Metabolically, it is very active in energy homeostasis. The colour of 
these cells derives from a dark pigment, which is also a reflection of the high density of 
mitochondria in BAT. BAT is responsible for adaptive thermogenesis (heat production) 
and oxidation of lipids. Brown adipocytes are smaller than white ones, they contain 
more small lipid droplets and numerous large mitochondria. On the molecular level, they 
are characterised by the expression of the uncoupling protein 1 (UCP1), but not of 
leptin (which is a characteristic of WAT). BAT has a denser network of capillaries and 
sympathetic nerve fibers (noradrenergic) (13). 
 
Brown adipocytes originate primarily from the same mesenchymal stem cells as 
myocytes. This means that by origin, they are closer to muscle cells, but without 
contractility. This also drives their primary function towards lipid catabolism rather than 
fat storage (which is typical of WAT). A smaller part of BAT can probably be derived 
from white adipocytes, which is under genetic control. In adults, BAT is distributed in the 
neck, in supraclavicular, axillary, paravertebral, and mediastinal regions and in the 
upper abdomen. Such distribution implies a role in the heating of vital organs in their 
adaptation to cold. 
 
Exposure to cold and feeding increase BAT activity and the expression of UCP1, which 
is controlled by norepinephrine. Such stimulation is also promoted by the thyroid 
hormone, insulin, thiazolidinediones and retinoic acid. Glucocorticoids inhibit UCP1 
gene expression. 
 
The BAT-based thermogenesis involves non-shivering heat production. Brown adipose 
tissue on the internal mitochondrial membrane activates UCP1, a protein for oxidative 
phosphorylation (from ATP synthesis) and thus generates thermal energy.  
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The basic substrate for thermogenesis is fatty acids released from triglycerides 
(hydrolysis), the initial signal being noradrenaline stimulation of the β-adrenergic 
receptor. In response to the cold, norepinephrine binds to β3-adrenergic receptors in 
brown adipocytes, which activates adenyl cyclase. Cyclic AMP activates protein kinase, 
which activates hormone sensitive lypase (HSL) by phosphorylation. This enzyme 
releases FFAs from triglycerides. One part of FFAs is oxidized, while another part 
activates UCP-1 (thermogenin) that thermal energy in mitochondria. Norepinephrine 
stimulates all stages of differentiation and BAT functions. The stimulation of α2-
adrenergic receptors has opposite effects on BAT (20,21,22).BAT also has 
autocrine/endocrine functions (adipsin etc.), but they are less researched.  With an 
increase in obesity, BAT's ability for thermoregulation during cold adaptation is reduced. 
There are significant individual differences in adaptive thermogenesis during cold and 
dieting. 
Table 6. The difference between WAT and BAT in metabolic functions 
                   ↑ stimulation; ↓ inhibition – protective effect 
 
 
 
 
 
BAT has a protective effect on cardiometabolic risks, but also on adipose tissue 
accumulation. The differences between white and brown adipose tissue are shown in 
the Table 7. (20,21,22,23). 
 
 
 
 
WAT Function BAT 
↓ Thermogenesis ↑ 
↑ Inflammation ↓ 
↓ Insulin sensitivity ↑ 
↑ Cardiometabolic effects ↓ 
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Table 7: The differences between WAT and BAT 
 
Feature White fat – WAT Brown fat - BAT 
Function Energy storage 
Thermoregulation 
- heat production 
Morphology 
• Large lipid droplet 
• variable and fewer 
mitochondria 
• superficial organelles 
• many minor lipid 
droplets 
• numerous mitochondria 
• standard in the cell 
Target proteins Leptin UCP1 
Development 
• mesenchymal stem cells 
 transdifferentiation 
• other progenitor cells 
 Myf5+ 
Location 
• gynecoid phenotype 
• android phenotype 
• near WAT 
• near vital organs 
Human effect 
• obesity risks 
• energy homeostasis 
• warms the body 
• suppresses obesity 
• lower risks 
Aging 
• increase 
• redistribution 
 
• drop in quantity 
• ↓ cold tolerance 
 
The basic physiological functions of WAT include the balance between lipogenesis and 
lipolysis, i.e. deposition and mobilization of triglycerides, which opens the possibility of 
storing energy and supplying energy to the periphery. The imbalance of these complex 
mechanisms can redirect AT to adipogenesis, obesity and a cascade of metabolic, 
endocrine and reproductive disorders. Acute regulators of activity and adipose tissue 
are adrenaline and noradrenaline (epinephrine and norepinephrine) 
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1.1.5 Lipogenesis 
 
Lipogenesis is a process in which glycerol is esterified with free fatty acids and forms 
triglycerides.The lipogenesis sequence begins in the small intestine with the absorption 
of FFAs and triglycerides. Through lymph, chylomicrons (microscopic fat particles) enter 
the veins and liver, where new lipoproteins are formed. Chylomicrons consist of 10% 
cholesterol and 90% triglycerides. They break down into fatty acids and glycerol and 
enter adipose tissue, where they are resynthesised into triglycerol and stored in the 
WAT adipocyte cytoplasm (23,24,25,26,27). 
 
Triacylglycerol (TAG) or triglycerides (TG) are the main lipid reserves in humans. They 
are synthesized in the endoplasmic reticulum. The deposition of TG into adipose tissue 
mostly occurs by hydrolysis with lipoprotein lipase (LPL).  Fatty acids uptake and 
esterification into glycerol 3-phosphate are stimulated by insulin. Steroid hormones also 
act as fat storage regulators. Insulin suppresses the mobilization of fat, i.e non-esterified 
fatty acids (NEFA) or free fatty acids (FFA) from subcutaneous AT. It has a dual 
function - it inhibits hormone sensitive lipase (HSL) and stimulates the re-esterification 
of fatty acids. 
Lipogenesis entails the formation of TG in the liver from excessive glucose. This 
pathway ends with the release of very low-density lipoproteins (VLDLs) into the 
circulation. 
 
In AT, the most powerful antilipolytic hormone is insulin. It regulates a number of 
anabolic functions of adipocytes and promotes lipogenesis: 
• stimulates glucose uptake 
• promotes lipoprotein lipase (LPL) enzyme activity on circulating triglycerides 
leading to free fatty acids uptake 
• promotes FFA synthesis 
• regulates hormone sensitive lipase (HSL) 
• re-esterifies fatty acids into triglycerides 
• inhibits lipolysis. 
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The sympathetic nervous system also stimulates glucose uptake in AT. Adipose tissue 
undoubtedly participates in the regulation of insulin secretion and glucose homeostasis 
(22,23,24).  
Glucose has 3 functions in adipogenesis and physiology of adipose tissue. These 
functions include contribution of carbon atoms to create acetyl coenzyme A, hydrogen 
supply for the reduction and acting as a source of glyceralphosphate. This is important 
for the re-esterification of fatty acids and their storage in the form of triglycerides.  
 
Lipogenesis is also affected by growth hormone (GH), cortisol, and catecholamine 
balance. Recently, a local stimulator of fatty acid esterification has been discovered in 
adipose tissue. With the production of ASP (acylation-stimulating protein), adipocytes 
independently regulate how much fat is needed. Fatty acids act through the peroxisome 
proliferator-activated receptor (PPAR). The main transcription factor of lipogenesis and 
adipogenesis is PPARγ-2, an exclusive mediator of lipid storage in WAT and initiator of 
energy delivery. It is also required for FFA and perilipine (protein on the surface of lipids 
in adipocytes) transport. Genes controlled by PPARγ are involved in most lipid 
metabolism and glucose homeostasis phases. Expansion of fat storage and creation of 
new adipocytes require neoangiogenesis, which is locally controlled by leptin, cytokine, 
matrix metaloproteinase and vascular endothelial growth factor (VEGF). 
A negative energy balance leads to the reduction in adipocytes and finally to apoptosis 
(16,20,23,26). 
Adipocytes of the gluteofemoral region exhibit higher lipoprotein lipase activity than 
other fatty depots. 
 
These differences in pathophysiology are partially controlled by estrogen, progesterone 
and androgens. Patients with polycystic ovary syndrome (PCOS) have a lower 
expression of LPL in subcutaneous AT as hyperandrogenism leads to the dysfunction of 
adipocytes. The importance of ovarian hormones in feeding control is supported by 
evidence that estrogens inhibit emotional and binge eating (occasions for overeating), 
while progesterone has the opposite effect and stimulates eating dysregulation 
(28,29,30). 
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1.1.6 Lipolysis 
 
Lipolysis is a biochemical pathway responsible for the catabolism of triglycerides stored 
in adipose tissue. TG hydrolysis is possible in all cells and tissues but is primarily 
inherent and most common in WAT and BAT. 
White adipose tissue is the main store of energy in humans. When there is energy 
demand, fat mobilization occurs, i.e. lipolysis causes triglycerides to break down into 
glycerol and free fatty acids, which satisfies peripheral energy needs. Lipolysis is 
performed in 3 steps with the participation of three enzymes (lipases) under the control 
of the β-adrenergic system (23,26,27): 
• Adipose triglyceride lipase (ATGL) - or desnutrin 
→ hydrolyzes TG to diacylglycerols and FFAs 
• Hormone sensitive lipase (HSL) 
→ hydrolyzes all glycerols 
• Monoglyceride lipase (MGL) 
→ breaks down monoglycerol into glycerol and FFAs. 
Epinephrine and norepinephrine together with glucagon stimulate the release of FFAs 
from triglycerides stored in adipocytes, while insulin is a potent inhibitor of these 
processes. The modulators of these activities are the growth hormone and cortisol. 
Adrenergic stimulation activates protein kinase, which phosphorylates perilipin 1 (and 2) 
and HSL, and the phosphorylation of perilipin further activates ATGL. These are the 
main steps in TG hydrolysis. Lipolysis is the most active in the visceral AT depot, 
followed by the subcutaneous abdominal depot. In the conditions of high release of 
FFAs and glycerol, the liver has on its disposal the elements for the synthesis of 
gluconeogenesis and lipoproteins. The relationship between FFA and glucose 
metabolism is negative in both directions. The lowest lipolytic activity is seen in 
peripheral subcutaneous AT. 
 
In obesity, the functions of adrenergic receptors and afferent signalling to the brain are 
altered, affecting the amount, function and distribution of AT. Obesity increases FFA 
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levels and the accumulation of fatty acids and TG in non-adipose tissue (muscles, liver, 
heart). Ectopic lipids are lipotoxic and compromise the function of insulin.  
In the conditions of insulin resistance and low levels of glucose transporter-4, inhibition 
of lipolysis by insulin is impaired. This contributes to increased levels of glycerol, FFAs 
and VLDL in the circulation. 
Insulin suppresses fat mobilization by HSL inhibition (dephosphorylation) and re-
esterification of FFAs. 
Lipolysis is strongly stimulated by catecholamines, but stimulation of α2-adrenoreceptors 
inhibits lipolysis. Adipose tissue metabolism depends on the nutritional status and 
physical activity, cold and psychic stimuli (26,27,28). 
 
Energy expenditure involves the basal metabolic rate (BMR), non-shivering 
thermogenesis, diet-induced thermogenesis and physical activity. BMR accounts for 
70% of the total energy expenditure, whereby the brain accounts for up to 20% of total 
energy expenditure. Another aspect of energy expenditure is adaptive thermogenesis in 
BAT. Physical activity (moderate) accounts for 20-30% of energy expenditure. For 
energy, the CNS uses glucose rather than lipids. A normal woman has 18 kg of fat 
corresponding to 170,000 kcal, which is an energy equivalent enough for 2.5 months. 
Pregnancy requires at least an additional 400,000 kcal. Understandably, enough AT 
reserve is a prerequisite for a normal menstrual cycle. 
1.1.7  Endocrine and paracrine functions of adipose tissue – adipokines 
 
Adipose tissue maintains extensive communication and is characterized by receptors 
activated by 3 types of signals: 
• endocrine signals – hormones travelling through the circulation 
• paracrine signals – adipokines from the neighbouring cells 
• neural signals – sympathetic and parasympathetic fibers. 
 
In the neural control of AT, the sympathetic autonomic system (adrenergic) is dominant, 
while the cholinergic (acetylcholine) system has antagonistic effects. The dominant 
adrenergic receptors are α1, α2 and β3 receptors. Parasympathetic neurotransmitters 
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bind to muscarinic and nicotinic cholinergic receptors. The activity of fat cells stimulates 
norepinephrine and epinephrine (adrenaline), mainly via β3 adrenergic receptors. 
Visceral abdominal adipocytes are most susceptible to lipolysis induced by 
catecholamines. Catecholamines (epinephrine and norepinephrine) and glucagon bind 
to their receptors on adipocytes, activate adenylate cyclase, and increase cAMP.  
The activation of cAMP promotes protein kinase (PKA) that phosphorylates and 
activates HSL (TG hydrolysis). 
Important among endocrine hormone receptors in AT are glucocorticoid receptors 
involved in the metabolism and distribution of adipose tissue. Androgen receptors have 
a higher density in visceral fat. Estrogen receptors also exhibit regional differences. 
They are the most active in the gluteofemoral depot of AT, with estrogens promoting a 
corresponding subcutaneous phenotype. With the decline of estrogen levels in 
postmenopause, the distribution of adipocytes shifts to visceral AT. Estrogens and other 
steroids play an important role in AT metabolism from lipogenesis to lipolysis and affect 
fat distribution. The metabolism of adipocytes and the pathophysiology of obesity are 
also affected by vitamin D, xenobiotics and oxysterols. It has been found that many 
steroid hormones show higher concentrations in AT than in the circulation. Adipose 
tissue is undoubtedly the most important reservoir of steroid hormones (1,7). 
 
Estrogens induce the "browning" of white adipocytes via ERβ (transformation into BAT) 
and the emergence of subcutaneous AT in the gluteofemoral region and the upper 
body. This is associated with less inflammation and lower cardiometabolic risk. Low 
estrogen activity favours the build-up of abdominal and visceral AT, thereby supporting 
chronic inflammation and metabolic risks.Estrogens promote gene expression and 
jointly induce gynecoid adipose tissue. Estrogens and androgens inhibit lipoprotein 
lipase (LPL) activity (26,28,29). 
 
Androgens and hyperandrogenism are associated with an androgenic, abdominal AT 
phenotype. Androgen dysregulation (androgen/estrogen balance) has a strong influence 
on the various phenotypes of obesity and the metabolic syndrome. The availability of 
estrogens and androgens in peripheral tissues is also affected by the level of sex 
hormone binding globulin (SHBG) production in the liver. Central obesity has a lower 
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SHBG due to the production of insulin and androgens. A reduction in SHBG increases 
the concentration of free testosterone, which is highly typical of central obesity. 
1.1.8 Steroidogenesis in adipose tissue 
  
Steroid hormones are synthesized in adipose tissue (de novo) from cholesterol or are 
converted from various precursors from the circulation. In adipocytes in which the 
internal mitochondrial membrane contains the CYP11A1 enzyme, cholesterol is 
converted to pregnenolone in the presence of steroidogenic acute regulatory protein 
(StAR). The StAR protein located on the external mitochondrial membrane serves as a 
transporter (importer) for cholesterol. De novo steroidogenesis is possible in 
subcutaneous and visceral AT. The expression of the TSPO gene is also involved in the 
control of cholesterol transport. Both transporter proteins also play a role in 
adipogenesis. The enzymatic system of adipose tissue further regulates various types 
of steroidogenesis, secretion of adipokines and lipid metabolism. Further fate of 
pregnenolone is determined by the presence of 3β hydroxysteroid dehydrogenase 
(3βHSD) and P450c17 (CYP17A1) enzymes. This can lead to the formation of 
mineralocorticoids, glucocorticoids and sex hormones, depending on the activity of 
relevant enzymes (11βHSD, CYP21, CYP19-aromatase, 17βHSD, 5α reductase, 
steroid sulphatase, etc.) (26,28,29,30). 
 
In addition, adipose tissue can affect the levels of circulating steroids by local 
conversion of steroids and synthesis of numerous adipokines that affect steroidogenesis 
in adrenals and gonads through endocrine activity. Apart from the classic pathways of 
steroidogenesis, adipose tissue is also the site of oxysterol synthesis and vitamin D 
storage, which are also involved in the metabolism of adipocytes and lipids. Obesity is 
associated with disturbances in the levels of these substances. 
It has been proven that the gene expression for almost all enzymes involved in the 
transformation of steroid hormones or pregnenolone occurs in human adipose tissue. 
Pregnenolone can be converted to progesterone in mitochondria (3βhydroxysteroid 
dehydrogenase) or exits into the endoplasmic reticulum and is converted to 17α hydroxy 
pregnenolone (P450C17). These are the starting points for all further steroidogenesis 
toward progesterone, androstendione, estrone and estradiol, testosterone and DHT 
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(dihydrotestosterone). The basic enzyme that diverts steroidogenesis (delta 5 to delta 4 
steroids) is 3βHSD (type 2), located in the mitochondria and the endoplasmic reticulum. 
Today, the presence of the P450c17 enzyme in AT has been repeatedly confirmed. 
There are regional differences in the concentration of enzymes and consequently in the 
conversion of hormones. In obesity, cortisol in the blood is not increased, but its 
production is more intensive in visceral adipose tissue (elevated expression of the 
11βHSD1 enzyme). 
Steroid hormone levels in the circulation enable their conversion to adipocytes. The 
conversion of these (adrenal and gonadal) hormones and de novo production of steroid 
hormones make adipose tissue the most active tissue in steroidogenesis. 
In adipose tissue, the enzymes P450 aromatase, 17βHSD and 3βHSD convert 
androstendione, DHEA, DHEA-s, and testosterone into: Regardless of the source of 
these steroids, the metabolic effects are both local, in adipose tissue, and global with 
endocrinological effects. 
The main part of estrone in the body (E1), 50% of total testosterone in women, and a 
variable amount of estradiol (E2) are produced in adipose tissue. In stromal cells of 
subcutaneous AT, the expression of P450arom is regulated by glucocorticoids, leptin, 
and cytokines – interleukin 6 and tumor necrosis factor alpha (TNF-α). The controller of 
aromatase activity in the breast and subcutaneous AT is prostaglandin E2. In case of 
breast cancer, there is increased activity of 17βHSD (type 1,7,12), sulphatase and 4-OH 
estrone in adipose tissue, leading to local estrogen levels in the breast that are 20 times 
higher than in the circulation. Type 12 of the 17βHSD enzyme is active in the 
conversion of estrone to potent E2. Out of the 14 isoforms of the enzyme 17βHSD family 
in AT, the expression of types 1, 2, 3, 5,7, 8 and 12 has been reported. Estradiol 
metabolism is disturbed in adipose tissue associated with breast cancer (1,7,8). 
Androgen levels are higher in visceral adipose tissue because of androgenic 17βHSD 
type 5 activity. Research shows that in adipose tissue androgenic activity dominates 
over estrogens. In obesity, the production of DHEA and androstenedione is increased. 
In sum, steroid activity in adipose tissue is a consequence of precursor supply, local 
synthesis and hydrolysis (decomposition) of steroid hormones. Local intra-adipose 
steroid metabolism determines the metabolic and health disorders, as well as the 
distribution of fat depots. This also applies to the identification of android or gynecoid 
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phenotype. Androgens play an important role in controlling the distribution of AT and 
endocrine and metabolic disorders (23,24,25,26). 
Exogenously applied hormones are deposited and transformed in adipose tissue, with 
the potential to change the success of programmed treatment. 
Therefore, obesity has a wide potential for the secretion of steroid and sex hormones, 
which contributes to endocrinological disorders and comorbidity. Endocrine, paracrine 
and autocrine activity of hormones has been observed in adipose tissue. 
In obesity, estrogen production, free estrogen fraction, and estrogen sulphate 
generation (active estrogen reservoir) are increased. Obesity also changes the balance 
and the activity of androgens. 
1.1.9 Adipokines 
 
Adipose tissue is a large and dynamic endocrine and paracrine organ. White adipose 
tissue produces proteins and cytokines that transmit signals to control feeding, body 
weight, metabolism, reproduction, inflammatory disorders, and several other 
physiological and pathophysiological changes. More than 50 adipokines have been 
identified so far, but not all of them have defined functions. The first enzyme to be 
identified was lipoprotein lipase (LPL), which hydrolyzes circulating TG to NEFA. WAT 
has a complex role in general physiological and control mechanisms, with extensive 
communication with other tissues and organs. Neither all WAT sites nor all adipocytes 
produce the entire spectrum of adipokines (30,31,32).  
The regulation of adipokine and hormone synthesis is very complex, and depends on 
the number of adipocytes, supply of precursors, and balance of the autonomic nervous 
system and local autoregulatory mechanisms. There are no classic feedback 
mechanisms. In adiposity, the mechanisms for the control of adipokine secretion are 
different in that they are capable of synthesizing pro-inflammatory and anti-inflammatory 
proteins. They induce the infiltration of macrophages into AT, which are a source of the 
tumor necrosis factor (TNF) α and IL-6 (fig 5). 
Many adipokines are not exclusive products of adipocytes and are also produced in 
other tissues. 
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Figure 4. Adipokines and the function of adipocytes, CRP-C reactive protein; TNF - tumor 
necrosis factor; IL - interleukin; TGF - transforming growth factor; PAI - plasminogen 
inhibitor activator; VEGF - vascular endothelial growth factor 
Leptin  
 
Leptin is a polypeptide hormone, a product of the ob gene (in WAT) with 146 amino 
acids. Its name derives from the Greek word "leptos" meaning thin, skinny. Women 
have higher leptin levels and higher pulse amplitudes. Leptin informs the brain about the 
energy stored in adipose tissue. The leptin gene expression is regulated by hormones, 
growth factors and cytokines. It is primarily a signal of white AT, minimally of brown AT, 
but leptin expression also exists in the hypothalamus, pituitary gland, placenta, breasts 
and gonads. Leptin and the sympathicus are the main links between adipose tissue and 
the CNS. Estrogens induce leptin production, while androgens suppress it (30,31,32). 
 
Leptin is an indicator of the body's adipose tissue and signals the energy balance. 
Leptin acitivities are performed through 6 receptors. The production and activities of 
leptin are proportional to the amount of WAT and stored energy. In such circumstances, 
leptin secretion and the amount of free leptin increase with obesity. This limit feeding 
(food intake) and increases energy consumption. Optimally, this would imply weight 
reduction. However, the chronic excessive intake of food in obesity is more frequently 
associated with leptin resistance and the effect on weight loss is minimal.  
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When food intake and body fat (energy) are reduced, low leptin levels cause hunger. An 
excess of AT and energy inhibits the hypothalamus, which reduces appetite, activates 
thermogenesis and energy expenditure, as well as the sympathetic tone. Low leptin on 
the other hand signals an increased need for energy. Leptin is secreted in a pulsatile 
manner, normally every 60 minutes. 
 
Leptin plays an important role in controlling the hypothalamic-pituitary axis and the 
reproductive system. It stimulates the release of GnRH and LH pulsatility and is also 
involved in folliculogenesis (1,7,33,34). 
In sum, leptin activities include: 
• signals the energy status to the CNS 
- reduces appetite and thermogenesis or 
- increases appetite and energy reserves 
• influences gonadotropic functions and puberty 
• influences the function of gonads 
• stimulates angiogenesis 
• immunomodulation 
• stimulates hematopoiesis and platelet aggregation  
• thermogenesis. 
 
Obesity is associated with an increase in the levels of leptin, which is a sensitive marker 
for the metabolic syndrome and cardiovascular risks. Essentially, leptin is anorexigenic. 
Increase in leptin expression is stimulated by sex hormones, glucocorticoids, cytokines, 
and some inflammatory toxins. Catecholamines reduce the circulating leptin levels. 
Insulin stimulates leptin, and both hormones have a lipostatic role. 
Adiponectin 
 
Adiponectin is a protein hormone with 244 amino acids like the TNF superfamily. It is 
produced by adipocytes in WAT, and binds to 3 receptors (AdipoR1, AdipoR2 and T-
cadherin) to affect the cell function of enzymes (AMPK). Adiponectin concentrations are 
lower in men, obesity, android obesity, diabetes and people with coronary heart disease 
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(CHD) and hypertension. Adiponectin has several positive effects, with a strong anti-
diabetic effect (30,31): 
• increases insulin sensitivity 
• increases insulin activity in the liver 
- reduces hepatic production of glucose 
- thereby lowering blood glucose 
• increases oxidation of fatty acids and lowers triglyceride levels 
• anti-inflammatory effects – increases IL-10 production 
• stimulates lipolysis and inhibits the synthesis of cholesterol, triglycerides and 
adipogenesis (increases LPL) 
• increases the production of nitric oxide (NO) and promotes vasorelaxation 
• has anti-atherogenic properties 
• concentration of adiponectin is low in patients with breast, endometrial, colon, 
and prostate cancers. It limits cell proliferation and stimulates apoptosis. 
Although it is undoubtedly present, the role of adiponectin in reproduction has not 
been fully defined. Lower levels of adiponectin in women with polycystic ovary 
syndrome (PCOS) are associated with insulin resistance. 
Resistin 
 
Resistin is an adipokine (cytokine) produced in adipocytes and macrophages. This 
dimeric protein is a mediator of insulin resistance and appears to be related to obesity. 
When resistin is elevated, AMPK (adenosine monophosphate activated protein kinase) 
activity is reduced, which affects cellular energy homeostasis. Low resistin levels are 
associated with elevated AMPK activity and a reduction of gluconeogenesis, and 
glucose production in the liver. Therefore, resistin is an important controller of glucose 
metabolism with the following effects (29,30): 
• increases insulin resistance 
• blocks insulin signals 
• increases hepatic production of glucose 
• controls adipogenesis 
- inhibits the differentiation of preadipocytes 
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• participates in chronic inflammation and immunomodulation 
• participates in central feeding control. 
The relationship between resistin, reproduction and PCOS is still being investigated. 
However, it has been established that resistin levels are elevated in obese women with 
PCOS. Resistin increases P450c17 activity in theca cells. 
Omentin and chemerin 
 
Omentin is an adipokine that is mainly produced in visceral adipose tissue (omentum 
etc.). It stimulates glucose uptake in fat cells. Its concentration in the circulation is lower 
in obese persons, i.e. when BMI and leptin are elevated.  It is also lower in people with 
diabetes and obese female patients with PCOS and insulin resistance. Metformin 
increases omentin levels. 
Chemerin is an adipokine (chemokine) involved in the control of adipocyte development 
and metabolism. Its levels increase with obesity, metabolism of fat and glucose, DM, 
and inflammation. Insulin up-regulates chemerin, exacerbates glucose tolerance and 
insulin resistance. 
It seems that both adipokines may be involved in the function of granulosa and theca 
cells of the follicle. 
 Other adipokines 
 
Adipose tissue (adipocytes) as well as numerous other tissues and cells produce a 
variety of other cytokines and cell metabolism control factors characterized by autocrine 
and paracrine activities. 
Complement-like factors are adiposine and acylation stimulation protein (ASP), the 
factors of adipogenesis or lipolysis autocontrol. Inflammatory cytokines are circulatory 
and local inflammatory markers, pro-inflammatory and acute-phase proteins. Their 
importance is reflected in the fact that obesity is a low-grade inflammatory condition. 
The inflammatory condition in obesity may cause insulin resistance, hyperlipidemia and 
metabolic syndrome. It remains unclear whether obesity is a result or a cause of 
inflammation. Inflammatory markers are generated in several ways. They are produced 
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in other organs; adipose tissue finalizes liver products (CRP) or they are self-produced 
with adiposity in adipocytes (or in infiltrated macrophages) (fig 6). 
Visceral adipose tissue has a higher capacity to produce TNF-α, CRP and IL-6 (26,30). 
 
 
 
 
 
 
 
 
Figure 6. Inflammatory cytokines potentially produced in AT , TNF - tumor necrosis 
factor; IL - interleukin; NGF - nerve growth factor; MCP - monocyte protein; CRP - C 
reactive protein; PAI - plasminogen activator inhibitor 
Tumor necrosis factor alpha (TNF-α) is a product of WAT and a powerful autocrine 
and paracrine adipocyte regulator. It is elevated in obesity and inhibits the signalling of 
insulin receptors and leads to insulin resistance. It is the main regulator of IL-6 
synthesis and haptoglobin, and controls apoptosis. In addition to its local effects, IL-6 
also acts centrally because it regulates the energy balance in the hypothalamus (along 
with leptin). Elevated BMI and WHR are accompanied by an elevation in the 
abovementioned cytokines. In obesity, IL-8 and IL-18 production is increased. 
Plasminogen activator inhibitor-1 (PAI-1) is an important factor in maintaining 
hemostasis. Its production in WAT has been proven in obesity. It is also associated with 
a tendency to atherogenesis, diabetes, and cardiovascular risk, which accompany 
obesity. The stimulation of the PPAR gamma nuclear receptor (by thiazolidinediones) 
inhibits haptoglobin, TNF-α and leptin. 
Whether obesity is a state of chronic inflammation can be seen from an elevated 
production of C-reactive protein (CRP) in the liver. Elevated levels of high sensitivity 
CRP (hsCRP) are a surrogate marker for the expression of visceral obesity and PCOS. 
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Neurotrophin (NGF) is produced in adipocytes, and is important for maintaining neural 
sympathetic connections, and for immune and inflammatory processes. The main 
stimulator for NGF expression is TNF-α. 
The following activities are common to TNF-α, IL-6 and CRP are: 
• increase in vascular inflammation 
- proatherogenic action 
• reduction of insulin sensitivity and signalling 
- insulin resistance 
- prodiabetic effects 
• they are elevated in abdominal obesity 
• 30% of IL-6 in the circulation is from AT 
• there is mutual production control 
• they are potent adiponectin inhibitors. 
 
Visfatin has proinflammatory and proatherogenic effects. It causes vascular dysfunction 
and stimulates angiogenesis. 
 
Vaspin is an adipokine with beneficial effects. It improves insulin sensitivity and reduces 
ROS. It reduces food intake. 
 
Retinol binding protein-4 (RBP-4) increases insulin resistance and glucose 
intolerance (30). 
 
AT products include adipokines functioning as vascular cell adhesion molecules – 1 
(VCAM-1), collagen, fibronectin, matrix metalloproteinase (MMPs 1/7/9/10/11/14/15), as 
well as products for the synthesis of prostaglandin (cox pathway), nitric oxide (NO), 
renin-angiotensin system and tissue inhibitors of MMPs (TIMPs). 
BAT primarily produces paracrine factors – vascular endothelial growth factor (VEGF), 
NGF, FGF-2 angiotensinogen and NO, which enables more vascularization and 
sympathetic stimulation of brown adipocytes and enhances the positive effects of BAT. 
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BAT also produces adiposine, which inactivates ASP and contributes to reduced 
adipogenesis. This occurs through paracrine effect on white adipocytes. 
The increase in inflammatory adipokines in obesity is considered as a local response of 
WAT to hypoxia. Growth of AT depot with weaker vascularization and expression of 
hypoxia-inducible factor-1 (HIF-1) may stimulate the production and activity of 
proinflammatory cytokines.  
Gastrointestinal hormones in energy control 
In addition to adipokines, which are anorexins involved in energy homeostasis and 
feeding (leptin, adiponectin, resistin), there are also digestive tract hormones involved in 
the central control of hunger and appetite. These are peptide hormones of the stomach 
and the intestines – orexins and anorexins (37). 
 
Ghrelin 
Ghrelin is a peptide consisting of 28 amino acids, named after its growth hormone 
release stimulating function. It is produced mainly in the stomach (70%), the intestine 
and the pituitary gland. Apart from participating in feeding control and energy 
metabolism, it is active in the stomach and pancreas. The most important are its central 
functions regulating energy homeostasis in the hypothalamus. Its levels increase during 
hunger and in lean persons, stimulating appetite and food intake by modulating 
neuropeptide-Y (NPY) functions. Its levels and activity are high in starved and anorectic 
persons, and low in obesity and postprandially. Ghrelin inhibits the expression of 
kisspetin, which inhibits GnRH and LH pulsatility. It stimulates the secretion of the 
growth hormone, prolactin and ACTH. Ghrelin has orexigenic effects both in the 
metabolism and in reproduction. It is an important link between peripheral energy 
balance, CNS and reproduction. 
Ghrelin and leptin are the main coordinators between reproduction, body composition 
and energy metabolism. Ghrelin inhibits and prevents reproduction in conditions of 
energy deficit, whereas leptin has the opposite effect. Ghrelin is the only known 
hormone to stimulate appetite. 
 
 
31
 
 
 
 
Peptide YY i oxyntomodulin (OXM) 
Gut hormones, enterokins, (PYY) and OXM have different effects compared to ghrelin. 
Like leptin, they are anorexigenic and inhibit food intake through the hypothalamus. In 
response to a meal (filled intestines), they function as anorexins. They are suppressed 
during hunger and inhibit food intake by 40%. PYY also exerts effects on the 
reproductive axis and the development of puberty. Food intake and a filled ileum 
stimulate PYY release. 
 
Obestatin 
Obestatin is a stomach hormone with 23 amino acids. Its effects on central and 
reproductive functions are undefined. Its activities seem to be like those of ghrelin. 
Glucagon-like peptide I, insulinotropic polypeptide and cholecystokinin are gut 
hormones that also seem to balance food intake and reproduction. 
Cholecystokinin is produced in the duodenum and jejunum. It reduces food intake. 
Enterostatin, bombesin and amylin are enterokines with anorectic effects. 
 
1.1.9.1 Neurophysiology and neuropathology of adipose tissue and obesity 
 
The brain is an important regulator of energy homeostasis, used to coordinate 
reproductive functions. The hypothalamus and the dorsal medulla are the main sites 
that receive and integrate peripheral energy storage signals and feeding behaviour. In 
normal conditions, an optimal energy reserve in AT is a physiological stimulus for timely 
puberty, menarche and ovulatory menstrual cycle. Obesity is a result of a chronic 
disorder of energy homeostasis accompanied by changes in the peripheral metabolism, 
resulting in a hormonal, metabolic and inflammatory imbalance (32,33,34,35). 
With food intake, glucose, fatty acids and amino acids are hydrolysed to ATP, CO2, 
water and heat. Feeding behaviour and all accompanying sensations are mutually 
dependent in the CNS. 
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The periphery affects the brain with signals from three directions. 
• humoral factors – hormones 
• metabolic factors – metabolic components 
• autonomic nervous system – two-way system. 
 
The hypothalamus contains centers for hunger (appetite) and satiety, with numerous 
links and signals that affect these functions. and make them directly involved in any 
potential disorder, from anorexia to obesity. The functions of hypothalamic centers are 
coordinated by both peripheral signals and other CNS regions through important 
pathways: hypothalamocortical, hypothalamolimbic, endocannabinoid pathways, n. 
vagus and reproductive centers. Thus, serotonin and allopregnenolone have a positive 
effect on appetite, while cortical releasing hormone (CRH), IL1/6 and TNF- α have a 
negative (inhibitory) effect. 
Four basic hormones control energy homeostasis through the hypothalamus: leptin, 
insulin, ghrelin and PYY (34,35,36,38,41). 
 
Leptin regulates physiological processes in two ways. In case of an optimal body 
weight, leptin is an indicator of the body’s AT reflecting the balance between energy 
input and expenditure. In case of increase or decrease in BMI, leptin signals energy 
imbalance. In obesity, it encourages cessation of food intake with a tendency of AT loss, 
while a fall in energy reserves signals to the brain that energy is needed (low leptin). 
Therefore, by regulating fat and body weight, leptin has a crucial role in energy 
expenditure or build-up. In obesity, leptin, in synergy with insulin, inhibits appetite and 
food intake in the hypothalamus and increases energy expenditure and thermogenesis, 
as well as the sympathetic tone. Hunger and leanness reduce leptin activity resulting in 
energy conservation, increased appetite, and parasympathetic activity. In chronic 
obesity conditions, "leptin resistance" develops. 
In controlling energy homeostasis and obesity, leptin and insulin use the same pathway 
in CNS (phosphatidylinositol 3-kinase), which is the basic anorexigenic enzyme (fig 7, 
table 8). 
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In nucleus arcuatus (n.A.) and n. paraventricularis of the hypothalamus leptin has 
neuromodulatory effects on two systems: POMC (pro-opiomelanocortin) with the 
melanocortin pathway (α MSH), and neuropeptide Y (NPY) agouti-related protein 
(AgRP). Leptin also suppresses the expression of endocanabinoids, stimulates α MSH 
and cocaine- and amfetamine-regulated transcripts (CART). All these actions reduce 
appetite and food intake. Increased or low leptin (and insulin) can stimulate or inhibit 
energy accumulation (food intake) through anabolic and catabolic pathways. These 
actions are shown in Table 8: 
Table.8. Different hormonal activities in feeding control 
↑ high; ↓low; MCR- melanocyte recptor; CART- cocaine amfetamine regulated transcripts 
Anorexigenic  catabolic pathways Orexigenic anabolic pathways 
• POMC 
• αMSH 
• CRH 
• TRH 
• CART 
• IL-1β 
• Inhibition of MCR (low) 
• Leptin ↑ 
• Insulin ↑ 
• Enterokin ↑ 
• NP-Y 
• AgRP 
• Ghrelin 
• Leptin ↓ 
• Insulin ↓ 
• Inhibition of MCR (high) 
Negative energy balance Positive energy balance 
Figure 7. Central control of appetite in the hypothalamus, The inhibitory pathway AgRP-
MCR is unidirectional; MCR melanocyte receptor 
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With the loss of MSR function (αMSH receptors), morbid obesity develops (5% of obese 
population). Obesity is associated with chronically high neuropeptide Y (NPY) levels. 
Leptin and insulin circulate at the levels determined by AT and energy balance. In the 
CNS and the hypothalamus, they inhibit orexigenic activity and promote catabolic 
pathways of reduced food intake and increase energy expenditure. In leanness (loss of 
AT), these two hormones stimulate anabolic signals that promote food intake and 
energy saving. They inhibit catabolic pathways. The intake of food triggers satiety 
signals, and leptin/insulin regulate the size of the meal. In the described synergism, the 
role of leptin is more important for definitive effects in the CNS (34,38,39,40). 
 
Neuropeptides are the most powerful anabolic effectors that stimulate food intake, while 
inhibiting energy expenditure. At the same time, they promote lipogenic enzymes in 
adipose tissue and the liver. Anabolic signals (orexines) are also produced by agouti-
related proteins. In contrast, catabolic signals in the CNS are POMC, melanocyte-
stimulating hormone alpha (MSH), CRH, tyrotropine-releasing hormone (TRH), CART 
and interleukin-1 beta. They all promote a negative energy balance, with the 
melanocortin system having the most powerful effect (40,41,42). 
Simply put, leptin and insulin stimulate catabolic pathways and inhibit anabolic signals. 
 
 
Figure 8. Adipose tisue signalling and feeding behaviour. Balance of αMSH and AgRP 
activity regulates appetite; Insulin and leptin are appetite suppressors; AT - adipose 
tissue 
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High leptin/insulin levels inhibit NP-Y/agouti-related peptides and stimulate the POMC 
melanocortin pathway. This reduces appetite and increases energy expenditure. Also 
contributing to negative energy balance control is weak (or no) inhibition of MSR 
through AgRP activity (fig 8). 
 
Low leptin/insulin levels arising from leanness and AT and energy deficits have an 
opposite effect. NP-Y/AgRP is stimulated, MCR inhibition is increased and the POMC 
system is inhibited. Food intake increases while energy is preserved (34-42). 
Adipose tissue and energy homeostasis signals are linked through the hypothalamus of 
the lymbic system with the control of the reproductive axis. 
 
Adipose tissue reserves, and energy reserve signals are prerequisites for a timely 
course of female puberty, menarche and ovulation cycle. The menstrual cycle is 
established only with optimal body weight (≈ 48 kg) and the desired body composition 
(AT i.e. BMI ≈ 19-21 kg/m2). Excessive undernutrition (BMI < 18) or obesity (BMI > 30) 
send signals to the CNS that seriously disrupt ovulation and the cycle (30). 
Taste centers and the cognitive CNS are involved in feeding control. Dopamine (DA) 
neurons in the corpus striatum and the amygdala evaluate food characteristics and 
visual effects of food (enjoyment). 
 
Estrogens modulate AgRP effects and MCR expression and thus affect food intake. The 
inhibition of NP-Y and stimulation of αMSH neurons are variable estrogen functions 
during the cycle. Peripheral hormones and adipokines have a different effect on the 
hypothalamus in conditions of high or low estrogens.  
Low estrogen status makes numerous signals inhibitory. It has been shown that 
estrogens in women influence AT distribution (with adipocyte genes), so that AT is 
increased with their depletion. Increased estrogen levels in periovulation reduce the 
daily intake of food, and RBM increases in the luteal phase (29,30). 
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Figure 9. Relationship between adipose tissue, food intake and GnRH neurosecretion 
 
In maintaining energy homeostasis, adipose tissue and adipokines are directly (CNS) 
and indirectly (ovarian and endocrine functions) involved in the control of the 
reproductive axis. Via the hypothalamus, leptin controls the development of sexual 
organs and sexual maturation. Adipose tissue signals control POMC and 
neuropeptides, and their further secretion is dependent on estradiol levels, i.e. the 
activity of the estrogen receptor beta (Erβ) in n. arcuatus. The effects of leptin, NP-Y, 
insulin and ghrelin are stimulatory in the presence of estrogens, and inhibitory in their 
absence. Lack of adipose tissue, lack of food and energy deficit will result in low leptin. 
NP-Y stimulation and POMC inhibition have an impact on the dysregulation of the 
kisspeptin system, resulting in the reduction of neurosecretion and pulses of the 
gonadotropin-releasing hormone (GnRH) (FSH/LH are affected).  
 
The expression of kisspeptin, the primary controller of GnRH secretion, depends on 
the nutritional status and adipokines. Additional relays between leptin and GnRH 
hormones are kisspeptin, glutamate and brain opiates as GnRH neurons lack leptin 
receptors (fig 9). 
 
Kisspeptin, the central controller of pulsatile neurosecretion of GnRH, depends on 
normal energy balance in multiple ways. Obesity, elevated androgen levels and insulin 
resistance inhibit the concentration of kisspeptin, and consequently that of GnRH. 
KISS1R receptors are located on GnRH neurons but are expressed elsewhere in the 
 
 
  
 
 
 
 
 
 
 
 
● β endorphin 
● norepinephrin 
● dopamin 
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brain and peripheral tissues. The neuropeptide kisspeptin is active in adipose tissue, 
liver, pancreas and the ovaries. It has been found that kisspeptin is an intermediary 
neuropeptide that links the metabolic status and reproductive functions, as a mediator of 
leptin activity. Leptin and estrogens promote the expression or transcription of 
kisspeptin-54. In conditions of leptin deficiency (in response to a negative energy 
balance) or leptin resistance, kisspeptin activity declines. Kisspeptin disorder can 
directly or indirectly affect the metabolism, obesity, and energy and glucose 
homeostasis. The effect of leptin on GnRH neurons can bypass the KISS1 pathway; in 
this case, signals are transmitted via glutamate (34,35,38,39 ). 
 
Obesity, high BMI and WC are negatively correlated with FSH and LH. Morbid obesity 
suppresses LH and its pulsatility. Also, elevated BMI, insulin resistance and elevated 
androgen levels (FAI) decrease (inhibit) kisspeptin neurosecretion. These changes 
disrupt the menstrual cycle, from ovulations to amenorrhea.  
1.1.9.2 Endocannabinoid regulation 
 
The endocannabinoid system (ECS) is a molecular system that maintains homeostasis 
by autocrine and paracrine activity. It is present in many organ systems and tissues, 
such as the nervous system, adipose tissue, and the immune system. 
Endocannabinoids suppress or limit cellular response to numerous signals. Each 
deviation and potent response of the cell exceeding physiological limits activates ECS, 
which tries to re-establish homeostasis. The endocannabinoid system consists of 3 
components (34,35,40): 
 
• endocannabinoids – molecules released from lipids as needed – anandamide 
and 2 AG 
• cannabinoid receptors – CB1 high levels in CNS and CB2 throughout the body 
• metabolic enzymes – destroy ECS molecules once used (limiting effect). 
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Among others, ECS is engaged in the following important activities: 
 
• CNS functions in neurosecretion – retrograde suppression of overactive neurons 
• control of the peripheral nervous system 
• control of homeostasis and chronic inflammation in adipose tissue 
• control of inflammation and autoimmune response – in chronic inflammation, 
limits the intensity and duration of the response and suppresses and limits 
cellular signals. 
In a special way (neuromodulators), ECS links brain activity to the health of organ 
systems. Among other neural functions, this system is involved in controlling appetite. 
ECS molecules are not neurotransmitters, but intracellular lipid messengers that inhibit 
excitation signals. 
CB1 concentrations in the hypothalamus are high, and the regulation (suppression) of 
these receptors in the brain reduces appetite and participates in thermoregulation. In 
adipose tissue and the liver, endocannabinoids control the energy metabolism. ECs 
also have a known psychotropic effect, also exhibited by marijuana. 
The endocannabinoid system interacts with the orexinergic system in the joint control of 
cognitive and physical energy functions. ECS induces a fall in cAMP levels and 
increases mitogen-activated protein kinase (MAPK).  
In this chapter, it is important to point out that ECS regulates appetite, and leptin 
activity, increases dopamine, and increases taste quality. It also controls the function of 
adipocytes and modulates insulin sensitivity. As already mentioned, this system is an 
important neuro- and immunomodulator. It is believed to regulate endometrial receptivity 
and implantation. 
1.1.9.3 Epigenetic effects and obesity 
 
Epigenetic changes alter the function of genes without changing the DNA sequence. 
These changes to genes and transcription are caused by external environmental factors 
or developmental issues (42,52). 
Epimutations change gene expression as well as the differentiation and function of the 
cell. They are frequently a normal occurrence but can also be abnormal (1,7,40,52). 
39
 
 
 
 
 
Functional changes of the genome without in intervention in the nucleotide sequence 
occur in several ways: 
• DNA methylation 
- hypomethylation 
- hypermethylation 
• histone modification 
- repressive marks 
- active marks 
• Non-coding RNA (micro RNA) 
• Methylation of mitochondrial RNA (mRNA) 
The selective and inherited alteration of chromatin, with modified gene transformation, 
changes the cell function. Epigenetic mechanisms are triggered in the following 
circumstances: 
• exposure in utero (during development, childhood) 
• aging 
• food 
• pollutants – environmental factors and chemicals 
• obesity. 
Epigenetic modifications can be inherited through both mitosis and meiosis, but the 
definition also extends to uninheritable alterations of transcriptional potential. The cell 
takes a different, epigenetic phenotype (with changed imprinting, gene silencing, etc.) 
Epigenetic changes mostly occur throughout a person's life, but transgenerational 
transfer (via sperm or oocyte) to the first or second generation is also possible. 
 
Epigenetic changes are frequently caused by DNA damage. External DNA modifications 
affect gene activity or inactivity. Physical inactivity and the intake of food impact the risk 
for obesity by changing the FTO (fat mass and obesity) gene. Congenital or acquired 
epimutations in neurotransmitter canonical pathway genes in the hypothalamus lead to 
an imbalance in energy expenditure and to obesity. 
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Obesity occurs through a combination and interference of genetic and environmental 
factors. It is assumed that obesity is 40-70% heritable, with many genetic reasons for 
obesity and fat distribution. As there are no precise interpretations of genetic obesity, 
the importance of numerous epigenetic effects is increasingly emphasized.  
 
Research has clarified three types of connections: 
• epigenetic effects of obesity – lipotoxicity 
- inherent mutations 
• transgenerational – vertical effects 
- intrauterine, effects on oocytes and sperm 
• environmental stressors – effects of pollutants 
- and endocrine disruptors. 
 
Obesity triggers epigenetic disorders associated with comorbidity and reproductive 
dysfunction. Adipose tissue dysfunction and lipotoxicity involve a state of chronic 
inflammation that promotes oxidative stress. This alters the synthesis of adipocyte 
hormones and cytokines. Tumor necrosis factor α (TNF-α), IL-6, CRP and matrix 
metalloproteinases, i.e. chronic inflammation, release the reactive oxygen species 
(ROS). Such disorders lead to epigenetic modification of a series of enzymes, 
damaging intracellular energy metabolism. Epigenetic changes to genes modify 
chromatin (DNA damage) in somatic cells and gametes. Alterations can therefore be 
transferred transgenerationally, vertically, through the epimutation of sperm or oocytes 
and induce inherited obesity or other disorders in the first or second generation 
(generations F1 and F2). 
Exposure to maternal obesity or undernutrition in pregnancy increases the risk and 
predisposition of the child for obesity and hypometilation of genes that promote 
adipocyte differentiation. Child development in suboptimal intrauterine conditions 
increases the risk for diseases later in life (51,52,53,54). 
Epigenetic modifications of genes can program the phenotype of adults if they induce 
changes in placenta function, foetal development, organ function and epigenome that 
regulates energy balance (POMC, NP-Y, dopamine, norepinephrine, etc.).  
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A disturbance in epigenetic regulation is present in many diseases: atherosclerosis, 
obesity, autoimmune and vascular diseases. 
Reproductive functions are very sensitive to environmental conditions such as nutrition, 
climate and chemical pollutants, which can cause epimutations. Epigenetic 
reprogramming is an important co-factor of PCOS (methylation disorders in 40 genes) 
and hyperandrogenism. In hyperandrogenism, epimutations of the peroxisome 
proliferator-activated receptor γ (PPARγ) gene have been identified, which is a 
significant transcription factor for the differentiation and function of adipocytes (42,52). 
 
Epimutations can be related to endocrine disruptor chemicals (EDC) that interfere 
with the endocrine system and hormone activity. All organ systems that depend on 
hormone control can exhibit a disruptor-induced dysfunction. ED has been proven to be 
related to obesity, diabetes, reproductive disorders and several diseases. The most 
sensitive to numerous environmental pollutants, toxins and chemicals are the earliest 
stages of embryogenesis and cell differentiation, as well as gametes. Food is the most 
common form of exposure to pollutants. There is a close correlation between epigenetic 
changes to gene transcription and the effects of endocrine disruptors, many of which 
directly affect lipoprotein lipase function, feeding control, energy homeostasis, obesity 
and insulin resistance. Environmental chemicals disrupt signalling in estrogen, 
androgen and thyroxine receptors (or imitate endogenous hormones). 
 
There are thousands of environmental toxins, including among others 
(42,47,50,51,52,53,54): 
• xenoestrogens – imitating estrogens 
- biphenyls (PCBs) 
- alkylphenols 
- bisphenol A (BPA) 
• pesticides (DDT, endosulfan) 
• phthalates (cosmetic products, sprays) 
• phytoestrogens 
• heavy metals, paints. 
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The endocrine disruptor BPA increases the transcription of estrogen receptors, 
promotes adipogenesis transcription factors (PPAR, C/EBPα) and significantly 
increases adipogenesis. Different ingredients of plastic, pesticides, insecticides and 
cosmetic products accumulate in adipose tissue and affect the metabolism and 
production of adipokines. The expression of genes encoding IGF-1 and LPL is also 
increased. BPA disrupts estrogen activity via ERs. Endocrine disrupting chemicals play 
a role in lipogenesis, obesity, insulin secretion, and insulin resistance. Even the sharp 
increase in the prevalence of obesity in the last 40 years is associated with frequent 
exposure to EDC. Some EDCs directly affect adipocytes and promote adipogenesis, 
while others interfere with gametogenesis and reduce fertility in men and women. It has 
been established that BPA is accumulated in the body of 95% of people. Pesticides, 
BPA and perfluorinated chemicals (protection of materials) have been proven to have 
an obesogenic effect directly via PPARγ or indirectly by disrupting thyroid and adrenal 
hormones, as well as an epigenetic effect on DNA methylation and metabolism of 
mitochondria. Intrauterine exposure to EDC leads to the transgenerational transfer of 
epigenetic markers up to generation F3. 
Chemicals that can alter adipocyte differentiation, lipid metabolism and promote obesity 
are called obesogenic chemicals. They may include endocrine disruptors, drugs and 
other chemicals impairing and disrupting: 
• metabolism of adipocytes 
• production and conversion of steroids 
• central control of energy balance. 
 
Neuroendocrine effects of obesogens directly affect the control of reproductive 
functions. Some of the more common obesogens are: bisphenol-A, sweeteners, 
nicotine, arsenic, some psychiatric drugs (SSRIs), other xenobiotics, antidiabetics, 
stilbestrol etc.Factors that lead to obesity undoubtedly affect reproductive dysfunction. 
The microenvironment promotes epigenetic modification of gene expression and 
enzyme activity, causing changes in DNA methylation and histones. Environmental 
toxins (stressors) and diet lead to obesity, while dysregulation of adipocytes (and their 
signalling) causes reproductive disorders (42-51).  
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1.2 Relationship between obesity and polycystic ovary syndrome 
 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women 
of reproductive age, with a frequency of 7% – 25%, depending on the diagnostic criteria. 
Symptoms and signs of this syndrome change with age (56,57,58,59) shown in table 9. 
 
Table 9. Symptoms, signs and risks of PCOS during life, EDC- endocrine disruptor 
chemicals; IUGR- intrauterine growth retardation; IR- insulin rezistence; HA- 
hyperandrogenism; ROS- reactive oxygen species; MetSy- metabolic syndrome; IGT- 
glucose intolerance; T2D- typ 2 diabetes; CVD- cardiovasculardiseases; CACS- coronary 
artery calcification score; AUB- abnormal uterine bleeding; OSA- obstructive sleep apnea 
 
 
There are significant geo-epidemiological differences in the prevalence of PCOS, and in 
the expression of individual phenotypes in different populations. The criteria for PCOS 
diagnosis were discussed for many years, as US expert societies considered that 
hyperandrogenism (HA) was a mandatory factor for diagnosis. Today, the extended 
Rotterdam criteria (2003) with the subsequent European and American Reproductive 
Society Consensus (ESHRE/ASRM) are widely accepted. The diagnosis of PCOS 
requires that two of three criteria are met: ultrasonographic polycystic ovary morphology 
(PCOM), ovarian dysfunction (OD–oligoovulation/anovulation), and hyperandrogenemia 
and/or hyperandrogenism (HA) (table 10). 
 
 
Simunic  2017 
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Table 10.    Criteria and classification of PCOS, PCOM- polycystic ovarian morphology; 
OD- ovulation disfunction; HA- hyperandrogenism 
 
Based on the presence of these disorders (PCOM/OD/HA), we distinguish between four 
PCOS phenotypes: phenotype A, B, C and D. The most common are phenotypes A and 
B (70%), which are considered ‘classic PCOS’, with strongly expressed 
hyperandrogenism and hyperinsulinemia, and the highest metabolic and reproductive 
risks (58-64). 
 
In adolescence, and in normal circumstances, the occurrence of cycle disorders, PCOM 
(50%) and acne (about 30% of the population) is more frequent, and it is not 
recommended that PCOS is diagnosed until two years after menarche if all three criteria 
are expressed. High levels of the anti-Müllerian hormone (AMH) also contribute to the 
diagnosis.Recently, there are more and more recomendations to use high AMH values 
as valid finding for PCOS (65-69). 
PCOS in peri- postmenopause is diagnosed based on anamnesis from the reproductive 
period, and relative hyperandrogenism (1,7,57).Diseases that imitate indicators of this 
syndrome should be excluded before any final PCOS diagnosis. Those may be 
congenital adrenal hyperplasia, Cushing syndrome, hyperthecosis, ovarian and adrenal 
tumors, hyperprolactinemia and severe insulin resistance, as well as androgenic drugs, 
whose incidence among all hyperandrogenism causes is 5-7% (1,7,57,59). 
Legro 2013/2014 
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There are ongoing debates about the significance of PCOM (and phenotype D) and 
whether it should be included in the syndrome. Such occult PCOS involves mild 
changes and minimal metabolic risks, but the finding is significant to reproductive 
endocrinologists considering the difficulties in infertility treatment and risks for the 
ovarian hyperstimulation syndrome (OHSS). PCOM is more frequently expected to 
occur in women with infertility. Detailed work-up will identify mild biochemical and 
hormonal disorders, and a higher sensitivity of follicles to FSH can be expected. AMH is 
a surrogate marker for PCOM and may be a discriminatory finding for hypothalamic 
anovulation and hyperprolactinemia (which have PCOM in 30-50% of cases) (64-77). 
 
Formerly, the traditional PCOM criterion was the ultrasound finding of more than 12 
antral follicles (AF 2-9 mm) in one or both ovaries. With improved precision and 
resolution levels of today's ultrasonographic devices, a count of more than 25 AF (20 
AF) per ovary (follicular number per ovary - FNPO) is proposed as the new criterion. 
This type of precise diagnostics requires the use of a vaginal probe (≥ 8 MHz), a 
multiple section scan, a grid section system, or an automated sono-AVC (56,59). 
Additional ultrasonographic criteria for PCOM (ovarian morphology) are ovarian volume 
(OV) > 10 ml, stromal volume > 7ml, and ovarian area > 5 cm2. The ratio of ovarian 
stroma and ovarian area is higher than 0.32. 
 
In classic PCOS, antral follicles with a diameter of 2–5 mm dominate, and antral 
follicular count (AFC) is 5 to 10 times higher than in the normal population. The count of 
small 2–5 mm AFs strongly correlates with HA, while those with a diameter of 6–9 mm 
is less strongly correlated (table 11). 
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Table 11.    Ovarian reserve findings in different populations 
Population Follicle number(per ovary) AMH pmol/L 
Ovarian 
volume 
(ml) 
Normal 12-20 10-20 5-9 
PCOM 22-30 40-60 10-12 
PCOS 
-ovulatory 
     -anovulation 
      -amenorrhoea 
 
25-30 
35-80 
> 70 
 
30-50 
60-100 
> 80 
13-22 
According to these criteria, in our (peri-Mediterranean) region the incidence of PCOS is 
15-22%, and in infertile patients the incidence is even higher. The question whether 
PCOS confers a predisposition to obesity or vice versa remains unanswered. 
Obesity and adipose tissue dysfunction are closely related to the polycystic ovary 
syndrome (PCOS). It has been established that 40-50% of obese women develop 
PCOS, while 60% of PCOS patients are obese. Women with a pronounced syndrome 
have more adipose tissue in the upper body, with expressed abdominal (visceral 
obesity).  
The following obesity and PCOS relationships have been established (70-75): 
• the prevalence of PCOS in obese women is 30-40% 
• obesity in 50-75% of women with PCOS 
• abdominal (central) distribution of obesity in 50-60% of women with PCOS 
• gynecoid distribution of AT in only 30% of women with PCOS; most women 
exhibit abdominal (visceral) obesity. 
• lean women with PCOS may have an increased amount of visceral fat 
• 70-90% of obese women with PCOS exhibit insulin resistance (IR) 
• 30-50% of lean (normal) women with PCOS have IR 
• chronic inflammation occurs in both obesity and PCOS 
• WC > 88 cm in 83% of PCOS patients. 
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There are studies pointing to a high prevalence of AT disorder in PCOS patients 
(75,77): 
• 85% of women with PCOS are overweight or obese (USA, Australia) 
• 83% of PCOS patients in the United Kingdom have a WC > 88 cm (abdominal 
obesity) 
• 65% of abdominal obesity (visceral) is accompanied by PCOS in Italy and USA 
 
Prevalence and clinical expression of PCOS are predominantly induced by obesity. In a 
meta-analysis of 21 studies, the prevalence of obesity in PCOS patients was 61% (75). 
The risk for PCOS increases by 9.2% for each BMI unit (BMI above 25) (73). There is 
evidence that elevated BMI is associated with more frequent and severe abnormalities 
of the cycle and more pronounced hyperandrogenism. There is no doubt that high BMI 
and visceral obesity increase insulin resistance (IR) with known consequences. The 
molecular mechanism of insulin resistance in obesity (and type 2 DM) is different from 
that in PCOS patients. In PCOS patients, insulin sensitivity is primarily exhibited in 
skeletal muscles, while hepatic IR is exclusive to obesity (with or without PCOS) 
(77,78).Both syndromes act in synergy to promote IR and the metabolical syndrome 
expression. 
 
Obesity, PCOS and hyperinsulinemia significantly affect the reproductive function. 
Different PCOS phenotypes carry different risks, which are highest with 
hyperandrogenemia and oligomenorrhea/amenorrhea. Metabolic and reproductive risks 
are further increased by adiposity. Such phenotypes are also the main risk factors for 
glucose intolerance, gestational and type 2 diabetes mellitus (DM), dyslipidemia and 
hypertension (78-86). 
 
Defective insulin signalling in PCOS consists of a 30% decrease in insulin receptor (IR) 
phosphorylation in adipocytes, elevated serine phosphorylation in fibroblasts in 50% of 
patients and lower phosphoinositide-3 kinase activity in muscle cells. Hyperinsulinemia 
is the main cause for PCOS, but a synergistic effect of insulin on steroidogenesis in 
ovarian theca cells has also been recorded. Adrenal steroidogenesis in PCOS 
contributes to hyperandrogenemia. Visceral adipocytes are involved in local 
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steroidogenesis as they possess the enzymes 3βHSD, 17βHSD, 11βHSD and 
aromatase (87,94). 
Visceral adipocytes exhibit a higher sensitivity to lipolysis, i.e. in PCOS the activities of 
protein kinase A and hormone sensitive lipase are increased. In PCOS adipocytes have 
an increased capacity for steroidogenesis and stronger conversion of androstendione to 
testosterone. Visceral adipocytes can convert cortisone into metabolically active 
cortisol. Increased testosterone and cortisol additionally stimulate central obesity and 
IR. As the production of SHBG is reduced, levels of free T and free E2 in the circulation 
increase. 
 
Adipokine disorder can occur in PCOS. Leptin levels and leptin resistance can be 
higher. There is an increase in the levels of TNF-α, IL-6 and PAI-1, which are involved 
in the paracrine activity of adipocytes, as well as ovarian and adrenal stimulation. 
In obese and PCOS patients, the production of adiponectin is lower, which also plays a 
role in IR. Resistin is significantly elevated in these patients, especially in case of 
anovulation, which is associated with the paracrine control of insulin resistance. Resistin 
also increases the activity of P450C17 in theca cells, which is an additional incentive for 
ovarian contribution to hyperandrogenism. 
 
Yildiz and Azziz (73) found the impact of obesity on the prevalence of PCOS to be 
minimal. However, they found the average BMI in the PCOS population to be 37.3 
kg/m2. The prevalence of obesity (BMI≥30 kg/m2) in their PCOS population was 74%. 
In obesity and elevated BMI there is a higher incidence (with PCOS) of menstrual 
irregularity (oligomenorrhea/amenorrhea), together with elevated levels of total 
testosterone (T), free T and free androgen index. At the same time, the levels of sex 
hormone binding globulin (SHBG) in these patients are lower. Some researchers point 
to a more frequent occurrence of ovarian cysts in obese patients. 
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In PCOS patients, obesity is associated with (68,70,71,72,80): 
• elevated insulin and insulin resistance (IR) 
• elevated cholesterol and LDL, lower HDL 
• elevated blood pressure 
• central obesity – lower SHBG and higher T, higher IR 
• findings of association with hirsutism are not consistent 
• hepatic IR 
• central obesity has a higher lipolysis rate, and therefore elevated free fatty acid 
levels in the portal vein. 
•  
Hyperandrogenism is a disorder that is inherent to PCOS and is further modified and 
amplified by insulin resistance.According to the current classification of syndromes and 
reproductive indicators, we distinguish between: 
 
• polycystic ovary syndrome (PCOS), where the above-mentioned phenotypes 
are expressed 
• polycystic ovary morphology (PCOM), where only polycystic ovaries are 
expressed. 
In PCOS, insulin exhibits synergism with the luteinizing hormone (LH) in stimulating the 
synthesis of ovarian androgens. Insulin also increases the sensitivity of granulosa cells 
to follicle-stimulating hormone (FSH), which increases the number of antral follicles. 
They are kept in a state of arrest by increased levels of intraovarian androgens and 
high AMH. For this reason, all circumstances including hyperinsulinemia may result in 
PCOS. Abdominal obesity (and obesity) induce the secretion of adipokines, which have 
a direct effect on the ovaries and the adipocyte metabolism. Hyperandrogenism is a 
result of androgen synthesis in the ovaries, adrenal gland and adipose tissue. Increased 
androgen levels and environmental factors (abdominal and general obesity, insulin 
resistance) result in PCOS. 
Chronic exposure to elevated androgens (in utero) alters gene expression and leads to 
the PCOS phenotype. In this way, increased androgens and androgen-induced obesity 
become a circulus vitiosus for PCOS (64,66,69,80). 
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The risk of infertility is 3 times higher in obese women and 15 times higher in women 
with PCOS.  
 
The main reproductive risks in obesity and PCOS are: 
• anovulation 
• impaired folliculogenesis, oogenesis 
• non-receptive endometrium 
• multiple pregnancies (with treatment) 
• early miscarriages 
• obstetrical risks; gestational DM; hypertension; preeclampsia; delivery 
• neonatal risks 
1.3 Obesity and ovarian reserve 
 
Ovarian reserve is the overall capacity of the ovaries for healthy folliculogenesis and 
oogenesis.Ovarian reserve is determined by several types of factors: 
• age 
• genetic factors 
• epigenetic effects 
- obesity 
- PCOS 
- environmental endocrine disruptors 
• diseases 
- endometriosis, inflammation, tumors 
- malignant 
- autoimmune 
• ovarian surgery 
• treatment 
- radiation 
- chemotherapy 
- other. 
 
Of the many tests used to determine ovarian reserve (OR), those routinely applied are: 
basal follicle-stimulating hormone (FSH) level, anti-Müllerian hormone level (AMH) and 
number of small antral follicles in reserve (AFC – antral follicle count). Additional OR 
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markers are ovarian volume and levels of inhibin B and estradiol. Ovarian reserve 
markers are not only a powerful predictor of fertility, but also of infertility treatment 
success. Today they are an indispensable indicator of the reproductive potential. 
Findings on the qualitative value of ovarian reserve markers are inconsistent because 
age diminishes the competence of oocytes which can be present in sufficient numbers. 
Tests consist of biochemical analysis and ultrasonographic ovarian evaluation. Age and 
epigenetic factors have the highest impact on ovarian reserve (81-100). 
Characteristics of the menstrual cycle (MC) may serve as a simple indicator of ovarian 
reserve and fertility. Short MC (≤ 23 days), shortening of the cycle, and increasingly 
scanty periods usually indicate a drop in or low ovarian reserve (101-105). 
 
The level of basal FSH, a pituitary glycoprotein hormone, is determined on day 2 or 3 
of the cycle (in case of long-term oligomenorrhea/amenorrhea the day is not important). 
Values above 10 IU/L indicate lower OR, while levels ≥ 18 IU/L are an indicator of 
primary ovarian insufficiency and inability to conceive. In addition to basal FSH, blood 
estradiol (E2) levels are also determined, supplementing the findings about cycle quality. 
Basal E2 ≥ 70 pg/ml is an unfavourable sign for reproduction and accompanies 
increased FSH levels (1,7,100,101). 
 
Anti-Müllerian hormone (AMH) is a representative of the TGF-β superfamily. 
Produced by the granulosa cells of preantral and small antral follicles (2-7 mm), its 
functions are both autocrine and paracrine. It controls the recruitment and growth of 
antral follicles with primarily inhibitory effects. AMH inhibits recruitment, FSH activity, 
and aromatase. It is an important controller of steroidogenesis and the selection-
dominance mechanism in folliculogenesis. The AMH levels vary minimally throughout 
the cycle, with the pill or ovulation stimulation. Therefore, it is today considered as the 
most reliable marker of ovarian reserve. It is a measure of the quantity of oocyte reserve 
(follicles), but not its quality. It is a reliable predictor of success and risks of ovulation 
stimulation (OS), as well as of female fertility. It works via Type 1 and Type 2 receptors 
with 3 transmembrane domains. As an expression of the functional reserve of the ovary, 
AMH is an indicator of follicles that can react to FSH. Also, AMH synergizes with LH and 
insulin in stimulating androgen production. Its normal serum levels are 12-20 pmol/L. 
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There are 4 generations of AMH laboratory tests, which can deliver different results (± 
20%):   DSL, Beckman coulter I and II, Elecsys (Roche). Today, the best (and 
compatible) are BCII and Elecsys (108,109,110). 
 
Antral follicle count (AFC) is the sum of follicles displayed by the ultrasound with a 
mean diameter of 2 to 10 mm in both ovaries. This measure has a good inter-cycle 
reliability with similar results in experienced diagnosticians. The administration and 
evaluation of the test changes with technological advances and resolution of modern 
US devices. That is why today AFC ≤ 9 is considered low, while the count of 10-20 
antral follicles of that size is normal. AFC is a quantitative, rather than a qualitative 
measure of follicles (oocytes). 
 
The expected ovarian response to ovulation stimulation is determined based on AMH 
and AFC ovarian reserve markers. The response may be: 
• poor ovarian response (POR) 
• normoresponse (NR) 
• high response (HR) 
Ovarian reserve markers are neither a reliable predictor of definitive fertility nor infertility 
treatment. These markers are directly related to natural fertility indicators and all 
negative effects on the ovaries. Evidence of poor ovarian reserve (POR) is associated 
with a small number of oocytes, poor response to treatment, frequent discontinuation of 
treatment and low success rate and live birth rate (fig 10). 
 
 
 
 
 
Figure 10. Ovarian reserve with aging, AFC - antral follicle count; AMH - anti-Müllerian 
hormone 
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AFC and anti-Müllerian hormone are good PCOS markers as numerous antral follicles 
in reserve exhibit particularly high values in patients with this syndrome. 
 
Interestingly, most analyses show that obesity is negatively correlated with AMH, while 
in PCOS/PCOM the anti-Müllerian hormone is significantly elevated. AMH is also higher 
with elevated androgens. Obese patients with PCOS also have lower AMH than normal 
weight patients. The highest values of ovarian reserve markers are found in PCOS 
patients with amenorrhea, hyperandrogenism and normal BMI (see table 12). 
 
Table 12. Approximate values of ovarian reserve markers and incidence in infertile 
population (some groups overlap in terms of prevalence), POR - poor ovarian response; HR - 
high response; PCOM - polycystic ovary morphology; PCOS - polycystic ovary syndrome 
 
Characteristic 
Patients 
FSH 
IU/L 
AMH 
pmol/L 
AFC oocyte number 
IVF 
Prevalence 
Normal 4-8 9-20 9-20 5-14 40 % 
POR 8-11 ≤ 8 ≤ 8 ≤ 3 16 % 
HR 3-5 > 20 > 20 ≥ 15 15 % 
PCOM 3-5 30-60 20-30 ≥ 20 15 % 
PCOS 
● normal cycle 
● oligomenorrhoea 
● amenorrhoea 
2-4  
50 
80 
≥ 100 
> 25 ≥ 25 30 % 
Obesity 4-8 10-20 10-20 4-12 30 % 
 
We used the most frequently cited data in literature to illustrate in the figure the findings 
concerning ovarian reserve markers in the infertile population of women 
(81,88,90,93,97,101,102,106). 
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Obesity - consequences and comorbidity 
The described pathophysiological changes of adipose tissue and adiposity have a 
strong effect on energy imbalance, metabolism and reproductive capacity. Today, 
obesity is on the rise as the most important factor of cardiometabolic risk and mortality. 
The relationship between complex AT functions and control centers in the CNS and 
peripheral organ systems and tissues undoubtedly exerts influence on energy 
homeostasis, metabolism, immune system and gonadal function. 
It has been shown that there is a close association between obesity and the metabolic 
syndrome (MS). The metabolic syndrome, i.e. energy imbalance, affects the control of 
the cycle and reproduction. The onset of puberty is delayed by excessive leanness and 
accelerated by obesity. The disturbed gonadal function further stimulates MS. Poor 
energy homeostasis affects the production of steroids and ovarian peptides, which 
hinder the function of adipocytes and induce insulin resistance (43,44,45,46,47). 
 
Metabolic syndrome and other health risks in obesity 
Nearly 300,000 people die annually in the US due to obesity. Adiposity comorbidity 
includes diabetes, dyslipidemia, cardiovascular disease, hypertension, obstructive sleep 
apnea and some types of cancer. Generally, excessive BMI has a strong impact on 
health (83,101,107). 
Metabolic syndrome (MS) has several definitions (according to the WHO and 
professional associations) depending on which component of the disorder is 
emphasized. According to the WHO, it is a combination of the following: 
• presence of diabetes mellitus (DM), elevated blood glucose, glucose intolerance 
or insulin resistance, and 2 of the following additional criteria: 
• abdominal obesity (WHR > 0.90 men; > 0.85 women) or BMI > 30 kg/m2 
• elevated triglycerides 
• low levels of high-density lipoprotein (HDL) 
• albumin excretion (proteinuria) 
• hypertension. 
Other definitions emphasize elevated BMI, WC and most importantly visceral obesity. 
Specific health risks include cardiovascular disease and type 2 DM. Also associated 
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with MS are hyperuricemia, fatty liver, PCOS, erectile dysfunction and acanthosis 
nigricans. Global prevalence of the metabolic syndrome is 20-30%. 
 
The relationship between visceral obesity, white adipose tissue (WAT) and its 
dysfunction, and general and liver insulin resistance (IR) has already been explained. 
Central and peripheral energy homeostasis disorder, and adipokine imbalance (leptin, 
adiponectin, resistin) induce IR and hyperinsulinemia. Insulin and adipokines steer 
ovarian steroidogenesis towards androgens, which provide in that closed circuit an 
additional stimulus for IR. Hyperinsulinemia reduces SHBG production in the liver, 
resulting in higher free testosterone and estradiol levels. High insulin levels impact the 
imbalance of TG transforming enzymes (LPL, HSL) and expression of PPARγ, which 
leads to visceral lipogenesis. The brain modulates the peripheral lipid and glucose 
metabolism and is therefore important for MS development (87,94,101). 
 
Pathophysiological changes in adipose tissue further disturb and amplify PCOS. Apart 
from contributing to IR, PCOS intensifies menstrual cycle disorders and leads to 
oligoanovulation. Absolute and relative elevation of estrogen (estrone and free E2) 
levels without counteracting progesterone effects creates a risk for pathological 
changes of the endometrium - polyps, hyperplasia and endometrial cancer. 
 
The described changes of visceral adipose tissue induce accelerated atherogenesis 
and cardiovascular diseases This risk is indicated by the inflammatory marker CRP 
(high sensitivity CRP is determined). Low adiponectin is a silent indicator of visceral 
adiposity and the risk for atherosclerosis and MS, i.e. cardiometabolic risk. 
Dysfunctional adipose tissue with adipokine and FFA metabolism disorder leads to 
ectopic fat accumulation in the muscles, liver and epicardium. 
 
All the described changes may cause early coronary heart disease (CHD) and stroke. In 
metabolic syndrome, the risk of type 2 DM, which is considered a complication of MS, is 
five times higher. The prevalence of metabolic syndrome in female patients with CHD is 
above 50%. 
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1.4  Obesity and reproduction 
 
Obesity has a strong negative effect on human reproduction, equally in men and 
women. Obese women have elevated risk of subfecundity and infertility, especially due 
to frequent association with polycystic ovary syndrome. Obesity affects the dysfunction 
of all fertility levels: natural, induction of ovulation, in vitro fertilization (IVF), donation 
programs. It has been found that reduced fertility is more pronounced with excessive 
BMI, central obesity and more severe PCOS forms. Obesity and hypogonadism reduce 
male fertility (109-123). 
 
Interpretations of the pathophysiology of obesity (and PCOS) distinguish between 
central and peripheral disturbances that impair fertility. 
 
The hypothalamic control of energy homeostasis and reproduction includes the 
following disturbances in obesity: 
• elevated leptin and insulin levels have a negative effect on the relationship 
between POMC (αMSH)/neuropeptide (NP-Y-AgRP) and kisspeptin 
• estrogen-androgen imbalance affects stimulation or inhibition of GnRH neurons 
• the concentration of kisspeptin is negatively correlated with BMI, insulin 
resistance and FAI 
• ghrelin suppresses the expression of KISS1 and inhibits the secretion of LH 
(GnRH) 
• LH activity (pulsatility) is decreased by obesity and increased by PCOS 
• adipokines, insulin, CRH and steroid hormones additionally disrupt the functions 
of brain opiates, dopamine, autonomic nervous system, and endocannabionid 
system 
• disturbed neurosecretion of GnRH translates into gonadotropin dysfunction 
(level, isoforms, activity, pulsatility) 
• this results in pubertal disorders, menstrual cycle disorders, oligoanovulation and 
potentially amenorrhea. 
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Increased leptin and endocannabinoid system activities have a negative effect on the 
central control of reproduction. 
 
Peripheral disturbances that impair fertility in obese (and PCOS) female patients are: 
• lower (or disturbed) FSH and LH activity in obesity and PCOS (↑LH and pulses) 
• negative correlation of BMI, visceral fat, waist circumference with FSH and LH 
• effect of insulin and adipokines on liver (SHBG, IGFBP-1) and ovarian (follicles) 
function 
• reduced SHBG and increased testosterone levels in central obesity 
• impaired folliculogenesis due to elevated androgen production (ovary, AT) and 
elevated free testosterone, leading to anovulation and follicular arrest 
• reduced oocyte biosignals (GDF-9 and BMP-15), elevated IGFBP-4 
• AMH and inhibin B: lower in obesity, significantly elevated in PCOS  
• positive correlation of AMH with insulin resistance, free T, cholesterol 
• inhibition of steroidogenesis, oocyte maturation and endometrial transformation 
affected by elevated leptin levels in the ovaries 
• compromised endometrial receptivity caused by obesity and PCOS  
• follicle functions undoubtedly affected by obesity and PCOS 
- differentiation, growth, steroidogenesis, gametogenesis 
• changed hemostasis factors and increased tendency to thrombosis (venous and 
arterial) in obesity and PCOS. 
 
Adipose tissue affects steroidogenesis disorders in all sources of production and the 
bioavailability of steroid hormones. As already described, obesity is accompanied by a 
dysfunction in the conversion of prehormones to androgens and estrogens in 
adipocytes. There is also a direct effect on steroidogenesis in follicular granulosa and 
theca cells, and a reduction in the peptide transporter (SHBG) of steroid hormones in 
the circulation.  
 
Obesity is characterized by hypersecretion of LH and elevated LH/FSH ratio, as well as 
increased pulse frequency with reduced amplitudes. This is particularly pronounced in 
obese persons with PCOS. Increased insulin reduces SHBG, ovarian IGF binding 
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protein-1, and increases the levels of ovarian androgens. Also, elevated TNF-α (with 
obesity) is an independent inhibitor of SHBG (1,7,40,110). 
 
Central and peripheral disturbances in obesity and PCOS interfere and are 
complemented by other epigenetic effects. This results in several consequences for 
reproductive capacity (Fig 11 and 12). Intrauterine impacts of obesity, endocrine 
disruptors and transgenerational transfer of abnormalities should also be considered. 
Since mother's obesity may cause child macrosomia, there is a 25% higher risk for 
childhood and adolescent obesity. Intrauterine exposure to androgens can cause 
intrauterine growth retardation (IUGR), later catch-up growth of the child, juvenile 
visceral obesity and hyperandrogenism. Obesity and endocrine disruptors are 
characterized by the ability of vertical, transgenerational, transfer of foetal gamete 
damage. Elevated androgen and AMH levels in utero cause subsequent development of 
PCOS phenotypes. 
 
Figure 12. Influence of obesity on reproduction (women) 
 
Obesity and PCOS in the mother increase the likelihood of the daughter later 
developing hyperandrogenism and PCOS phenotype. 
 
Menstrual cycle abnormalities are common in obesity, central obesity and PCOS. The 
amount of adipose tissue is associated with events in female puberty. Obesity induces 
early onset of menarche and PCOS can be the primary and long-term cause of 
menstrual cycle inhibition. Irregular cycles occur more frequently in obese adolescents 
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compared to those with normal weight (54% vs. 19%). Obese women have longer 
cycled, and 40% have cycle and bleeding disorders. Women with oligoamenorrhea 
have higher BMI, WC and higher insulin levels compared to women with normal cycles. 
Obesity and IR are associated with earlier menarche and anovulation and disturbed 
luteum function. Obese adolescents are at a significant risk of infertility later in life (OR 
2.84 CI 1.59-5.10). The Nurses' Health Study reported that in 2527 women a correlation 
was found between anovulatory infertility and elevated BMI (> 26 kg/m2) with a relative 
risk of 1.7-2.7 depending on the degree of obesity. In the same population (study), a 
significantly higher risk of anovulatory infertility was found in obese women (RR 3.1 CI 
2.2-4.4) than in women with normal BMI (1,7,50,109,110). 
A Danish study found that each increase in WHR by 0.1 units results in the fecundity 
rate drop by 30% (HR 0.70 CI 0.56-0.88). Other studies also point to reduced fecundity 
(probability of pregnancy in a single cycle) in obese women – OR 0.69 and OR 0.82 (CI 
0.72-0.95) compared to normal BMI. Time to pregnancy is also longer in obese women 
(longer than 1 year) OR 1.32 (CI 1.26-1.37) (50,110). 
 
 
 
 
 
 
 
 
 
Figure 13. Body mass index and fecundity in normal and PCOS women(Fecundity - 
probability of pregnancy per month), Central obesity (WHR> 0.85 / WC≥90 cm) 
significantly reduces fecundity – OR 0.80 (CI 0.59-1.0). 
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Pregnancy in obese women, regardless of whether it is natural, through ovulation 
induction or in vitro fertilization (IVF), is more frequently terminated by early 
miscarriage. Most studies show that after anovulation treatment, or in vitro fertilization, 
obesity increases the risk of miscarriage: 
OR 1.69 (CI 1.13- 2.51) Norwegian study 
OR 1.53 (CI 1.27-1.84) Meta-analysis Maheshwari 2007 
OR 1.67 (CI 1.25-2.25) Meta-analysis Metwally 2008 
OR 2.7 (CI 1.5-4.9) ET 1 blastocyst / Rittenberg 2011 
OR 1.31 (statistically significant) Meta-analysis of 33 IVF studies / Rittenberg 
2011 
These studies compared obese patients with those with normal BMI who were treated in 
the same way (50,110,111,112).Obese IVF patients exhibit relative gonadotropin 
resistance. 
There is an extensive literature that has consistently confirmed the negative effects of 
obesity on oocyte quality, which has been consistently supported by extensive 
literature. Obese patients treated with IVF have several intra-follicular disorders, 
elevated insulin, triglyceride, inflammatory marker and androgen levels, which change 
the function of the mitochondria and endoplasmic reticulum, granulosa and theca cells 
as well as the signalling of oocyte maturation. Such changes are more frequently 
accompanied by apoptosis, immature oocytes and aneuploidy (125-140). 
The fact that in obesity (BMI> 40 kg/m2) the chance of IVF pregnancy is reduced by 
50% is also an indication of lipotoxicity to follicles and oocytes (116,124). 
 
In obese IVF patients, ovulation stimulation takes longer, the dose of gonadotropin is 
higher, the cancelled cycles rate is higher and less oocytes are aspirated. Adiposity and 
dysfunctional AT are believed to accumulate hormones, while leptin changes the FSH 
response and paracrine activities (IGF system, AMH, BMP) that control ovarian 
steroidogenesis and oocyte maturation. Adipose IVF patients have smaller oocytes and 
significantly fewer metaphase II oocytes resulting in lower fertilization rates. Some 
researchers believe that obesity additionally impairs the development of the embryo, 
which in the blastocyst stage has fewer cells and disrupted TG, glucose and amino 
acids catabolism, more frequently leading to embryonic arrest. These findings are not 
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consistent because more comprehensive IVF cycle studies have demonstrated a 
minimal effect of obesity on oocytes and embryos. Today, however, an increasing 
amount of research shows that an BMI > 25 (30) is related to a significant reduction (-10 
to 15%) of the fertilization rate, which is a surrogate marker for oocyte quality (126,127). 
 
The effect of obesity on endometrial receptivity is also unclear due to inconsistent 
study findings. It has been found that obesity is associated with disturbed expression of 
endometrial implantation genes. This includes defective decidualization and placental 
dysfunction, as well as evidence of a negative correlation between BMI and endometrial 
leukemia inhibitory factor (LIF). In obese patients, implantation disorders and repeated 
miscarriages are a consequence of abnormalities in leptin and insulin signalling and 
elevated estrogens in obese patients. Hyperinsulinemia lowers local glycodelin and 
IGFBP-1 levels.  
 
Obesity also increases pro-inflammatory cytokines, which negatively affect implantation. 
Controversies over the significance of the relationship between obesity and endometrial 
receptivity have been resolved by steering research towards the oocyte donation model. 
This allows to establish whether obesity has an effect on oocyte/embryo or the 
endometrium. In 2656 cycles with donated oocytes, a lower ongoing pregnancy rate 
(OPR) was found in obese recipients of quality embryos (36.1% vs. 45.2% OPR). In a 
donor program with 22,000 patients, Provost et.al. (116). found that obesity in recipient 
patients was linked to reduced clinical pregnancy rates (CPR) – OR 0.78 (CI 0.69-0.87). 
In case of morbid obesity, live birth rate (LBR) was 40% lower (OR 0.64 - CI 0.51-0.81), 
and pregnancy loss rate was twice as high (15.9% vs. 8.6%). It has been concluded that 
obesity has a detrimental effect on embryo-endometrial dialogue. Bellver et al. 
(118,127). did not establish that obesity reduced the quality of the embryo, but the 
results of 9587 first ovum donation cycles showed that obesity progressively reduced 
implantation, CPR and LBR. Obese recipients have significantly lower LBR (27.7% vs. 
38.65) - OR 0.73 (CI 0.66-0.80), while the incidence of early miscarriage is the same. In 
surrogate procedures, LBR is 15% lower in obese recipients (133,134).  
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The relationship between obesity and embryo can be significant if it is assumed that 
excessive adipose tissue negatively affects oocyte maturation. In this regard, findings 
on the reduction of embryo quality are inconsistent. Approximately the same number of 
studies that supports either assumption is available, but evidence is weak, and it cannot 
be concluded that obesity affects the quality of embryos. It has been found that 
cryopreservation of embryos is twice as frequent in patients with normal weight than in 
obese patients (22.7% vs. 10.7%). Retrospective analysis of 6500 IVF cycles has not 
shown differences in embryo quality and freezing possibilities between obese and 
normal BMI patients. However, IVF in obese patients seems to create embryos of 
inferior quality, that formation of the morula is quicker, and that the blastocyst has lower 
cellularity. Negative effects on the embryo are exerted by leptin and FFA lipotoxicity. 
There is no correlation between obesity and embryo aneuploidy (125,126,123). 
 
Results of assisted reproductive technologies (ART) in obese patients are inferior to 
those in women with normal BMI. There is ample evidence that lower LBR is associated 
with higher BMI. Ovulation stimulation (OS) in adipose women (8145) undergoing IVF is 
characterised by a need for higher FSH doses, follicular asynchrony, higher cancellation 
rates, fewer oocytes. Higher doses and OS duration are explained by higher FSH 
threshold, absorption and metabolism of gonadotropins (relative gonadotropin 
resistance). There is a positive correlation between obesity and the amount of 
gonadotropin, with obese patients needing on average 771 IU of FSH more than normal 
weight patients (114,121,124,133). 
 
OS success is lower if WHR is higher (OR 0.60; CI 0.40-0.89), and in case of high BMI, 
ovulation rates are significantly lower - OR 0.44; CI 0.31 to 0.61. With each unit of BMI 
increase above 29 kg/m2, the rate of spontaneous pregnancy is decreased by 4%. 
 
In terms of lower IVF success in obese patients, findings are consistent (though not 
entirely). In two retrospective studies on 3586 and 2660 women, a significantly lower 
LBR was found in obese women (BMI > 30 kg/m2) - OR 0.73 (CI 0.57-0.96) and OR 
0.75 (CI 0.57-0.98). Central obesity (WHR > 0.8) significantly lowers CPR, i.e. by 58%. 
Meta-analysis of 33 IVF studies determined that obesity reduces the success rate - 
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CPR and LBR (RR 0.84). A recent study of 4609 women shows that an BMI above 30 
kg/m2 statistically reduces LBR by 37%, while an BMI ≥40 kg/m2 reduces LBR by 68% 
(133,134,137). 
 
In a study with 45,163 ART embryo transfers, Luke et al. (132). found that the freqency 
of the failure to achieve pregnancy is significantly higher in obese women. Failure to 
achieve pregnancy increases with increasing BMI - the probability of failure increases 
by 48% to 64% depending on obesity category. 
 
Obesity and PCOS occur together in 50-70% of patients, and as emphasized earlier, 
syndrome expression is increased with obesity. For this reason, obese women with 
PCOS exhibit a more severe syndrom phenotype with corresponding consequences. 
These patients have a high prevalence of menstrual cycle disorders (78%). 
Reproductive disorders are especially pronounced in PCOS patients with central 
obesity. Ovulation stimulation is compromised and more difficult, withdrawal rates are 
higher, and probability of ART success is reduced. There is a high risk of miscarriage – 
OR 3.05 (CI 1.45-6.44) due to combined pathophysiological disorders of obesity and 
PCOS. Anovulatory PCOS is associated with a more pronounced visceral obesity – 
average waist circumference is 93 cm (7 cm more than in PCOS patients with 
ovulation). Obese patients with PCOS have a 77% lower chance of pregnancy after ET 
than lean PCOS women (OR 0.23; CI 0.08-0.68). The odds ratio for live birth rate is 
similar (OR 0.29). Obesity combined with PCOS reduces the risk of ovarian 
hyperstimulation syndrome (OHSS). Morbid obesity further reduces CPR in PCOS 
patients (134,135,137). 
 
Congenital abnormalities are more common in children of obese mothers. Extensive 
epidemiological studies have shown that children of obese women have a more 
frequent incidence of heart conditions, disorders in the development of the neural tube, 
palate, and front abdominal wall as well as multiple anomalies. Absolute risk for these 
defects is low (127,134). 
Fetal abnormalities are associated with maternal metabolic disorders. 
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There is uniform evidence that a reduction in AT or body weight significantly improves 
metabolic and reproductive indicators. Traditionally, a reduction in body weight by 5% is 
believed to improve fertility, but there is still disagreement in that respect (136,138). 
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2.HYPOTHESIS  
 
Through this prospectivestudy, it has been proposed to do comparation and evaluation 
of theimpactof overweight andobesity of women’s in the reproductive age(≥23 y ≤ 38 y), 
in ovarian reserve and their reproductivefunctions, making comparisonbetween the two 
observed groups with ( BMI 25-29.9 kg/m2 and BMI ≥30 kg/m2),with control group  BMI 
18-24.9 kg/m2, measuring values ofhormones such are FSH, LH, Estradiol, AMH, 
Testosterone, SHBG, TSH, HbA1C, on day 3 of menstrual cycle and by ultrasound 
measuring of AFCand ovaries-volume's. 
Hypothesis: The ovarian reserve markers are disturbed more frequently in overweight 
and obesity group of infertile women than in infertile women with normal BMI and the 
standards and procedures for estimation of ovarian reserve in infertile women will be 
simplified for using in Kosovo health care conditions. 
3. AIMS AND THE PIRPOSE OF THE RESEARCH 
In line with the hypothesis the aim of the study is evaluation of the impact of overweight 
and obesity in ovarian reserveand doing comparison between three observed groups 
with different  BMI, changes in the values of hormones levels of and measurement of 
ovaries-volume’s and AFC, in follicular phase of menstrual cycle in infertile women’s of 
Kosovo population and based on the results of the comparison, the model of decision 
making for treatment of infertile women will be developed. 
SPECIFIC  OBJECTIVES 
• To do comparison between three observed groups with different BMI, changes in the 
values of hormones levels of and measurement of ovaries-volume’s and AFC, in 
follicular phase of menstrual cycle in infertile women’s of Kosovo population. 
 
• Based on the results of the comparison, the model of decision making for treatment 
of infertile women will be developed 
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4. MATERIALS AND METHODOLOGY 
 
This is a prospective cross-sectional cohort study (observational) on 182 women 
participants recruited during 2,5 years in infertility clinics in Kosovo (n=126) and 
Polyclinic IVF Zagreb (n=56). Primarily, we analysed 268 infertile patients who came on 
first visit and workout, but complete results we were able to collect for 182 women. 
Ethical boards of clinics involved in this investigation approved the study. 
All participants were informed about the study and signed the written consent form for 
participating in it. 
4.1 Observed outcomes measures. 
 
In a desire to research the impact of obesity on the ovarian reserve and some of the 
indicators of fertility, all women are grouped in 3 categories according to body mass 
index (BMI): 
Table 13. Three groups of patients according to BMI 
 
  I group      normal BMI                  18,5 – 24,9 kg/m2           –        64 patients 
 II group      overweight                   25    - 29,9 kg/m2           –        56 patients 
III group      obese                                      ≥ 30 kg/m2                -        62 patients 
We also investigated some effects of morbid obesity (BMI ≥ 40 kg/m2) on the indicators 
of fertility. We have also analysed the incidence of central (abdominal) obesity and its 
impact on the ovarian reserve. 
In the researched population of infertile women there are 52 patients with PCOS - 15 
patients with normal BMI; 16 PCOS patients were overweight, and 21 PCOS patients 
were obese. We performed anthropometric measurements on all patients, analysed 
the characteristic of the menstrual cycle, indicators of lowered fertility and detailed 
hormonal analysis.  
We connected these findings with indicators of ovarian reserve and determined the 
effect of obesity on the analysed hormones. 
Women with normal BMI, without PCOS, were the control group.  
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4.2 Inclusion criteria 
 
Infertile women aged 23 to 38 years, with BMI from 18,5- more than 30 kg/m2. Primary 
or secondary infertile PCOS women regardless BMI. Participants with poor response on 
infertility therapy, and patients with metabolic syndrome and glucose intolerance risks. 
Secondary infertile women with previous spontaneous abortions or deliveries. 
4.3 Exclusion criteria 
 
Women younger than 23 and older than 38 years. Infertility because of uterine 
anomalies, tubal factor, severe endometriosis, genetic and autoimmune diseases. 
Women with bariatric surgery, and patients with ovarian or uterine tumours, general 
endocrine diseases (pituitary, adrenal, thyroid) or diabetes mellitus type 1. Patients 
infertile because of husbands (partners) azoospermia. Also, a patients on hormonal 
medications were excluded (except those with subclinical hypothyroidism). 
4.4Definitions and measurement 
4.4.1 Infertility 
 
According to World Health Organization (WHO- human reproduction programme 2016): 
Infertility is disease of reproductive system defined by the failure to achieve a clinical 
pregnancy after 12 months or more of regular unprotected sexual intercourse. Infertility 
prevalence is 15-17%. 
We distinguish primary infertility when pregnancy is not achieved and secondary 
infertility after history of at least 1 pregnancy.  
Fecundability and fecundity is the probability of achieving pregnancy or giving birth in 
one menstrual cycle (normal is 20% or 10% respectively) subfertility is a term of 
lessened fertility which prolongs the time to pregnancy (TTP).  
All indicators of female fertility depend on the age of the woman. 
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4.4.2 Questionnaire 
 
All patients filled out a previously designed questionnaire regarding personal, familial 
and reproductive history, prior to getting examined and treated. 
They also answered the questions: 
• obesity, diabetes and PCOS in the family 
• when they gained weight 
• characteristic of menstrual cycle 
• previous pregnancies 
• what was their body weight when they conceived 
• how much time has passed until they achieved desired pregnancy 
• what was the excess of weight left after giving birth 
• start and prominence of acne andhirsutism 
• other eventual signs of hormonal disorder. 
4.4.3 Ovarian reserve 
 
Ovarian reserve is the overall capacity of the ovaries for healthy folliculogenesis and 
oogenesis. The main background is adequate number of antral follicles 2-10mm in 
diameter which is capable for recruitment. 
 
Table 14.  Markers of ovarian reserve are: 
 Normal Low 
• antral follicular count – AFC 9-20 ≤ 8 
• antimüllerian hormone AMH (pmol/L)      9-20 ≤8 
• ovarian volume OV (ml)    5-9 < 5 
 
Secondary biomarkers are FSH ≥ 11IU/L, and serum estradiol higher than 70 pg/ml. 
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4.4.4 Polycystic ovary syndrome 
 
Polycystic ovary syndrome (PCOS) was diagnosed according to Rotterdam extended 
criteria. The diagnosis of PCOS requires two out three criteria: 
1) ultrasonographic polycystic ovarian morphology (PCOM) 
- more than 12 antral follicles (AF 2-10 mm in diameter) in one ovary 
- ovarian volume ≥10 ml 
2) ovarian dysfunction (OD) 
- oligo/ anovulation 
3) hyperandrogenaemia and (or) hyperandrogenism (HA) 
- biochemically   high serum androgens 
- calculations of HA by free androgen index (FAI) 
orhirsutism (according to mod F-G score) 
- acne 
Additional criterion could be high AMH value (≥ 35 pmol/L). 
4.4.5 Ultrasonography 
 
Ultrasonographic (US) transvaginal examinations was performed by 3 experienced 
reproductive subspecialists using modern US machines with vaginal probe ≥8 MHz 
(General Electric LOGIQ E6/8). The ovarian scan analysis was made on 3 sections 
scans, or by automated sono - AVC. In brief, it was measured and calculated AF, and 
length high width of the ovaries x 0,523 was formula for ovarian volume. 
4.4.6 Menstrual cycle and ovarian dysfunction 
 
Subject were asked to report average menstrual cycle length in the last year, and 
oligomenorrhoea was defined as cycle length more than 35 days. 
Anovulation (or oligo-anovulation) were diagnosed by basal body temperature, repeated 
gynaecological and ultrasound examinations, LH estimation, and low luteal serum 
progesterone values. 
Amenorrhea was defined as loss of menstrual cycle for longer than 3 months. 
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Heavy menstrual bleeding was diagnosed by periods longer than 7 days, clots in 
menstrual blood, use of more than 8 sanitary pads per day, blood analysis. 
4.4.7 Anthropometric obesity measurement 
 
All participants were grouped according to body mass index (BMI) in 3 groups (as it was 
mentioned). The physical measurements were: 
• height (cm), weight (kg), BMI (kg/m2) 
• waist circumference (WC) 
• hip circumference (HC) 
• waist to hip ratio (WHR) 
• waist to stature (height) ratio (WSR) 
Body mass index was for general obesity assessment, and WC, WHR and WSR are 
measures of central (abdominal, visceral) obesity. The cut-off values (abnormal) for 
overweight, obesity and central obesity are: 
Table 15. Cut-off abnormal values of WC, WHR and WSR 
 
Measure Cut-off values 
BMI (kg/m2) 25-29.9 
Overweight 
≥ 30 
obese 
WC (cm) 88  
WHR 0,85  
WSR 0,50  
BMI is defined as persons weighted in kilograms divided by square of his height in 
meters (kg/m2) 
Waist circumference was measured after full expiration, from the front at the narrowest 
point between the rib cage and iliac crest (the smallest part of waist). 
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Hip circumference was measured from the side at the maximal extension of buttocks 
(distance around the largest part of hips). Measurements should always be strictly 
horizontal, using a non-expansible tape measure. 
For both measurements, the WHO STEPS protocol recommends that the subject 
stands with arms at the sides, feet positioned close together, and weight evenly 
distributed across the feet (WHO, 2008b) 
WHR was calculated by dividing waist circumference by hip circumference.  
The aim was to assess the associations between general and central obesity 
anthropometric measures with hormonal production and ovarian reserve. 
4.4.8 Hormonal analyses 
 
On the 2nd to 4th menstrual cycle day serum was analysed for folliculostimulating 
hormone (FSH), luteinising hormone (LH), prolactin (PRL), estradiol (E2) total 
testosterone (T), antimüllerian hormone (AMH) and sex hormone binding globulin 
(SHBG) using assays and instrument from Beckman Coulter Inc. or Roche (by medical 
equipment ROCHE Cobas- Elecsys E411), by ECLIA methodology, which consist by 
taken intravenous of 3ml of blood, waiting for 30 minutes  and then separated serum 
was used.  
ECLIA is the Novel Electrochemiluminescence (ECL) technology and provides superior 
analytical performance. Increased sensitivity means that extremely low levels of 
antigen, as well as subtle changes in levels, can be detected. The very wide measuring 
range facilitates cost and time efficient testing by reducing the need to dilute and repeat 
samples). Total testosterone was mostly assayed by imunochemiluminescence method. 
If needed progesterone (P4) was analysed in the mid luteal phase. 
Free androgen index (FAI) was calculated according to formula FAI= total testosterone 
(nmol/L) x100/ SHBG (nmol/L). Normal values (our laboratories) for hormones in 
women are shown in table 10.Test HbA1C have been performed by ROCHE Cobas 
integra 400 plus by turbidimetric inhibition immunoassay 
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Table 16. Normal values of hormones and FAI 
 
Hormone Normal values 
FSH (IU/ L) 5-10 
LH (IU/ L) 5-10 
PRL (IU/L/ μg-L) 100-500/ 4-23 
AMH (pmol (L) 9-20 
E2 (pg/ ml) 30-70 
T (nmol/ L) 0,20- 1,80 
SHBG (nmol/ L) 18-144 
FAI 1-4 
We have analysed the impact of obesity and PCOS on hormonal activity of ovaries and 
fat tissue. Also, the associations of central obesity with ovarian reserve and 
hyperandrogenaemia. 
4.4.9 Hyperandrogenism 
Hyperandrogenism is the possible indicator of the more severe phenotype of PCOS, 
high ovarian reserve and reproductive risks. Signs are hirsutism, acne, male type 
baldness (android alopecia).Hirsutismwas graded base on modified Ferriman- Gallwey 
scale (m FG score), a cut-off for increased hairness was taken according to 
recommendations (m FG>7). 
 
Figure 14. Modified Ferriman- Gallwey score (57) 
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Acne, oily skin and hair (scalp) are signs of hyperandrogenism. Acne were 
characterized as mild, moderate and severe (Allen) and alopecia, according to Ludwig 
scale. Hirsutism (hyperandrogenism) is expressed in 10-15% of normal women and 
in 60-70% PCOS patients. 
 
4.5Statistical analysis: 
 
Statistical analysis were performed by using statistical package SPSS 17.0. Data are 
reported as mean ± standard deviation. 
Student’s t test/ANOVA was used to compare means of parametric data and Man-
Whitney test/ Krusckal Wallis test to compare non-parametric data. Chi square test for 
analysis of categorical outcomes.  
For statistical significance the value of the factor alpha is ≤ 0.05. 
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5.RESULTS 
 
Following the study inclusion criteria, a work-up was performed on the first 268 long-
term infertile female patients who came for their first visit to the (tertiary) infertility clinics 
in Kosovo (Priština, Gjakova) and Zagreb (Poliklinika IVF). A full work-up was possible 
in 182 women (from the same ethnic group), of which 126 in Kosovo and 56 in Zagreb. 
The research took place over a period of 2.5 years, with the same criteria used to 
collect patient demographics, anthropometric measurements, ultrasound biometry and 
hormone analyses. Polycystic ovary syndrome (PCOS), inevitably associated with 
female infertility and obesity (Table 11), was diagnosed in 52 patients. All patients were 
classified in three groups according to body mass index (normal BMI - 64 patients, 
overweight - 56 patients, and obese - 62 patients) and their results were compared. 
Results were classified and analyzed according to PCOS status into non-PCOS and 
PCOS patients (n=130 and 52, respectively). The primary objective was to investigate 
how patient characteristics were associated with ovarian reserve (Table 17). Results are 
presented as mean ± standard deviation, with the prevalence (%) in each investigated 
group (% within group, % of total). 
5.1 Patients characteristics and distribution 
Depending on body mass index, patients were categorized into group I, II or III. These 
groups were analyzed on the basis of two basic characteristics. Non-PCOS patients 
were affected only by obesity, while PCOS patients exhibited both PCOS and obesity. 
Table 17. Incidence and categorization of participating women 
 
Patients All Non PCOS PCOS 
I Group 
BMI 18,5-24,9 kg/m2 
64 (35,16%) 49 (37,69%) 15 (28,84%) 
II Group 
BMI 25-29,9 kg/m2 
56 (30,77%) 40 (30,77%) 16 (30,77%) 
III Group 
BMI ≥ 30 kg/m2 
62 (34,06%) 41 (31,54%) 21 (40,38%) 
TOTAL 182 (100%) 130 (71,43%) 52 (28,57%) 
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It should be noted that this prevalence results from the selection of patients as we 
recruited the first 60 patients from each BMI group who underwent full work-up. 
Of the total number of patients (n=182), 1/3 had normal BMI, 1/3 were overweight and 
1/3 were obese. In the population of long-term infertile female patients, 71.43% were 
classified according to growing body mass index, while 28.57% were diagnosed as 
PCOS. Such prevalence is expected in an infertile population. The incidence of obesity 
is predictably the highest in PCOS patients (40.4%). Overweight and obesity prevalence 
in infertile women is 62.3%, and 71.1% in PCOS patients. BMI range was between 18.6 
and 49.6 kg/m2.Overweight and obesity prevalence is shown in Table 12. (see also 
Table 18) 
Table 18. Prevalence of patients with abnormal BMI 
 
Patients 
All 
n= 182 
Non PCOS 
n= 130 
PCOS 
n= 52 
Overweight 56 40 16 
Obese 62 41 21 
TOTAL 118 (64,83%) 81 (62,31%) 37 (71,15%) 
 
Among infertile patients without PCOS, 62.3% are overweight and obese, while a higher 
(abnormal) BMI is found in 71.1% PCOS patients. Occurrences were compared within 
BMI groups, as well as non-PCOS and PCOS patients. Non-PCOS patients exhibited 
impacts only of obesity, while PCOS patients exhibited impacts of both that endocrine 
disorder and of obesity.A body mass index < 20 kg/m2 was found in 8 women (4.4%), 
and morbid obesity (BMI ≥ 40kg/m2) in 10 patients (5.5%).The highest obesity incidence 
is in PCOS patients (40.4%). 
Demographic characteristics of patients in all three groups of different weight and BMI 
were the same and are shown in Table 19. 
76
 
 
 
 
Table 19. Demographic characteristic in patients (n=182) distributed by BMI 
 
 BMI 
Parametar 
I Group  
normalweight 
n=64 
II Group  
overweight 
n=56 
III Group 
obese 
n=62 
Age- years 
mean/ range 
32,20 
24- 38 
31,09 
23- 37 
32,16 
24- 38 
Height (cm) 
mean/SD 
165,7 
6,77 
164,3 
7,49 
164,7 
6,67 
Weight (kg) 
mean/SD 
62,6 
7,37 
72,9 
8,07 
92,7 
14,36 
BMI kg/m2 22,7 26,9 34,1 
Previous pregnancy/ birth 
                     n/ % 6 (9,4%) 12 (21,4%) 12 (19,3%) 
Primary infertility 
n/ % 52 (81,3%) 36 (64,3%) 38 (61,3%) 
Infertility duration(years) 
mean/ range 
4,11 
1-11 
3,80 
2-10 
4,65 
1-17 
Previous gynaecologic 
surgery 
n/ % 
7 (10,9%) 6 (10,7%) 9 (14,5%) 
Male subfertility 
n/ % 19 (29,7%) 13 (33,9%) 16 (25,8%) 
Hypothyroidism 
n/ % 4 (6,2%) 4 (7,1%) 5 (8,1%) 
PCOS 
n/ % 15 (23,4%) 16 (28,6%) 21 (33,9%) 
 
Average patient age was also approximately the same, as well as average infertility 
duration (around 4 years). Only 38 patients (20.9%) had previously received intensive 
infertility treatments, out of whom 8 with in vitro fertilization (IVF). In 25% to 33% of 
couple’s male subfertility was a cofactor of infertility, but this prevalence was 
disregarded due to the selection according to BMI, while couples with total male 
infertility were excluded from the study. Primary infertility is the most frequent in the 
normal weight population (81.3%), which is significantly more frequent than in patients 
with an abnormal BMI (61.3 - 64.3%). Around 20% of overweight and obese patients 
had already given birth. 
The differences between weight and BMI by patient groups are predictably statistically 
significant (p < 0.001), as that was the principle of sample creation (Fig. 15). 
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Figure 15. Group differences for weight and BMI (mean) 
 
The incidence of polycystic ovary syndrome in normal weight patients is 23%, compared 
to 29% and 34% respectively in overweight and obese patients. 
Of the 30 patients who had previously given birth and were now examining secondary 
infertility, 15 had been overweight or obese before pregnancy, and 11 were normal 
weight, but have later developed post-pregnancy obesity (body weight increase of 10 - 
16.5 kg). 
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Other anthropometric measurements and central obesity 
In order to explore the relationship between central (abdominal) obesity and general 
and hormonal characteristics of women in this study, the measurements for waist 
circumference (WC), hip circumference (HC), waist to hip ratio (WHR) and waist to 
stature ratio (WSR) were analyzed. The patients in BMI groups had a similar WC. 
However, WC significantly increases with increased BMI, which makes the difference 
between WC in overweight and obese patients and WC in normal weight patients 
statistically significant (p < 0.001). 
Table 20. Waist- circumference in participating patients (mean and SD) 
 Waist circumference (WC) cm 
Patients All Non PCOS n= 130 
PCOS 
n= 52 
B     I Group 
n= 64           SD 
71,66 
7,58 
70,57 
7,0 
75,20 
8,56 
M    II Group 
n= 56           SD 
78,4 
7,16 
77,62 
7,06 
80,8 
7,23 
I      III Group 
n= 62            SD 
95,52 
11,71 
94,24 
11,27 
98,00 
12,43 
TOTAL 
n= 182          SD 
81,87 
13,55 
80,20 
13,14 
86,03 
14,11 
• BMI body mass index • PCOS- polycystic ovary syndrome 
 
 
 
 
 
 
 
 
Figure 16. Waist circumference (all patients) in 3 BMI groups 
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Obese PCOS patients have the highest WC, but without a statistically significant 
difference compared to non-PCOS women. WC value distribution in study groups is 
also presented in a histogram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. WAIST circumference histogram of distribution  
 
 
 
 
p < 0,001 
 
p < 0,001 
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Figure 18. WAIST circumference differences according to BMI 
• NW- normal weight • OV- overweight • OB- obese 
 
 
 
Waist circumference greater than 88 cm is a reliable indicator of central obesity in 
women, which represents an additional metabolic and reproductive risk. 
 
Table 21. Prevalence of central obesity in two populations (according to WC> 88cm) 
 
 Waist circumference > 88 cm 
Patients All Non PCOS PCOS 
B     I Group 
 
3 (4,7%) 
n= 64 
1 (2,04%) 
n= 49 
2 (13,3%) 
n= 15 
M II Group 
 
8 (14,3%) 
n= 56 
4 (10,1%) 
n= 40 
4 (25,0%) 
n= 16 
I   III Group 
 
42 (67,7%) 
n= 62 
26 (63,4%) 
n= 41 
16 (76,2%) 
n= 21 
TOTAL 
 
53 (29,1%) 
n= 182 
31 (23,8%) 
n= 130 
22 (42,3%) 
n= 52 
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Central obesity (WC > 88 cm) was recorded in 53 patients (29.1%), of which 23.8% 
were non-PCOS patients and 42.3% patients with PCOS. More than 60% of obese 
patients also exhibit abdominal obesity, while as many as 76.2% of obese PCOS 
patients have WC > 88 cm. 
According to that parameter, the prevalence of central obesity is statistically significantly 
higher in PCOS patients who are overweight or obese. 
 
Inter-BMI-group prevalence of central obesity is similar, without statistically significant 
differences, while normal-weight patients have a low incidence of visceral obesity 
(2.04% and 13.3% respectively). 
 
 
 
Figure 19. Prevalence of central obesity in PCOS and non PCOS populations 
Hip circumference (HC) is similar, without significant differences within BMI groups. 
Obese women have the highest HC, which is statistically significantly higher than HC in 
normal weight patients. 
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Table 22. Hip circumference in all participating patients (mean and SD) 
 
 Hip circumference (HC) cm 
Patients 
All 
 
Non PCOS 
n= 130 
PCOS 
n= 52 
B     I Group 
n=64                SD 
94,6 
6,13 
94,1 
5,79 
95,2 
7,37 
M    II Group 
n= 56           SD 
102,2 
6,22 
100,3 
6,50 
108,3 
5,46 
I      III Group 
n= 62            SD 
112,5 
8,88 
111,6 
7,24 
113,5 
11,59 
TOTAL 
n= 182         SD 
103,1 
9,55 
102 
7,66 
105,7 
12,10 
 
 
 
 
 
 
 
Figure 20. Hip circumference in all patients by BMI groups 
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In addition to using WC, central obesity is often diagnosed using the waist to hip ratio 
(WHR). Cut-off values recommended for women is 0.85 or even 0.80. The normal upper 
limit of 0.85 was used, as most frequently recommended by the WHO. Normal average 
WHR values were observed in the normal weight and overweight groups, while in obese 
patients the ratio was pathological. Obese patients (BMI > 30 kg/m2) more often exhibit 
abdominal obesity, i.e. a higher WHR. 
 
Table 23. Waist to hip ratio in participating populations (mean and SD) 
 
 
 
Waist to hip ratio-WHR 
Patients All 
Non PCOS 
n= 130 
PCOS 
n= 52 
B     I Group 
n= 64            SD 
0,76 
0,08 
0,75 
0,06 
0,79 
0,1 
M    II Group 
n= 56            SD 
0,78 
0,06 
0,77 
0,05 
0,79 
0,08 
 I      III Group 
n= 62            SD 
0,85 
0,07 
0,84 
0,07 
0,88 
0,05 
TOTAL 
n= 182          SD 0,80 0,79 0,81 
 
 
 
Figure 21. Waist to hip ratio in 3 BMI groups 
 
84
 
 
 
 
In the obese group, non-PCOS women have border-line WHR, while patients with 
PCOS have a pathological WHR (0.88). When these values were compared to the 
normal-weight group, the difference was statistically significant. Central obesity has a 
high prevalence in obese women and is almost exclusive to obese women with PCOS 
(66.7%). Obesity (BMI ≥ 30kg/m2) in PCOS patients significantly contributes to central 
obesity. Further, central obesity prevalence is statistically significantly higher in obese 
PCOS patients. 
Table 24. Incidence of central obesity according to WHR higher than 0,85 
 
 WHR > 0,85 
Patients All Non PCOS PCOS 
B     I Group 
 
7 (10,9%) 
n= 64 
4 (8,2%) 
n= 49 
3 (20,0%) 
n= 15 
M   II Group 
 
7 (12,5%) 
n= 56 
4 (10,0%) 
n= 40 
3 (18,7%) 
n= 16 
 I  III Group 
 
30 (48,4%) 
n= 62 
16 (39,1%) 
n= 41 
14 (66,7%) 
n= 21 
TOTAL 
 
44 (24,2%) 
n= 182 
24 (18,5%) 
n= 130 
20 (38,5%) 
n= 52 
 
Central obesity incidence is most accurately shown if we include in the calculation all 
patients with one or both indicators: waist circumference > 88 cm and/or waist to hip 
ratio > 0.85. Another good indicator is a WSR ratio (waist to stature (height)) higher than 
0.50. 
Table 25. Prevalence of central obesity according to high WC and WHR 
 
Central obesity 
WC > 88 cm and (or) WHR > 0,85 
Patients All Non PCOS PCOS 
Overweight 
 
11 (19,6%) 
n= 56 
6 (15%) 
n= 40 
5 (31,2%) 
n= 16 
Obese 
 
47 (75,8%) 
n= 62 
28 (68,3%) 
n= 41 
19 (90,4%) 
n= 21 
TOTAL 
 
58 (49,1%) 
n= 118 
34 (41,9%) 
n= 81 
24 (64,9%) 
n= 37 
 WC- waist circumference; WHR- waist to hip ratio 
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An analysis of these two parameters shows that 90.4% of obese PCOS patients also 
exhibit central obesity, which is statistically more significant than in obese non-PCOS 
patients. There is also a statistically significantly higher incidence of abdominal obesity 
in obese than in normal weight participants. According to these criteria almost all PCOS 
patients (90.4%) exhibit central obesity. 
 
Figure 22. Prevalence of central obesity according to WC/ WHR 
 
Normal weight PCOS patients exhibit 2.5 more central obesity than women with the 
same BMI, but without PCOS.Waist to stature ratio (WSR) is the ratio of waist 
circumference to height. When this ratio exceeds 0.50, it is an indicator of central 
obesity. 
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Table 26. Waist to stature ratio in participating patients (mean) 
 Waist to stature ratio, WSR* 
Patients All Non PCOS PCOS 
B     I Group 
           n= 64 0,43 0,43 0,45 
M    II Group 
          n= 56 0,47 0,46 0,48 
I      III Group 
         n= 62 0,57 0,56 0,58 
• Value > 0,50 sign of central obesity 
 
WSR shows a similar incidence of central obesity. Both populations of obese women 
(PCOS and non-PCOS) have a high prevalence of WSR > 0.50, which is an important 
indicator of abdominal obesity. Obese PCOS patients have a high WSR in 95.2% of the 
cases, which is statistically significantly higher than among overweight and normal 
weight participants. 
 
 
Figure 23. Waist to stature ratio > 0,50 in PCOS patients 
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5.2 Menstrual cycle characteristics 
We explored a possible effect of obesity and PCOS on some characteristics of the 
menstrual cycle and menstrual bleeding in the participating patients. The onset of the 
first menstrual cycle (menarche) is shown in Table 27. 
Table 27. Age of menarche in participating patients (mean and range) 
 Menarche (year) age 
Patients 
All 
                         n= 182 
Non PCOS 
n= 130 
PCOS 
n= 52 
B     I Group 
range 
12,40 
10,5-14,5 
12,20 
10,5-13,5 
13,06 
11-14,5 
M    II Group 
                  range                            
12,80 
10-15 
12,07 
10-13,5 
13,50 
12-15 
I      III Group 
range 
12,90 
10,2-15,5 
11,60 
10,2-13,0 
13,94 
12-15,5 
 
In the studied population, menarche occurred between the ages of 10 and 15.5 years. 
No primary amenorrhea was recorded in the participating patients. A trend of early 
menarche (at the age of 11.6) was observed with obesity, while it is a known fact that 
PCOS postpones menarche. In the PCOS population, menarche occurred at an 
average age of 13.5 years in overweight women, and at the age of 13.9 in obese 
women. These differences exhibited no statistical significance. 
The difference (in terms of menarche) between obese (BMI>30 kg/m2) non-PCOS and 
PCOS patients is statistically significant. 
 
 
 
 
 
 
Figure 24. Difference in menarche age in obese patients 
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The duration of menstrual bleeding (MB) widely varied, from 2 to 8 days. The longest 
menstrual bleeding occurs in PCOS patients (BMI>25) withan average of almost 6 days 
(5.8 days). In general, the duration of MB is longer in obese than in normal weight 
women.Obese and overweight PCOS patients have statistically significantly longer MB 
than normal weight women. 
 
 
Figure 25.Menstrual bleeding duration (days) in participating women, NW- normal weight; 
OV- overweight; OB- obese 
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Irregular cycles are defined as prolonged cycles, oligomenorrhea lasting from 35 to 199 
days, uneven and unstable cycles, anovulation. Amenorrhea is defined as absence of 
menstruation longer than 199 days (≈6 months). More severe cycle disorders are 
associated with more serious hormonal disorders and insulin resistance. 
Obesity and PCOS are characterized by irregular cycles, with 62 occurrences (34.1%) 
in all patients, and significantly more in PCOS patients than in the population of only 
obese women (69.2% vs. 20.8%). 
Table 28. Irregular menstrual cycles in non PCOS and PCOS populations (n and %) 
 
 Irregular cycles n (%) 
Patients 
All 
                        n= 182 
Non PCOS 
n= 130 
PCOS 
n= 52 
B     I Group 
            n= 64 18 (28,1%) 
9 (18,4%) 
n=49 
9 (60%) 
n=15 
M    II Group 
           n= 56 17 (30,3%) 
8 (20%) 
n=40 
9 (56,2%) 
n=16 
I      III Group 
           n= 62 27 (43,5%) 
10 (24,4%) 
n=41 
17 (80,9%) 
n=21 
TOTAL 
 62 (34,1%) 27 (20,8) 36 (69,2%) 
 
In obese PCOS patients, 80.9% had irregular cycles and 85% had anovulatory cycles. 
This is statistically significantly more frequent than in the normal weight population (60% 
compared to 46.7%). 
On the other hand, anovulation was identified in 39% of patients who were only obese 
(BMI > 30 kg/m2). As many as 35 (67.3%) PCOS patients had anovulatory cycles. 
Further, 5 non-PCOS patients reported amenorrhea (3.8%), while the incidence of 
amenorrhea accompanying obesity was 3 (7.3%). In the PCOS population, 9 patients 
reported amenorrhea (17.3%), mostly among obese PCOS participants 5 (23.8%). 
Anovulation was also identified in these patients. 
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Table 29. Anovulatory cycles in participating patients (n and %) 
 
 Anovulations (%) 
Patients 
All 
                        n= 182 
Non PCOS 
n= 130 
PCOS 
n= 52 
B     I Group 
            n= 64 17 (25,6%) 
10 (20,4%) 
n=49 
7 (46,7%) 
n=15 
M    II Group 
           n= 56 22 (39,3%) 
12 (30%) 
n=40 
10 (62,5%) 
n=16 
I      III Group 
           n= 62 34 (54,8%) 
16 (39,0%) 
n=41 
18 (85,7%) 
n=21 
TOTAL 
 73 (40,1%) 38 (29,2%) 35 (67,3%) 
 
Figure 26.Incidence of anovulatory cycles in obese and normal weight populations 
 
Anovulatory cycles (including amenorrhea) were recorded in 85.7% of obese PCOS 
patients and in 46.7% of normal weight PCOS women. This prevalence is statistically 
significantly higher than the prevalence in non-PCOS patients. Anovulation coincided 
with obesity in 39% of women. 
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In all BMI groups incidence of anovulatory cycles is statistically significant higher in 
PCOS patients: (Two sample t-test and CI) 
 
I group 
II group 
III group 
T-value 7,83 
T- value 3,91 
T – value -3,55 
p < 0,001 
p < 0,001 
p < 0,001 
Obese non PCOS patients have significantly higher rates 
of anovulations than normalweight women- t- value- 28,29 
p < 0,001 
 
Heavy menstrual bleeding (HMB) is predictably frequently associated with obesity and 
PCOS cycles. The data collected in this study is not based on objective menstrual blood 
loss measurement, but on subjective impressions and anamnestic data. HMB was 
reported by 42 patients (23.3%), with the highest incidence, of 9 patients (24.3%), in the 
overweight and obese PCOS population. This is statistically significantly higher than in 
the patients with normal body weight. 
 
 
 
 
 
 
 
Figure 27. Heavy menstrual bleeding in 182 participants 
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Menstrual cycle duration changes with obesity, anovulation, hyperandrogenemia and 
PCOS, and most frequently with anovulatory PCOS.  
Table 30. Menstrual cycle length in participating women (mean and SD) 
 
 Menstrual cycle length (days) 
Patients All Non PCOS PCOS 
B     I Group 
n=64                SD 
29,13 
4,16 
27,53 
3,51 
33,66 
5,66 
M    II Group 
n= 56            SD 
29,75 
4,60 
28,5 
3,17 
34,6 
5,64 
I      III Group 
n= 62            SD 
32,35 
4,25 
30,12 
4,30 
39,54 
4,31 
TOTAL 
n= 182         SD 
30,41 
4,11 
28,63 
3,8 
36,42 
5,7 
 
Menstrual cycle was prolonged in all BMI groups (I, II, III) in the study, less prominently 
in case of obesity only and more prominently with higher BMI and PCOS. Patients with 
polycystic ovaries have statistically significantly longer cycles than non-PCOS 
participants (36.4 days vs. 28.6 days). 
 Obese PCOS women have the longest menstrual cycles (39.54 days), which is 
statistically significantly longer than the cycles of obese women and normal weight 
patients (p < 0,001). 
 
 
Figure 28. Menstrual cycle length inobese and normal weight patients 
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5.3 Previous pregnancies 
Among 56 secondarily infertile patients (30.76%), there were 91 pregnancies, 41 births 
(45.05%) and 50 early spontaneous abortions (SAB) (54.94%). Of 50 SABs, 44 (88%) 
occurred in the overweight and obese population, while 12% occurred in normal weight 
patients.This study found that the population with long-term infertility has a high 
prevalence of early spontaneous abortions. Over one half of all early-stage pregnancies 
were terminated by miscarriage, especially in obese patients. 
These 56 subjects provided data in the questionnaire regarding time to pregnancy. In  
the normal, healthy population time to pregnancy (TTP) is 4.8 months (48,50). 
 
Table 31. Time to pregnancy in two different populations(months) 
 
BMI 
Non PCOS 
n= 38 
PCOS 
n= 18 
18,5- 24,9 
SD 
9,5 
3,5 
15,6 
4,2 
25- 29,9 
SD 
16,8 
4,1 
18,7 
5,2 
30- 34,9 
SD 
19,9 
5,8 
25,6 
6,1 
≥ 40 
SD 
27,2 
7,1 
33,4 
7,3 
 
This small sample shows subfecundity and a prolonged TTP with increased BMI up to 
morbid obesity. This data should be taken with caution due to confounding with other 
causes of infertility that are independent of obesity and PCOS in our sample as well.  
Time to pregnancy is also prolonged in cases of extremely low and high BMI. With an 
increase in BMI, fecundity decreases in PCOS and non-PCOS populations. Obese 
women were also subfertile or infertile prior to this study. 
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Time-to-pregnancy is significantly longer only in normalweight PCOS patients 
comparing to non PCPS women (Two sample t-test and CI) 
I group 
II group 
III group 
T-value - 2,71 
T- value - 0,83 
T – value - 2,01 
p < 0,030 
p < 0,427 
p < 0,080 
Obese non PCOS patients and PCOS patients have 
significantly longer TTP in comparison to normalweight 
patients. TTP is significantly the longest in morbid obesity. 
T-value – 5,75 
T- value – 3,24 
T – value – 4,75 
p < 0,001 
p < 0,012 
p < 0,003 
 
 
 
5.4 Hormone analysis 
Serum concentrations of folliculostimulating hormone (FSH), luteinizing hormone (LH) 
and prolactin (PRL) were determined and analyzed. In addition to these pituitary 
hormones, estradiol (E2), testosterone (T) and sex hormone binding globulin (SHBG) 
were also analyzed. The aim was to determine how the levels of these hormones were 
associated with increased body mass index and obesity, and to examine the correlation 
of hyperandrogenemia (HA) with obesity and polycystic ovary syndrome. In addition to 
total T, the calculation of free androgen index (FAI) was used. The influence of obesity 
and PCOS on gonadotropic hormones (FSH, LH) is shown in Table 32. 
Table 32. Body mass index and PCOS effects on FSH and LH 
 FSH IU/L LH/ IU/L 
Patients 
Non PCOS 
n= 130 
PCOS 
n= 52 
Non PCOS 
n= 130 
PCOS 
n= 52 
B     I Group 
            SD 
7,53 
2,81 
4,97 
1,16 
6,77 
3,01 
9,98 
5,05 
M    II Group 
           SD 
6,87 
2,72 
5,41 
1,26 
6,82 
3,95 
7,53 
3,17 
 I      III Group 
           SD 
6,14 
1,80 
4,67 
1,47 
5,72 
2,23 
7,31 
3,03 
TOTAL 
SD 
6,85 
2,30 
5,02 
1,32 
6,44 
3,15 
8,27 
3,86 
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FSH and LH distribution is shown in histograms, i.e. Figures 30 and 31.High LH is 
expected in normal weight PCOS patients, while excessive adipose tissue slightly 
decreases LH levels and activity in groups with a higher BMI. 
 
 
 
Figure 29. Distribution of FSH in PCOS and non PCOS patients 
 
 
Figure 30. Histogram of LH distribution in two populations 
 
96
 
 
 
 
In the group of normal weight patients with PCOS, the LH/FSH ratio is higher than 2.0 
due to an elevated LH(LH 9.98/FSH 4.97). Obesity minimally decreases gonadotropin 
levels, which are the highest with a normal BMI. FSH is lower and LH is higher in PCOS 
patients compared to non-PCOS patients. 
The differences in FSH and LH in obese patients are shown in Figure 32. 
 
 
 
 
 
 
 
 
 
Figure 31. FSH and LH values in obese non PCOS and PCOS patients 
  
In obese patients the difference in serum FSH was statistically significantly higher in 
non-PCOS patients than in PCOS patients. 
According to Kruskal-Wallis test the LH levels are statistically significantly different in 
PCOS and non-PCOS patients (P 0.001 - ChiSq). 
The expected LH level was statistically significantly different by BMI groups. 
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Prolactin is a stress hormone secreted by the pituitary gland. Apart from its role in 
lactation, it also affects the endometrium and ovaries. There is no correlation between 
prolactin and obesity, but prolactin is slightly elevated in 20 to 30% of women with 
PCOS. 
The distribution of prolactin findings is illustrated in the histogram below, clearly showing 
a wide range of established values: 
 
Figure 32. Distribution of serum prolactin in participating patients 
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Table 33. Serum prolactin values (mean and SD) 
 
 Prolactin ng/ml 
Patients Non PCOS PCOS 
B     I Group 
            SD 
14,67 
6,40 
21,22 
8,42 
M    II Group 
           SD 
15,04 
5,89 
22,53 
10,41 
 I      III Group 
           SD 
16,02 
8,15 
18,89 
8,70 
TOTAL 
          SD    
15,22 
6,86 
20,37 
8,12 
 
There was no difference in PRL concentrationsamong different BMI groups, which 
means that obesity is not associated with higher PRL production. However, there is a 
statistically significant difference in mean PRL values between PCOS and non-PCOS 
patients.  
In the participating patients PRL is significantlyhigher (p < 0,001) with PCOS compared 
to the patients without that syndrome. All mean values are in the normal range. 
 
 
 
 
 
 
 
 
 
Normal estradiol and TSH levels were also determined, and these were not affected by 
obesity and PCOS. 
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Table 34. Serum hormonal concentrations in 3 groups of patients 
 BMI 
Parametar I Group II Group III Group 
Estradiol (E2) pg/ml 54,1 56,7 56,2 
Prolactin (P4) μg/L 17,7 19,8 19,2 
Thyroid stimulating 
hormone (TSH)  
mU/L 
2,17 2,76 2,35 
 
Hyperandrogenemia 
An increased activity of androgens is characteristic of excessive adipose tissue and 
PCOS. HA parameters in the study subjects were investigated by comparing the levels 
of total testosterone (T), sex hormone binding globulin (SHBG) and FAI (normally 1-4 
points). It is known that hyperandrogenism depends on the level of androgen production 
and on the level of androgen transporters in the circulation. Obesity and PCOS play a 
role in these mechanisms. 
Table 35. Total serum testosterone in two populations (mean and SD) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. testosterone concentration in all PCOS and non PCOS patients 
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Testosterone levels do not change with weight gain and increased BMI in PCOS subject 
group. In this study a statistically significantly higher T was determined in all BMI groups 
of PCOS patients compared to non-PCOS women. Positive correlation was found 
between increased adipose tissue and testosterone production in non PCOS 
participants. 
 
 
 
 
 
 
 
 
 
 
 
 
Testosterone levels are statistically significantly higher in PCOS patients, but there are 
no statistically significant differences in T levels by BMI in these women. Obese non 
PCOS women have statistically significant higher T comparing to normal weight 
participants (T 1,82 vs. 1,38; p < 0,05).Obesity does affect serum testosterone levels in 
patients with and without PCOS. 
Sex hormone binding globulin is the main transporter of T and E2 in the circulation. With 
a reduced production of SHBG in the liver, the share of these free, unbound hormones 
increases, and so does their activity. SHBG is a highly sensitive biomarker of HA and 
PCOS. 
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Table 36.SHBG values in two groups ofpatients 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Difference in SHBG values in PCOS/non PCOS patients 
 
The difference in serum SHBG levels between PCOS and non-PCOS patients (in each 
BMI group and total) is statistically significant. However, there is no significant 
difference in the expected levels of SHBG in different BMI groups. Obesity decreases 
the production and levels of SHBG in both patient groups, but the decrease is not 
statistically significant. 
 SHBG nmol/L 
Patients 
Non 
PCOS 
PCOS 
B     I Group 
            SD 
61,10 
30,42 
35,39 
15,3 
M   II Group 
           SD 
50,63 
25,8 
40,89 
14,5 
 I  III Group 
           SD 
55,0 
37,5 
32,60 
19,6 
TOTAL 
        SD      
55,96 
31,6 
35,96 
17,0 
p<0,001  
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Figure 35. Histogram of SHBG distribution in our patients 
 
Increased androgen activity is best shown by calculating the free androgen index (FAI). 
Based on T and SHBG results, it was determined that hyperandrogenism is related to 
PCOS, rather than obesity. In non-PCOS patients FAI was statistically significantly 
lower in all BMI patient groups. In non-PCOS patients FAI minimally increases with 
obesity, while FAI is significantly the highest in normal weight PCOS women. 
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Table 37. Free androgen index in our groups of patients (mean and SD) 
 FAI 
Patients Non PCOS PCOS 
B     I Group 
            SD 
2,07 
0,9 
7,28 
2,2 
M    II Group 
           SD 
3,43 
1,0 
5,75 
1,9 
I     III Group 
           SD 
3,12 
1,2 
7,45 
2,1 
TOTAL 
        SD      
2,87 
1,25 
6,83 
2,12 
 
 
 
 
 
 
 
 
 
Figure 36.Differences in FAI in all patients and normal weight patients 
 
Statistically significant differences in FAI between PCOS and non PCOS patients and 
obese PCOS women and control. 
BMI increase is associated with unchanged FAI in PCOS subjects, while a minimal FAI 
increase was found in non-PCOS women. 
Table 38 shows all HA markers that were determined in the two patient groups. 
Overweight and obese patients have higher androgen activity if they are in the non-
PCOS group, while in PCOS patients hyperandrogenism is significantly more 
pronounced in normal weight patients. 
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Table 38. Markers of hyperandrogenism in PCOS and non PCOS patients according to 
BMI 
 
 Markers of hyperandrogenism 
Patients 
NON PCOS PCOS 
OV+OB Normal W OV+OB Normal W 
Testosteron  
nmol/L 1,55 1,27 2,12 2,53 
SHBG  
nmol/L 52,8 61,1 36,7 35,4 
  FAI 2,93 2,07 5,78 7,15 
OV- overweight; OB- obese; NW- normal weight 
In analyzed populations the signs of hyperandrogenism were found mostly in PCOS 
patients: 
• acne  11 patients (21,1%) 
• hirsutism  32 patients (61,5%) 
According to modified Ferriman- Gallwey score ≥ 7 hirsutism in PCOS women was 
expressed in 27 patients (51,9%). Hyperandrogenism in non PCOS women has less 
prevalence- 18 (13,8%), mostly in obese participants. 
 
5.5 Biomarkers of ovarian reserve 
The biomarkers of ovarian reserve identified in the patient population are the anti-
Müllerian hormone (AMH), antral follicular count (AFC), and ovarian volume (OV). 
Table 39. Serum Antimüllerian hormone values in non PCOS and PCOS patients (mean 
and SD) 
 AMH  pmol/L 
Patients 
All 
n= 182              
Non PCOS 
n= 130              
 
PCOS 
n= 52   
B     I Group 
SD 
24,60 
12,8 
13,43 
8,02 
59,68 
23,7 
M    II Group 
SD 
29,52 
11,6 
15,73 
8,38 
51,49 
23,9 
I      III Group 
SD 
28,14 
13,9 
15,47 
6,81 
57,18 
32,6 
TOTAL 
SD 
28,60 
12,6 
14,76 
7,80 
56,15 
27,4 
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BMI does not affect serum AMH production and values, as there are no intergroup 
differences. Therefore, obesity does not affect AMH. AMH also remains unchanged 
when comparing the overweight and obese patient groups with that with a normal BMI. 
The wide distribution of AMH results is shown in the histogram below. 
 
Figure 37.AMH Difference between PCOS 
 
 
 
 
 
 
 
 
 
 
Figure 38. Histogram AMH distribution and non PCOS patients 
 
56.15
14.8
0
20
40
60
AMH pmol/L
All patients 
p < 0,001 
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In all BMI groups AMH in PCOS patients is statistically significantly higher than in 
women without PCOS (p< 0,001). Despite expectations, there was no negative 
association of obesity with AMH production. 
 
 
 
 
 
 
 
 
 
Figure 39. AMH values in non PCOS (mean and range) 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. AMH values in PCOS  (mean and range) 
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Antral follicular count (AFC) is a measure of the number of 2-10 mm antral follicles in 
reserve. This ultrasound examination depends on the sensitivity of the vaginal probe, 
the number of sections through both ovaries and the experience of the reproductive 
gynecologist performing the examination. Criteria for this examination were set at the 
beginning of this study with AFC being determined in two sections through each ovary. 
More recent instructions and more advanced US devices have changed the 
recommendations and criteria for AFC assessment. For the purpose of uniformity, the 
earlier criteria were kept for this examination. These are the reasons why AFC levels in 
all participating patients are uniformly lower. 
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24.3
9,0
0
5
10
15
20
25
AFC
All patients PCOS                                 NON PCOS
p < 0,001
Table 40. Antral follicular count in our populations (mean and SD) 
 AFC                      n     
Patients 
All 
n= 182              
Non PCOS 
n= 130              
PCOS 
n= 52   
B     I Group 
SD 
12,88 
8,86 
8,28 
4,28 
24,73 
7,17 
M    II Group 
SD 
13,91 
9,39 
9,37 
5,50 
22,51 
10,13 
 I     III Group 
SD 
15,15 
10,09 
9,41 
4,16 
25,76 
9,66 
TOTAL 
SD 
13,98 
9,25 
9,02 
4,20 
24,33 
7,85 
 
Obesity (BMI) does not affect follicular ovarian reserve and there are no intergroup 
differences. In all the BMI groups AFC is statistically significantly higher in PCOS 
patients.In individual BMI groups of patients an increase in obesity is not associated 
with a rise in AFC levels. Obesity does not affect the number of antral follicles. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Difference in AFC between PCOS 
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Figure 42. AFC in PCOS patients and non PCOS patients 
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Ovarian volume increases with the total number of reserve follicles (AFC). Ovarian 
volume (OV) was expressed as the mean value of measured volumes of both ovaries. 
An increased ovarian volume is one of the US criteria for polycystic ovary morphology 
(PCOM) or PCOS. 
Table 41. Ovarian volume in participating women 
 Ovarian volume      ml     
Patients 
All 
n= 182              
Non PCOS 
n= 130 
PCOS 
n= 52   
B     I Group 
SD 
7,10 
2,69 
6,18 
1,98 
10,07 
2,59 
M    II Group 
SD 
7,05 
2,28 
6,08 
1,56 
9,49 
1,95 
  I     III Group 
SD 
7,79 
2,25 
6,69 
1,60 
9,87 
1,79 
TOTAL 
SD 
7,31 
2,21 
6,32 
1,76 
9,81 
1,85 
 
As obesity and BMI do not affect the number of antral follicles in the ovaries, there are 
no differences in OV across BMI patient groups. Obesity does not affect the OV in 
PCOS patients nor in non-PCOS patients. 
Figure 43. Ovarian volume in non PCOS                     Figure 44. Ovarian volume in PCOS 
 (mean and range)                                                                                         (mean and range) 
 
 
111
 
 
 
 
PCOS patients have a statistically significantly higher ovarian volume than women who 
do not have this syndrome. 
  
 
 
 
 
 
 
 
 
 
 
Figure 45. Difference in ovarian volume 
 
Less than 1% of non-PCOS patients and 33 (63.46%) PCOS patients have an ovarian 
volume greater than 10 ml, which is an expression characteristic of PCOS. 
It was investigated whether the duration of the menstrual cycle (≥ 40 days), which is a 
characteristic more common in PCOS, and anovulation affect AMH levels. Also 
explored were the levels of the anti-Müllerian hormone in ovulatory and anovulatory 
cycles of PCOS and non-PCOS patients. 
 
A menstrual cycle longer than 40 days (oligomenorrhoea) is associated with anovulation 
and an elevated ovarian reserve. Long cycles were identified in 44 patients (24.2%). In 
all the BMI groups long-lasting oligomenorrheas are associated with elevated AMH 
levels. In obese patients (group III), long cycles have the highest prevalence of 42%, 
and these women have a slightly lower AMH than leaner women. 
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Table 42. Oligomenorrhoea and ovarian reserve 
 Long menstrual cycle ≥ 40 days 
Patients 
All 
n= 182 
AMH pmol/L 
B     I Group 
            n= 64 9 (14,1%) 59,2 
M    II Group 
           n= 56 9 (16,1%) 52,1 
 I      III Group 
           n= 62 26 (41,9%) 45,4 
TOTAL 
 44 (24,2%) 52,2 
 
By contrast, anovulation in obese women, and particularly in obese women with PCOS, 
is associated with statistically significantly the highest AMH. Women with anovulation 
are more obese (increased BMI) and they have more severe endocrine disorders. 
Anovulatory PCOS is characterized by statistically significantly the highest AMH. 
 
Table 43. Comparison of ovulatory and anovulatory menstrual cycles 
Parametar 
Non PCOS PCOS 
Ovulatory  
n= 94 
Anovulatory 
 n= 38 
Ovulatory  
n= 17 
Anovulatory  
n= 35 
BMI kg/m2 26,2 28,4 28,5 32,4 
AMH pmol/L 14,1 17,8 45,8 66,4 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. Antimüllerian hormone concentration in ovulatory and anovulatory women 
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Table 44. Ovarian reserve markers in all patients 
 
 Biomarkers of ovarian reserve 
Parameter 
All 
n= 182              
Non PCOS 
n= 130              
PCOS 
n= 52   
AMH                pmol/ L 28,60 14,76 56,15 
AFC                      n 13,98 9,02 24,33 
Ovarian volume   ml 7,31 6,32 9,81 
FSH                     IU/L 6,94 6,85 5,02 
 
With an overall illustration of ovarian reserve markers in all participating patients, we 
want to confirm the findings presented above. No negative effect of obesity on ovarian 
reserve was found. Only PCOS patients exhibit a statistically significant elevation of 
reserve markers. Although the prevalence of morbid obesity in studied populations is 
low, the findings for this population are also shown. 
Table 45. Ovarian reserve markers in morbid obese patients 
 
 
Morbid obesity BMI> 40/kg/m2 
Non PCOS    4,6% PCOS    7,7% 
AMH             pmol/ L 10,56 33,47 
AFC                      n 7,33 17,52 
Ovarian volume   ml 5,52 7,72 
FSH                    IU/L 4,6 5,97 
 
Although this is not statistically significant, it seems that morbid obesity reduces ovarian 
reserve markers.Endometrial thickness measured at the beginning of the menstrual 
cycle was the same in all 3 groups of patients 3.0 to 3.5 mm, and in PCOS patients it 
was 2.68 to 2.98 mm. 
In 133 participating patients we investigated HbA1c which has some advantages over 
the OGTT because it can be performed at the initial visit with no fasting required.  
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Obese and PCOS women are at high risk of prediabetes and diabetes (T2D). The 
OGTT is still regarded primary screening tool for IR and T2D. The American Diabetes 
Association defines raised HbA1c as > 5,7%, and cut-off value for T2D at >6,4% (101). 
In 133 patients we have found HbA1c > 5,7% in 33 (29,3%) women. Association of 
raised HbA1c with overweight and obesity was in 37,4% and in PCOS patients 11,9%. 
Incidence of HbA1c> 6,4% was 6 (4,5%). It should be mentioned that this test has not 
been validated in PCOS so far. 
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6. DISCUSSION 
 
Adipose tissue (AT) is a highly variable body component both in terms of its total 
amount and by location. There is a typical gynecoid and android distribution of AT, 
subcutaneous or central (visceral) fat deposition or distribution in smaller, discrete 
depots. Adipose tissue is the main energy storage, the controller of its homeostasis and 
balance. In addition, AT exhibits extensive hormonal activity and controls 
thermoregulation. Obesity is a multifactorial chronic disease characterized by excessive 
storage of adipose tissue subcutaneously and viscerally. Obesity is associated with a 
variety of health disorders, from insulin resistance, metabolic syndrome, glucose 
intolerance, hormonal disorders to reduced fertility and reproductive risks. The highest 
risk is caused by central obesity which, along with the above-mentioned risks, is a low-
grade inflammation condition (1,7,10,12,11). 
 
The frequency of obesity in the world has doubled over the past 30 years, and in many 
countries the prevalence of overweight women is 30%, while obese women account for 
20-30% (and more) of the population. The prognosis is even worse because the 
incidence of obesity (with significant geo-epidemiological differences) continues to grow 
and is considered as a warning epidemic. There is abundant evidence that obesity and 
especially central obesity reduce fecundity, thus prolonging time to pregnancy, reduce 
female fertility and increase the risks and complications of pregnancy and childbirth 
(2,3,4). 
 
Infertility is a disease of the reproductive system that reduces conception and birth. 
There are numerous female and male causes of infertility, and obesity is becoming an 
increasingly important epigenetic factor of reduced fertility. Interestingly, in parallel with 
a rapid increase in obesity, the incidence of infertility in the last 3 decades has 
increased from 10% to 17% of couples. That is why these two disorders are interrelated. 
An additional reason for relating obesity and infertility is the frequent association of 
obesity with polycystic ovary syndrome (PCOS), which also has a high prevalence in 
the infertile female population (25-35%). It has been shown that obesity and PCOS 
alone or jointly disturb the menstrual cycle, cause anovulation and cause reproductive 
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risks through severe hormonal activity disorders and insulin resistance. Each of these 
diseases can have an important effect on ovarian reserve (OR), which is an important 
precondition for normal fertility (14,17,20,31,37). 
 
These are the reasons why we investigated the effect of obesity on ovarian reserve. 
Anthropometric obesity parameters were analysed in order to correlate the independent 
effect of obesity on ovarian reserve and fertility with the effect of PCOS on these 
parameters. Obesity alone, and jointly with PCOS, creates an unfavourable hormonal 
and metabolic milieu, oxidative stress, dyslipidaemia, subclinical inflammation and 
impaired fibrinolysis. While the effects of PCOS are unquestionable, many effects of 
obesity, especially on ovarian reserve, remain controversial and no consensus has 
been achieved (26,40,45,47-59).  
 
Analysis of the ovarian reserve should consider the natural decrease of OR with age, 
where AMH shows an annual decrease from 0.7 to 1.5 pmol/L after the age of 32 (≈ 5% 
per annum) (61,67,77).Therefore, this study included young patients of an average age 
of 32 years. 
 
The study included 182 participants who were divided by BMI values into normalweight 
(BMI 18.5-24.9 kg/m2), overweight (BMI 25-29.9 kg/m2) and obese (≥ 30 kg/m2). There 
were 130 (71.4%) participants affected only by infertility and increased BMI, and 52 
(28.5%) PCOS patients. Similarly, the prevalence of PCOS in obese infertile women 21 
(33.8%) was identified by several authors (63,73,75). Also, large epidemiological 
studies (meta-analysis of 35 studies) have found a high incidence of overweight and 
obesity (61%; OR 2.31: CI 1.67-3.19) in the PCOS population, i.e. 30% of PCOS in the 
obese population and 75% of obese women in the PCOS population (70,72,77). 
 
In our non-PCOS female population, there were 81 (62.3%) women who were 
overweight and obese, and the prevalence of such a BMI in the PCOS population was 
71.7%. Yildiz and Azziz found the impact of obesity on the prevalence of PCOS to be 
minimal (73). 
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Today, the incidence of obesity in the infertile population is 30-35%, and the incidence 
of anovulatory infertility is 3 times higher than in the normal-weight population. Each 
increase of BMI by 1 unit (above 25 kg/m2) reduces fecundity and CPR by 4% and live 
birth rate (LBR) is lower by 2%. Each further increase of BMI by 1 unit above 30 kg/m2 
reduces IVF success by 7% (14,48,52). 
 
It has been found that an increase in obesity in the PCOS patients significantly 
increases the incidence of insulin resistance. In normal-weight PCOS women the 
incidence of IR is 55%, in overweight women 75%, and in obese PCOS patients the 
incidence of IR is higher than 90% (60,68,74).  
 
Morbid obesity was found in only 5% of the patients, which is less than the numbers 
found in literature (73). 
 
Participating patients exhibited long-term infertility, primary or secondary, longer than 4 
years (ranging from 1 to 17 years), and only 21% had received infertility treatment. This 
information is indicative of the social environment in which most of the research was 
carried out. Women marry early and wait long to see a doctor. Obesity is not considered 
a handicap for fertility, and sometimes infertility lasts for more than 10 years. The 
average age of our patients was 32 years. The duration of infertility is not prolonged by 
an increase in obesity (BMI). 
In western literature data is different and women report infertility at an average age of 
34 years, after 2 years of failure (1,49). 
 
The incidence of male infertility factor today is 40-55% according to most relevant 
studies (14,40). In our population, male subfertility was identified in 25% to 34% of 
couples, but it should be noted that women with a completely infertile partner 
(azoospermia) were excluded from the study. Here we recall that the probability that an 
obese infertile woman also has an obese partner is around 70% (40). 
 
By analysing the demographic characteristics of our participants, it is understandable 
that body weight increases significantly with increased BMI. Interestingly, we found 
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significantly more previous pregnancies, births (secondary infertility) in overweight 
(21.4%) and obese population (19.3%) than in normal-weight patients (9.4%). Such 
findings are difficult to interpret because there is less PCOS and anovulation in patients 
with normal BMI. It is probable that there may be other unidentified causes of infertility 
in normal-weight women. 
 
Thyroid disorders have roughly the same incidence in all three groups of patients. 
Therefore, obesity in our patients is not related to subclinical and overt hypothyroidism 
(TSH > 4.2 mU/L). However, if we observe BMI groups II and III and morbid obesity, 
elevated TSH levels above 3.5 mU/L are found in 26 patients (22.3%). This is in 
accordance with more frequent claims in the literature about a positive correlation 
between TSH and progressive weight gain (BMI).It is also stated that hypothyroidism 
has a higher prevalence of obesity and that obesity occurs with thyroid dysfunction 
(1,7). Such findings are expected because the thyroid is involved in the control of 
energy homeostasis, thermoregulation and leptin activity. 
 
Waist circumference is the basic measure of central (abdominal) obesity, leading to 
the most severe hormonal and metabolic disorders. No WC differences were found 
within individual BMI groups. Obese patients have a statistically significantly higher WC 
than overweight and normal-weight women. Obese PCOS patients have a high 
prevalence of visceral obesity according to all anthropometric parameters, WC is 
greater than 88 cm in 76% of these patients, WHR > 0.85 in 66.7% of women. 
Combined indicators of central obesity are positive in as many as 90% of obese PCOS 
patients. Obesity alone (without PCOS) is associated with central obesity in 68% of 
participants. Normal-weight participants have a low incidence of central obesity. 
 
Waist-to-hip ratio (WHR) is a reliable indicator of upper body obesity (and visceral 
obesity) and points to the predominance of android obesity over gynecoid obesity. 
Borderline WHR was found in obese non-PCOS patients (0.84), while WHR was 
pathological (0.88) in obese PCOS women. WHR is statistically significantly higher in 
obese participants compared to lean women. Half of our obese patients had central 
obesity according to WHR. In our anthropometric analyses, the most powerful indicator 
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of central obesity was the ratio of WC to patient height – waist to stature ratio (WSR). 
Pathological values of that ratio (>0.50) were recorded in almost all obese patients. 
According to all indicators, the prevalence of central obesity in our patients was as 
follows: 
Patients Non-PCOS PCOS 
Normal-
weight 
10% 20% 
Overweight 15% 31.2% 
Obese 68.3% 90.4% 
 
Similar incidence of central obesity in women with increased BMI was also found in 
other studies, where the prevalence ranges between 65% and 85% (5,9,10,11). There 
is sample evidence of a strong effect of central obesity on subfertility, due to frequent 
occurrence of oligomenorrhea and anovulation (OR 0.60, 0.4-0.89) and the association 
with insulin resistance (IR). Palomba found statistically significantly lower fecundity in 
women with: BMI > 40 kg/m2, WHR > 0.85 or WC > 90 cm (70). Conversely, Dumešić 
(141) claims that obesity leads to reproductive disorders only with IR, and increased 
insulin levels are found in more than 90% of women with BMI > 30 kg/m2 and central 
obesity. Central obesity phenotype induces higher risk PCOS phenotypes (A and B), 
thereby contributing to higher reproductive risks. Obesity alone decreases ovarian 
reserve by 40-60% (56,59,70). By contrast, Escobar-Morreale finds that while obesity 
alone does not diminish the ovarian reserve, that effect is exerted by obesity and 
PCOS. It was also found that any increase in WHR by 0.1 reduces fecundity by 30% – 
OR 0.70 (CI 0.56-0.88) (110). It is emphasized that WHR > 80 reduces in vitro 
fertilization (IVF) success rates by more than 50% – clinical pregnancy rate (CPR) OR 
0.42 (CI 0.2-0.90). In Carmina et al., the prevalence of central obesity was reported to 
be 30% for lean PCOS patients, and 71% for overweight and obese PCOS women 
(89,104). 
 
Several (direct and indirect) associations have been highlighted where central obesity 
with polycystic ovary syndrome affects the anti-Müllerian hormone levels and ovarian 
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reserve. These include increased LH and androgen activity, the effect on AMH 
receptors (AMH-R2), recruitment of small antral follicles and IR (1,46,47,110). 
 
Hip circumference (HC) is a measure of subcutaneous gynecoid obesity phenotype, 
which does not increase metabolic and reproductive risks. In this study, no HC 
differences were determined within BMI patient groups, while increased BMI led to 
statistically significant differences between obese and lean patients. The more 
pronounced the gynecoid obesity type, there is less likelihood of central obesity. Our 
patients were characterized by expressed upper body fat and a high WC contributing to 
central obesity. 
 
Menstrual cycle -Obesity and PCOS are powerful factors that disturb the menstrual 
cycle because both syndromes are involved in the control of the hypothalamic-pituitary 
axis. The adipokine leptin is an important central biosignal that informs the brain of 
energy stored in adipose tissue. It participates in modulating the function of the appetite 
centre and the neuroendocrine control of GnRH and its pulsatile neurosecretion. 
Adipokines also affect the function of follicles in the ovaries. The necessary amount of 
adipose tissue (energy reserve) influences menarche and the ovulation cycle, while 
excess AT, or obesity, can disturb the menstrual cycle, cause earlier onset of menarche 
and induce anovulation (14,20,24,34). Central obesity and PCOS lead to chronic 
oligo/anovulation, hyperandrogenism and IR (48,49). 
In this study, earlier onset of menarche was recorded in obese patients with PCOS 
(11.6 years), which is statistically significantly earlier than late menarche in polycystic 
ovary patients (13.9 years). PCOS sometimes postponed menarche until the age of 16. 
Irregular cycles, oligo/anovulation, were recorded in 21% of all non PCOS women and 
in 25% of obese patients in that group. In contrast, 69.2% of PCOS patients had 
irregular menstrual cycles and anovulation. The highest prevalence of chronic 
anovulations was found when obesity was combined with PCOS (85.7%), and likewise 
irregular cycles in 80.9% of patients. This frequency is significantly higher than that in 
lower BMI patients and non-PCOS patients. With obesity alone, amenorrhea was rare 
(4-7%), depending on BMI, while 17.3% of PCOS patients reported amenorrhoea. 
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Obese women had longer and heavier menstrual bleeding than normal-weight 
participants. In obese PCOS patients, the average duration of menstruation was 5.82 
days (3-8 days), and HMB was reported by 24.3% of obese and overweight PCOS 
women. Heavy menstruation is less common in women of normal body weight. 
Menstrual cycle is prolonged by obesity. In our study, the average cycle in obese 
women was 3 days longer (30.12 vs. 27.53 days) in non PCOS patients, and PCOS 
women had 6 days longer cycle (39.5 vs. 33.7 days). Oligomenorrhea is characteristic 
of overweight and obese PCOS patients. In all BMI groups, patients had shorter cycles 
if there was no polycystic ovary syndrome. Obese PCOS patients have a statistically 
significantly longer cycle (39.5 days) compared to all other patient groups. Menstrual 
cycle characteristics in participating populations were the following: 
Patients Non-PCOS PCOS 
Menarche 
Age/Y 
11.9 13.5 
Menstrual cycle 
length 
Days 
28.6 36.4 
Irregular cycles  
% 
20.8% 69.2% 
Anovulation  
% 
29.2% 67.3% 
Heavy menstrual 
bleeding OV/OB  
% 
13.6% 24.3% 
  OV - overweight; OB - obese 
There is a lot of ongoing discussion on the impact of obesity or PCOS on the menstrual 
cycle. Several studies have found that increased BMI prolongs the cycle and leads to 
oligomenorrhea and irregular cycles (RR 3.1 CI 2.2-4.4). Obese adolescents have a 
higher incidence of irregular cycles than the lean control (54% vs. 19%), and 40% have 
cycle disturbances with abnormal uterine bleeding (AUB). These patients are at a 
significant risk of infertility later in life (OR 2.84; CI 1.59-5.10) (14,50,52).  
 
122
 
 
 
 
Elevated BMI and obesity significantly reduce ovulation (OR 0.92; CI 0.88-0.96) 
(14,139,141). The incidence of infertility with obesity is 30-35% (52,75), mainly due to 
anovulation.The prevalence of anovulation in occult PCOS is 14.5%, while in real PCOS 
anovulation incidence is 58% (141). 
Women with BMI ≥ 30 kg/m2 were also found to have statistically significantly more 
endometrial polyps (52% vs. 15.6%) and AUB (131). 
Women with oligomenorrhea or amenorrhea have a 90% probability for PCOS, but it is 
stated that 20-30% of PCOS cycles may be ovulatory (80). The same consensus points 
out that according to the Rotterdam criteria, 20-30% of PCOS patients have regular 
cycles, 40-50% have oligomenorrhea, 21% have amenorrhea and 7% have 
polymenorrhea. According to NIH criteria for the diagnosis of PCOS, all patients have 
hyperandrogenism and irregular cycles (70,72,77,80,101). 
 
In a study of 26,000 women it was found that cyclic irregularity and anovulation are 
correlated with overweight and obesity. Obese women have 3.1 times more menstrual 
disorders than lean women (B and B). Elia et al. emphasize that oligomenorrhea is 
associated with central obesity (48). 
 
In 1741 British women with PCOS, 70% have menstrual cycle irregularities, while obese 
PCOS women have a higher prevalence (78%) of cycle irregularities (14,110). Similarly, 
a smaller study with 263 PCOS women found that obese women have an 88% chance 
of cycle irregularities, while non-obese women have an irregular cycle in 72% of cases 
(110). Central obesity with or without PCOS has a strong effect on chronic anovulation, 
cycle irregularities and reduced fertility in women.  
The disorders described in the conclusions of these studies are associated with central 
and peripheral hormonal and metabolic effects of adipokines and PCOS. The 
pathophysiology of anovulation is based on the disturbed control of kisspeptin and 
neurosecretion of GnRH, and on the effects of hyperandrogenemia and 
hyperinsulinemia (70,74). 
The mechanism of prolonged and heavy menstrual bleeding (HMB) involves a 
disbalance in the production and activity of estrogen and progesterone, and focal and 
abnormal endometrial transformation. Also interesting are meta-analysis findings about 
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weight loss in morbidly obese patients. A significant drop in BMI decreases the 
prevalence of PCOS and hirsutism, leading to a reduction in menstrual cycle irregularity 
(from 56.2% to 7.7%) and infertility (from 18.2% to 4.3%) (14,79,135,138,139). 
 
Previous pregnancies- Unlike normal-weight women who achieve an 81.4% 
probability of pregnancy in one-year, obese women have a 66.4% chance of getting 
pregnant (14,45). This means that obese women are subfertile, while obese PCOS 
women are 10 times more likely to be infertile. While for normal couples it takes 4.8 
months on average to achieve pregnancy (TTP – time-to-pregnancy), with obesity and 
PCOS this time is extended 3-5 times (1,12). If both partners are obese, it takes 60% 
more time to achieve pregnancy (1,7,124), i.e. OR for subfecundity is 2.74 (CI 2.27-
3.30).Although our research does not have the strength (because of the number of 
patients) or design to investigate fertility parameters, some findings are unexpected. 
This primarily concerns the number of earlier pregnancies and developed secondary 
infertility. In 56 (30.8%) secondary infertile patients in the investigated population, there 
were as many as 91 pregnancies. In that number, there were 50 early spontaneous 
abortions (59.9%), significantly more in overweight and obese populations (88%). In the 
normal population TTP reported by the patients was 9.5 months. Obesity alone without 
PCOS prolongs the time to earlier pregnancy two times. In obese PCOS patients, 
pregnancy (birth or miscarriage) occurred after two years of exposure (25.6 months). 
Morbid obesity further prolongs TTP by 26% or 23%, depending on whether PCOS is 
involved. These results, although obtained on a small sample, are consistent with larger 
studies (136,139). 
Ramlau-Hansen et al. analysed 47,835 couples from the Danish registry and found that 
female obesity prolonged TTP by 30% (OR 1.32: CI 1.26-1.37) (50). According to 
Broughton and Moley, obesity significantly increases TTP and reduces fecundability, 
obese women are subfertile even without anovulation (124). This fact is explained by IR, 
hyperandrogenism and adipokine dysfunction, as well as the effects on oocyte 
development and endometrial receptivity. Obesity is associated with subfecundity (OR 
0.72: CI 0.63-0.83), as shown in a study conducted on 7,327 women (14). 
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A high incidence of early spontaneous abortions (SAB) with elevated BMI and (or) 
PCOS has been demonstrated by numerous studies, although findings are not fully 
consistent. (14,106,110,111,117,120,126,127,139). 
 
In a meta-analysis of 33 studies and 47,967 IVF cycles, Rittenberg et al. (120) have 
demonstrated that an elevated SAB risk is associated with patient obesity – OR 1.43 (CI 
1.22-1.67). This finding is confirmed by other studies and meta-analyses in which an 
analysis in natural and IVF pregnancies increases RR risk for SAB by 30-60% (14). Tian 
et al. (122) link the high risk of SAB with insulin resistance, which creates a big 
difference compared to the normal population – 47.8% vs. 9.5% (OR with IR = 8.32: CI 
2.65-26.17). This finding is even more significant if we take into consideration that 90% 
of obese PCOS patients are IR (31,45,49,58,139,140). 
 
In a large study including 9,068 women with PCOS who were obese in 54% of the 
cases (14). The increased incidence of spontaneous abortions in this population was 
statistically significant - OR 1.70 (CI 1.56-1.84).  
Important research has also been published that does not confirm an association 
between obesity and SAB (80,133,134). In contrast to this controversy, findings about 
the association between spontaneous abortions and PCOS are consistent. On a sample 
of 1,962 cycles it was found that with elevated levels of testosterone and AMH (> 50 
pmol/L), which are characteristic of a riskier phenotype of PCOS, there is a significant 
increase of SAB incidence (30% vs 19%), i.e. OR 1.39 (CI 1.22-2.86) (103). There are 
findings about SAB incidence of 30-50% in obese PCOS patients (117,122). Goldman 
did not find more aneuploidies in miscarriages, which has been confirmed by other 
authors (123,130).In 2,349 pregnancies of obese and morbidly obese women Wang et 
al. found a high risk for SAB (OR 1.71 and 2.19 respectively) (130). 
 
Effects of obesity and PCOS on regulatory hormones- Normal folliculogenesis, 
ovulation and endometrial maturation require a complex interaction and balance of 
hormones. Obesity and PCOS disturb the production and activity of regulatory 
hormones by direct and indirect mechanisms. Hormone disorders also include 
adipokine imbalance and hyperinsulinemia, and the effect of both syndromes on 
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neurophysiological events in the hypothalamus and the pituitary gland. Central and 
peripheral hormonal disorders are even more complex when obesity and PCOS are 
combined. In accordance with our possibilities, we have investigated the changes in 
some pituitary hormones and the response of ovarian hormones in patients with 
infertility due to obesity and PCOS. It is known that obesity reduces FSH and LH and 
decreases LH amplitudes and increases hyperandrogenemia. PCOS reduces FSH, 
increases LH and its pulsatility, mildly increases PRL, and more strongly increases the 
androgens. Elevated LH in lean women with PCOS opens a path to 
hyperandrogenemia. Defective insulin signalling leads to IR, and receptor 
phosphorylation and abdominal AT phenotype increase de novo androgen production in 
adipocytes. Both syndromes reduce the production of SHBG and thus increase the 
activity of androgens. Gonadotropins and androgens are co-factors in the control of 
ovarian reserve and anti-Müllerian hormone (1,7,34,40,47). 
 
In this study, we have found that weight gain and increasing BMI lead to a reduction of 
FSH, which is significantly lowest in the obese PCOS population (4.67 IU/L). Obesity 
also reduces LH, which is highest in the lean non-PCOS and PCOS patient group. It is 
expected that LH levels (and activity) are the highest in the normal-weight PCOS 
population (9.98 IU/L), in which only the LH/FSH ratio recorded the inversion 
characteristic for PCOS (> 2.0). In all BMI groups of participating women with PCOS, LH 
levels were higher than FSH levels. These results are in accordance with the data about 
the pathophysiological changes in obesity and PCOS, especially with the interpretations 
of oligo/anovulation and cycle prolongation due to disturbed gonadotropins, as 
described above. All hormonal analyses were performed under basal conditions. The 
mean prolactin level (PRL) in our infertile patients was within the normal range. In all 
BMI groups PRL is statistically significantly higher in PCOS patients. Overall, PCOS 
patients had 25% higher PRL (20.37 ng/mL vs. 15.22 ng/mL) and 6 (11.5%) had slightly 
abnormal PRL levels. Only 4 (3.1%) women without PCOS had abnormal PRL levels. 
The levels of estradiol are similar in all three investigated BMI groups. No 
difference in E2 was found between obese only and PCOS patients. This hormonal 
analysis is partially in line with the findings in the literature, with more mildly expressed 
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hormonal changes than described. It should be noted that the basal E2 is an indirect 
ovarian reserve marker. 
Hypersecretion of LH and elevated LH/FSH ratio have been shown to be 
unfavourable controllers of folliculogenesis in obese infertile women (1,34,35). These 
disorders are even more strongly expressed in polycystic ovarian syndrome (58,59,61). 
High LH and increased pulsatility stimulate AMH hypersecretion and are the main 
pathophysiological mechanism of hyperandrogenemia. In obese PCOS patients, the 
path to elevated androgens is also achieved with IR. Insulin is an active factor 
(cogonadotropin) in the stimulation of steroidogenesis in theca cells. An imbalance of 
FSH and LH in the follicle is transmitted to autocrine and paracrine secretion disorders 
(1,40,141,142). The hormonal ovarian disorders in obesity also include leptin, which 
disrupts steroidogenesis and folliculogenesis. Leptin participates (with insulin) in 
controlling the secretion of gonadotropin (41,49). Weight loss leads to a reduction in LH 
secretion but does not affect pulsatility.The central effects of hormones in PCOS disturb 
dopamine secretion and may result in mild hyperprolactinemia (1,7,57). 
 
Androgen activity- Androgens play an important role in pathophysiological disorders 
associated with adiposity, visceral obesity and polycystic ovary syndrome. 
Hyperandrogenemia regularly occurs with more severe obesity and PCOS phenotypes. 
Since both obesity and PCOS are combined in 60-80% of patients, the mechanism of 
increased androgen activity in these syndromes is complex. Increased androgen activity 
depends on the production in theca cells, adipocytes and the adrenal gland. In adipose 
tissue, androgens are created de novo from cholesterol, or by the conversion of 
androstedione to testosterone. Serine phosphorylation of the enzyme P450c17 
additionally stimulates hyperandrogenism (26,28,29,70,72,94). SHBG level is an 
important regulator of androgen and estrogen activity. As insulin and TNF-α inhibit 
SHBG, its low levels lead to more free androgens in the circulation. This means that IR 
and elevated androgens are interdependent. In addition, elevated LH levels and 
pronounced pulsatility in PCOS upregulate LH receptors in theca cells, which are the 
main source of ovarian androgens. Hyperandrogenemia stimulates lipolysis and induces 
central obesity adipocyte hypertrophy. It stimulates IR and disturbs the cycle centrally 
127
 
 
 
 
and peripherally, leading to anovulation. Androgens accumulate in adipose tissue. 
Increased androgen activity positively correlates with ovarian reserve (81,85,87). 
 
In this study we investigated the relationship of obesity and PCOS with testosterone 
levels, SHBG and free androgen index (FAI). In patients without PCOS, BMI increase is 
associated with mildly elevated testosterone levels (T), and T is significantly higher in 
overweight and obese patients compared to normal-weight women (1.82 vs. 1.38). T 
levels in PCOS patients are significantly higher than those of non PCOS women (2.44 
vs. 1.66 nmol/L), but there are no differences in T levels in PCOS women of different 
weights. The insignificantly highest T levels appear in lean PCOS patients. SHBG levels 
in our patients show a wide distribution. In line with expectations, the production of 
SHBG and its levels in the circulation are reduced with obesity. SHBG was statistically 
significantly lower in PCOS patients compared to patients with obesity alone (35.96 vs. 
55.96 nmol/L). Obesity alone slightly reduces SHBG, and when combined with PCOS, 
SHBG decrease is more pronounced (32.60 nmol/L).  
 
Androgen activity is expressed by an average FAI index which was within normal limits 
in all groups of patients without PCOS. No association was found between increased 
androgen activity and weight gain. All BMI groups of PCOS patients have elevated FAI 
(average 6.83). FAI was statistically significantly higher in lean and obese PCOS 
patients compared to non-PCOS patients of the same weight:  
Patients Non-PCOS PCOS 
Testosterone 
nmol/L 
1.66 2.44 
SHBG 
nmol/L 
55.96 35.96 
FAI 2.87 6.83 
 
In our normal patient’s androgen activity measurements were the following: testosterone 
1.38 nmol/L, SHBG 61.1 nmol/L, and FAI 2.07. These androgen results correlate well 
with the data about oligo/anovulation and general and central obesity measurements. 
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Obesity has a smaller independent effect on androgens than the expected findings from 
the literature. Therefore, even a mild increase in androgen levels can influence cycle 
disorders, most likely through changes in androgenic receptors. 
 
Crujeras et al. (52) explain that obesity affects the reduction of reproductive capacity by 
supressing LH amplitudes and SHBG, and the reduction of free androgens through 
insulin stimulation. The same findings on the effects of obesity are highlighted by the 
Practice Committee ASRM (14). The significance of hyperinsulinemia for HA in PCOS 
patients is also frequently highlighted. When BMI is normalized, the significance of HA 
(66,67) may be reduced 50 percent. Broughton et al. (124) have found subfertility in 
obese patients due to lipotoxicity and oxidative stress even when there is no ovulation 
dysfunction. 
 
Norman et al. (77) state that 75% of PCOS patients have gonadotropin dysregulation. 
Also, the concentration of the KISS neuropeptide is negatively correlated with BMI, FAI 
and IR. There is ample evidence that central obesity increases T levels and inhibits 
SHBG, thereby increasing FAI. Also described is the notion of asymptomatic 
hyperandrogenemia (functional HA), which is based on intracrine activity and variable 
androgenic synthesis (1,7). Androgens increase LH activity and inhibit FSH. 
Dumešić et al. (141) emphasize that SHBG is the most sensitive measure of 
hyperandrogenism due to elevated free T. The risk of complications in pregnancy is 4 
times higher with hyperandrogenism (78,139). Insulin resistance is the 
pathophysiological link between obesity and PCOS in the stimulation of 
hyperandrogenemia. Compensatory hyperinsulinemia affects ovaries, which remain 
responsive to insulin, stimulating androgenesis in theca cells (139,140). Elevated 
androgens in obese women and PCOS patients thus lead to oligoovulation/anovulation 
and subfertility. In 20 to 40% of PCOS patient’s androgen levels are not elevated (1,7), 
but there may be a stronger effect on androgen receptors. Increased androgen levels 
increase the ovarian reserve of preantral and small antral follicles, which is important in 
the pathogenesis of PCOS (66). 
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Ovarian reserve- Ovarian reserve (OR) is the total number of follicles in early stages of 
development that can be recruited and further developed by folliculogenesis. Ovarian 
reserve is a fundamental factor in female reproductive potential and is estimated by the 
number of small antral follicles measuring 2 to 10 mm in diameter, AMH levels and 
ovarian volume (OV). Antral follicle count (AFC) is determined using vaginal ultrasound 
by scanning multiple sections of the ovary. The results of this test depend on the 
sensitivity of the US machine, the number of scanned sections, and on the experience 
of the expert. Many reserve follicles directly increase ovarian volume. In an increased 
number of follicles and in more active granulosis, a larger amount of AMH is produced. 
The ovarian reserve, i.e. the results of its biomarkers, depends on a number of factors 
such as age, genetic and epigenetic effects. Also, some diseases such as 
endometriosis, tumours, malignant and autoimmune diseases can significantly reduce 
OR. Any ovarian surgery or oncological treatment can significantly reduce the 
reproductive potential. Age, or aging, is the most constant factor of OR reduction. It has 
been found that with every year after the age of 32 AMH levels are naturally reduced by 
0.7-1.4 pmol/L, or 2.5-5% per year. In contrast, excision of endometrioma can reduce 
AMH by as much as 35% (32,81-93). 
 
Several studies have warned that obesity may reduce ovarian reserve by as much as 
40-50% (56,81). In contrast, PCOS is characterised by high ovarian reserve, dominated 
by abnormal AMH and AFC. An indirect measure for normal ovarian reserve and fertility 
is a favourable level of basal FSH and E2(100,141,142). 
 
Ovarian reserve markers are not only a powerful predictor of fertility and sensitivity of 
the ovaries to gonadotropins, but also of infertility treatment success. High OR may also 
point to the risk of ovarian hyperstimulation, while low ovarian reserve is an indicator of 
poor ovarian response and resistance to gonadotropins. The findings about OR as a 
measure of oocyte quality are inconsistent, as there are claims that reserve biomarkers 
are only an indicator of quantity (95-104). 
In investigating this population, we wanted to determine the ovarian reserve in 
obese and PCOS patients. We also sought to explore other fertility indicators and their 
correlation with OR biomarkers. 
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 It was found that increased BMI did not lead to changes in AMH levels in the 
circulation, i.e. obesity in neither non-PCOS or PCOS patients reduced the production 
of that hormone. As expected, AMH is statistically significantly higher in PCOS patients 
in all body weight categories (56.15 pmol/L vs. 14.76 pmol/L). 
 Antral follicle count (AFC) is also independent of the amount of adipose tissue, 
i.e. obesity, because there are no intergroup differences. PCOS patients in all BMI 
groups have statistically significantly higher AFC (24.3 vs. 9.02). These findings are 
consistent with the diagnostic criteria (Rotterdam) for PCOS/PCOM (80,88,89). 
 The highest ovarian volume was found in normal-weight PCOS patients, which is 
statistically significantly higher than in non-PCOS patients (9.84 vs. 6.33 ml). No 
correlation was found between OV and the amount of adipose tissue. Patients without 
PCOS do not exhibit a change of ovarian volume even when they are obese. Only 
PCOS patients (63.5%) have OV greater than 10 ml. 
 Oligomenorrhoea or menstrual cycle longer than 40 days and anovulation have 
an elevated ovarian reserve compared to AMH levels. Such cycles are characteristic of 
PCOS patients. Anovulation cycles always have higher AMH levels in the circulation 
compared to the normal cycle (66.4 pmol/L vs. 45.8 pmol/L in PCOS population). 
 In our morbidly obese patients, ovarian reserve markers are reduced, but these 
differences are not significant due to a small number of extremely obese patients. The 
effect of obesity on ovarian reserve biomarkers is shown in Table 38. 
Table 46. Ovarian reserve markers in obese patients 
 
Patients 
BMI ≥ 30 kg/m2 
Non-PCOS PCOS 
AMH 
pmol/L 
15.47 57.18 
AFC 
 
9.41 25.76 
Ovarian volume 
Ml 
6.69 9.87 
FSH 
IU/L 
6.14 4.67 
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Obesity is not a factor affecting the ovarian reserve in our patients, and FSH levels are 
not a reliable marker for OR evaluation. According to these findings, OR markers are a 
good indicator for infertility treatment and individualization of gonadotropin doses in 
ovarian stimulation. These findings can be a reliable predictor of treatment success. 
Since obesity does not reduce OR markers, it also does not diminish the risk of ovarian 
hyperstimulation. No association was found between obesity and weak ovarian 
sensitivity to fertility drugs, but this claim does not have a solid foundation in our 
analyses. Obese patients in our study have the same ovarian reserve as the lean 
(normal) population. All patients with PCOS and amenorrhea (9 women) had AMH 
levels above 90 pmol/L. 
 Numerous studies have investigated the relationship of obesity and PCOS with 
ovarian reserve markers and female fertility. AMH levels have become a criterion for the 
diagnosis of PCOS, and a positive correlation of AMH with LH, AFC (especially with 2-
5mm follicles), hyperandrogenism and anovulation (98,100,141) has been confirmed 
repeatedly. Also, the association of AMH with insulin resistance and ovarian 
hyperstimulation syndrome (OHSS) has been demonstrated, as well as a negative 
correlation of AMH with BMI, FSH and ovulation cycles (100,101,142). High levels of 
AMH (> 50 pmol/L) are combined with high ovarian sensitivity to FSH (ovarian 
sensitivity index) and an elevated risk for OHSS (OR 6.8: CI 4.9-9.6) (40,80,81). 
Elevated AMH levels and IR are associated with a significantly higher risk of 
spontaneous abortions (139,142). 
 The Practice Committee of ASRM (81) has confirmed that obesity alone does not 
affect AMH, but that AMH levels are reduced in obese PCOS patients. Responses to 
that question remain controversial. 
 Bhide et al. have established criteria for PCOS according to ovarian reserve 
findings: AMH 55 pmol/L, AFC 30, AMH/AFC ratio > 1.90 (86). An AMH/AFC ratio level 
lower than 1.20 was the criterion for PCOM diagnosis. 
 No correlation was found between high ovarian reserve in PCOS women and 
longer "window of fertility", because after the age of 40 these patients experience a 
faster decrease of ovarian reserve (84,90). AMH has central and peripheral effects on 
ovulation control and folliculogenesis, it inhibits FSH activity and is a diagnostic marker 
for hyperandrogenism (66,95). Dumešić claims that high AMH and androgen levels, and 
132
 
 
 
 
oligomenorrhea are clear signs of insulin resistance (141). This is also confirmed by 
Crujeiras, who finds that 94% of obese PCOS patients have IR (52). 
 Jungheim found that women who developed OHSS were lean with high AMH 
levels, while all women with poor ovarian response (POR) had BMI > 30 kg/m 2 and low 
AMH levels (136). 
 Although the number and quality of oocytes decline with age, fertility is highly 
variable within the same age group. Ovarian reserve tests are neither an absolute 
measure of fertility, nor of the onset of menopause. OR testing contributes to the 
diagnosis of women with diminished ovarian reserve (DOR) and poor responders to 
therapy (81,141,142). The same study and many others point out that ovarian reserve 
tests should not be the only criterion for withdrawal from treatment because they do not 
mean (even when they are very low) a complete impossibility of getting pregnant. With 
aging and decreased ovarian reserve, and with DOR, there is a rise in basal FSH (≥ 12 
IU/L) and estradiol (> 70 pg/ml) levels with a shortening of the follicular phase and the 
menstrual cycle as a whole (40). These indicators together with ovarian reserve tests 
have an important prognostic role in the treatment of infertility and IVF success. A high 
ovarian reserve points to a risk of OHSS and to high responders, while a low reserve is 
linked to a prognosis of POR and poor success. AMH levels lower than 5 nmol/L, AFC < 
4 and ovarian volume < 3 ml point to very low OR (40,139,142). In that case the 
prognosis for treatment and success (most frequently IVF) is very poor. 
 In contrast, very high ovarian reserve complicates treatment due to high 
response and decreased endometrial receptivity, which is avoided using "freeze all" 
technology. It has been shown that ovulation stimulation (OS) and laparoscopic ovarian 
drilling (LOD) are more successful if AMH levels are below 50 pmol/L (101,133). 
  In our young (32) but long-term infertile patients, we have not found that 
elevated BMI was associated with a higher frequency of low ovarian reserve. DOR or 
poor ovarian reserve was equally represented in all three patient groups. The POR 
criterion was one or more of the following findings: AMH ≤ 5 nmol/L, AFC ≤ 4 ili FSH > 
10 IU/L.            
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Table 47. Markers of poor ovarian reserve in non-PCOS patients 
 
BMI 
Group I  
n = 64 
Group II  
n = 56 
Group III  
n = 62 
PORn (%) 9 (14.1%) 10 (17.8%) 5 (8.1%) 
Estradiol> 70 pg/mL                n 
(%) 
7 (10.9%) 3 (5.3%) 5 (8.1%) 
 
Similar findings are also shown by elevated basal estradiol levels. Patients with 
polycystic ovary syndrome did not have POR results, and only 5 overweight and obese 
PCOS women had elevated E2 (5/32 – 14.3%). 
Increased FSH, and high or low AMH levels are not associated with the risk of 
aneuploidy in pregnancies following IVF (141,142,143). More frequent spontaneous 
abortions in these populations don’t seem to be related to OR, but to obesity (or PCOS) 
and insulin resistance. Single FSH value has limited value due to inter-cycle variability 
(40,81). Ovarian reserve screening tests are valuable for the clinician if they are 
predictive. Using only FSH is therefore less sensitive for the prediction of success or 
failure of infertility treatment. There is a similar consensus on the diagnostic and 
predictive value of basal estradiol (1,40). 
For a long time, research has been attempting to determine the cutoff AMH 
values for predicting reduced success, POR and high response in IVF procedures. As 
mentioned in the introduction, these AMH values are 7.5 for poor and 25 pmol/L for high 
response (81,91,92). AFC cutpoints are 3-4 follicles for POR and 20 follicles for HR. 
Ovarian volume in low ovarian reserve patients is lower than 4 ml and for PCOM/PCOS 
patients greater than 10 ml (81). Ovarian volume is a weak predictor for IVF 
pregnancies. It is increasingly recommended to use a combination of ovarian reserve 
tests to achieve a better prediction of success, failure and risks of treatment. Today's 
consensus is the recommendation to evaluate OR through a combination of AMH, AFC 
and ovarian volume (81,139,141,142,143). 
Opinions on AMH were presented as a good or unreliable predictor of IVF 
success differ (121). Longer cycles, elevated AMH levels and high AFC are predictors 
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of high LBR (88,112). It should be noted that gonadotropins and AMH have different 
isoforms and different types of receptors, which can significantly alter their activity. 
Also important is the transfer of pulsatility from growth hormone to leptin and 
FFA, and the fact that only changes in pulsatility may alter the activity of the hormones. 
According to the results of our study, obesity, central obesity and PCOS, either 
independently or jointly, are a significant factor of reduced fertility and infertility. Long-
term infertility (mean 4 years) in this population, where we excluded important potential 
causes such as age, tubal factor, infertile partner and severe endometriosis, has a 
greater potential of analyzing the effects of obesity and PCOS. In addition to these two 
main syndromes, the remaining possible causes of infertility in our sample are 
oligoovulation/anovulation, subfertile partner, mild endometriosis and idiopathic sterility. 
Proven or unproven hormonal disorders and likely insulin resistance associated with 
obesity and PCOS (50-90% of patients) should be linked with the negative effects on 
the oocyte and endometrium. We were not able to prove the positive or negative effect 
of obesity on the ovarian reserve. Therefore, with these mechanisms’ obesity does not 
alter the fertility of the investigated women. Since in this analysis obesity does not even 
alter the ovarian reserve of PCOS patients, it is useful to know that the risk for OHSS in 
these patients remains unchanged. This is also confirmed in our clinical practice. Some 
contrary findings have been reported in the literature about this risk (81,91,139). 
It is a consensus in world literature that obesity and PCOS alone, and especially 
when they are combined, significantly contribute to infertility and reproductive risks. The 
negative effects of these two syndromes result in low fecundity and reduced treatment 
success, especially in in vitro fertilization (IVF) procedures. Also, obesity and distribution 
of AT do not cause but may exacerbate the PCOS manifestations and phenotype. 
Women with PCOS have central obesity in 66 percent of the cases (70,75). Obese 
women are insulin resistant in 70 percent of the cases and more than 90 percent of 
obese PCOS patients have IR (31,78). Lean PCOS patients also develop IR in 30-50 
percent of the cases. There is thus a consensus that all obese PCOS women are in a 
state of hyperinsulinemia (70,74). An equally significant disorder for the reproductive 
axis is hyperandrogenemia or hyperandrogenism (HA). The effects of elevated 
androgens exist in 30-40% of obese patients and in 80% of women with PCOS 
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(28,60,61). According to findings in literature, the effects of obesity and PCOS on 
reproduction are shown in Table 48. (48,49,52,58,61,68) 
 
Table 48 Obesity, central obesity and PCOS effects on reproduction 
 
Fertility impairment Risks 
• Menstrual cycle irregularity 
• Anovulation 
• Low fecundity 
• ↑ Time to pregnancy 
• Infertility 
• Low oocyte quality 
• Gonadotropin resistance 
• ↑ Cycle cancellation 
• ↓ Ovulation rate 
• ↓ Endometrial receptivity 
• ↓ Implantation  
• Lower IVF success 
 
• Venous thromboembolism 
• Multiple pregnancies 
• OHSS 
• Spontaneous abortions (SAB) 
• Perinatal risks 
- gestational DM 
- hypertension 
- prematurity 
- mortality 
• Congenital abnormalities 
• Neonatal 
• Maternal (SC, bleeding) 
 
SC - Caesarean section; OHSS- ovarian hyperstimulation syndrome 
 
The negative effects of obesity and PCOS on reproduction have been recorded in all 
forms of conception–natural, ovulation stimulation, IVF/ICSI, oocyte donation 
(139,141,142,143). 
 In a meta-analysis of 13 studies with 2326 cycles, Mulders et al. a significantly 
more frequent cycle cancellation (OR 1.86: CI 1.13- 3.06), and a significant decrease of 
clinical pregnancy rate (CPR) and increase of SAB (OR 3.05: CI1.45-6.49) as a result of 
obesity and IR. Numerous studies have confirmed the reduction of CPR, live birth rate 
(LBR) and a significant increase of spontaneous abortions with obesity and PCOS 
(125). The highest rate of SAB has been shown by Tian et al. (122), who claim that IR is 
associated with a high risk of spontaneous abortion – OR 8.32 (CI 2.65-26.17), where 
the incidence of spontaneous abortions compared to control subjects is 47.8% vs. 9.5%. 
The risk for SAB is 2-3 times higher due to hyperandrogenism, elevated LH, IR and high 
PAI-1 (116,117). High T and AMH levels increase the risk for spontaneous abortion 
136
 
 
 
 
(103). Obesity decreases LBR by 30-60%, and success is significantly reduced with the 
progressive increase of BMI (126). With morbid obesity, IVF success is lower by 70% 
(116,117,118,132). Bellver and Provost (115,116) associate the reduction of LBR in 
obesity with reduced endometrial receptivity. In the same model of study conducted on 
obese donor recipients, Luke and Jungheim (132,136) did not find endometrial 
receptivity to be significant for IVF success. The highest rate of IVF success is achieved 
in lean PCOS patients with a larger number of available oocytes. It has been proven 
that these women have the highest OHSS risk (19.6%), while this risk is reduced with 
obesity to 3.2% (141,142,143). 
 Findings about the adverse effects of obesity on reproduction are not consistent 
and there is no consensus on the causes of reduced fertility. There is an ongoing 
debate about reduced count and quality of oocytes, fertilization rate, embryo quality and 
implantation disorders (139,142). There is a uniformly confirmed consensus on the 
effect of obesity and PCOS on the cycle, decreased fecundity, anovulation, and more 
frequent withdrawal from treatment (45,50,139). Obese patients are less sensitive to 
gonadotropins and it has been proven that 10-20% more drugs are needed to stimulate 
ovulation. Metabolic disorders in these patients appear to affect LBR and SAB. These 
are primarily IR, low grade of chronic inflammation and the consequences of high 
androgen levels. A crucial role is played by the molecular activity of hormones and 
sophisticated central and peripheral (paracrine) control of folliculogenesis. LH pulsatility 
or leptin disorders, which are frequent in obesity, may alone affect neurosecretion and 
folliculogenesis. A complex control of the density and function of the receptors is 
involved in the expression of hormonal activity. Also affecting fertility are a number of 
non-provable epigenetic effects and endocrine disruptors. 
 The silent effects of adipokines, vitamin D, oxysterol, oxidative stress and intra-
follicular signals can significantly disturb fertility without clear biosignal disturbances in 
the circulation. It is an undisputable fact that obesity increases the incidence of infertility 
three times, and obesity and PCOS together 10-15 times. Spontaneous abortions are 
more common, but they are euploid (123,130). 
 Obesity is associated with low responders, which are 70% more frequent in IVF 
(OR 1.70: CI 1.27-2.26) (132,139). 
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 Due to a low number of quality oocytes and embryos, the possibility of 
cryostorage is reduced to 10% (128). It is interesting that weight loss does not lead to a 
significant increase of LBR (135,138), but regular exercise increases LBR even without 
weight loss (139). Brewer and Balen have reported that infertility (OR 2.7) significantly 
increases with obesity, anovulatory infertility even more so (OR 3.1) (110). In 1721 first-
time procedures, Shah et al. (45) found that the treated patients were 20% overweight, 
18% obese and 5% morbidly obese. Success of CPR was 50% lower in obese women, 
but BMI had no influence on SAB. In PCOS and obesity, there is a high level of 
intrafollicular leptin, leading to local disorders in the communication with the oocyte (48). 
There is an opinion that obesity causes reproductive disorders only with insulin 
resistance (14,31,70). Hospitalization due to infertility is more frequent with obesity 
(40.9% vs. 4.6%) and IVF treatment is 3-5 times more frequent (77). Elevated high 
sensitivity CRP levels as a sign of silent inflammation with obesity have been proven to 
lead to decreased fecundity and higher SAB rates (134). Broughton warns that obese 
women are subfertile due to a reduction of LH amplitudes and lipotoxicity of FFA, and 
ectopic lipid accumulation. Chronic inflammation leads to diminished fertility and euploid 
spontaneous abortions (124). The embryo rapidly progresses to blastocyst, and 
trophoectoderm exhibits lower cellularity. There are incoherent findings on the effect of 
obesity on lower fertilization rates and the reduction of embryo quality (110,132). 
 In our study, a high prevalence of obesity and PCOS was determined in younger 
infertile patients. PCOS incidence was different in 3 BMI patient groups – 23.4%, 28.6% 
and in obese women 33.9%. Such prevalence was expected about known geo-
epidemiological data and exclusion criteria. About one-third of the patients in each BMI 
group had normal body weight. In 56 (30.8%) secondary infertile women there were 91 
pregnancies, of which 50 were SAB (59.9% of all pregnancies). Significantly more 
abortions were recorded in the overweight and obese population, which is consistent 
with the findings in the literature. In secondary infertile women obesity and PCOS 
prolonged time-to-pregnancy to 2 years. The minimum prolonged waiting time to 
previous pregnancy was 9.5 months for lean women. According to the criteria WC > 88 
cm and WHR > 0.85, central (abdominal) obesity was determined in 42% of PCOS 
patients and 28% of non PCOS patients. Obese women in these subgroups had 
visceral obesity in 76% and 63% of cases respectively. Central obesity was statistically 
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significantly more frequent in PCOS patients. Considering all parameters of central 
obesity (and WSR), its prevalence is 50% in women with a high BMI (≥ 30 kg/m2). 
Oligo/anovulation was determined in 30% of non-PCOS patients and 67% of PCOS 
patients, and as many as 86% of obese PCOS patients. 
 Increasing BMI leads to a significant increase of central obesity and anovulation 
rates. Cycles are often irregular, especially in PCOS patients. Weight gain prolongs the 
cycle by 2.6 days in normal patients and by 6 days in PCOS patient. PCOS patients on 
average have 9 days longer cycles than control patients. FSH levels are higher in 
patients without PCOS, while LH is significantly higher in women with PCOS. Weight 
gain increases hyperandrogenemia (increase in T) and androgenic activity due to a 
significant decrease in SHBG levels. T, SHBG and FAI levels are significantly different 
between PCOS and non-PCOS patients. Androgen activity is not dependent on BMI in 
PCOS patients. Ovarian reserve markers are normal in non-PCOS patients and high in 
PCOS women. The determined values of AMH, AFC, OV do not show intergroup 
differences. No negative effect of obesity on ovarian reserve was found. Obesity in our 
patients does not diminish or increase the ovarian reserve. This finding is important for 
the programming and individualizing of infertility treatments. Specifically, 60 to 80% of 
infertile patients should be treated with ovarian stimulation (with or without IVF). 
According to our findings, opinions that obesity protects women from OHSS, frequently 
encountered in literature, are incorrect and may mislead the clinician. Also, no 
relationship was established between obesity (BMI) and prevalence of POR. Therefore, 
the findings from this study population show that young women with high BMI can 
expect the same treatment results and the same risks. It can be assumed that the 
reasons for infertility in this population include obesity, HA, anovulation, and several 
previously described pathophysiological events associated with adipokine and insulin 
disorders. 
 We believe this research can have multiple benefits for clinicians and 
reproductive subspecialists. In analysing and treating infertility, a close association 
between obesity and reduced fertility should be considered. Our findings may contribute 
to clinical decision-making about the individualization of treatment and care for the 
safety of this vulnerable population. 
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7. CONCLUSIONS 
 
 In the investigated sample of infertile patients, 35% were normal-weight women 
and 65% were overweight and obese. Of that number, 28.6% exhibited clear results 
supporting polycystic ovary syndrome. The highest prevalence of abnormal BMI, 71%, 
was in the PCOS group. Only 5.5% of patients were morbidly obese (BMI > 40 kg/m2). 
 The participating women were of approximately the same age (32 years) and 
height, and based on the study design, they were assigned to 3 groups according to 
increasing BMI, i.e. weight. Primary or secondary infertility lasted on average for 4.2 
years. 
 Secondary infertility was found in 56 patients (30.8%), least frequently among 
normal-weight participants. Out of a total of 91 previous pregnancies, there were 41 
births and 50 early spontaneous abortions (54.9% of all pregnancies). Most SABs 
(88%) occurred in the overweight and obese populations, more than one half in PCOS 
women with an increased BMI. These results are consistent with some findings in the 
literature which link SAB to obesity and PCOS, but mainly to IR. Around 20% of 
overweight and obese women had previously given birth. 
 Around 80% of all participants had not previously intensively investigated 
infertility or received infertility treatments. This percentage reflects the perception and 
the attitude towards infertility in the investigated population. Passive behaviour in some 
participating women was justified because of secondary infertility. 
 According to all anthropometric studies, statistically significant differences of WC 
and HC were found among patients with different BMI characteristics. On average 
obese women had abnormal WC and HC measurements, with the highest values 
recorded in obese PCOS patients. Following the recommended criteria, central 
(visceral) obesity (WC > 88 cm, WHR> 0.85, WSR> 0.50) was diagnosed in 68% of 
non-PCOS women and 90% of obese PCOS patients. Abdominal obesity was a 
reliable surrogate marker for insulin resistance because there is uniform evidence of a 
high correlation between central obesity and IR. 
 In our study obese women also have menstrual cycle disorders. Menarche 
occurs early in obese patients (11.6 years), while in PCOS patients it was postponed 
until 13.9 years on average. Obese PCOS women have longer and heavier menstrual 
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bleeding (5.8 days vs. 4.3 days) than normal-weight patients in the same group. 
According to subjective impressions and anamnesis, heavy menstrual bleeding was 
reported by 23% of patients, most frequently by overweight and obese PCOS women. 
 Obesity alone prolongs the menstrual cycle by 2.6 days on average. When 
obesity is accompanied by PCOS, the duration of the cycle in most overweight patients 
is almost 40 days on average (statistically significantly the longest). Even in normal-
weight participants PCOS significantly prolongs the cycle. In overweight and obese 
PCOS women, oligomenorrhea dominates (mean cycle duration of 37.1 days) and 
more than 80% of participants in that group have a cycle > 35 days. Of all patients, 
42% of obese patients have a menstrual cycle with the duration ≥ 40 days. Anovulatory 
cycles were recorded in 85,7% obese PCOS patients, and 39% obese woman. 
 Obesity doubles the required time-to-pregnancy rate in patients with secondary 
infertility (19.9 vs. 9.5 months). It took obese PCOS patients 25.6 months to achieve 
their first pregnancy. In this small sample, the established subfecundity should be 
taken with caution because it can be confused with other causes of infertility (other 
than obesity and PCOS). 
 FSH levels are the highest (7.53 IU/L) in normal-weight patients from the control 
group (non-PCOS), while obese PCOS patients have slightly lower FSH levels 
(4.67 IU/L). LH is the highest in PCOS patients with a normal BMI (9.98 IU/L). Further, 
obesity slightly decreases gonadotropin levels.  In addition, FSH/LH inversion (LH > 2 
times) was found in normal-weight PCOS women. These findings are consistent with 
the established pathophysiological mechanisms through which obesity and PCOS 
affect the regulation of the ovarian function and folliculogenesis. The negative 
correlation of AMH with FSH and the positive correlation of AMH with LH should be 
borne in mind. In PCOS patients, prolactin levels were significantly higher than in the 
control group (20.4 ng/ml vs. 15.2 ng/ml), but they are still in the normal range. 
 Elevated basal FSH (> 10 IU/L) and E2 (> 70 pg/ml) as surrogate markers of a 
low ovarian reserve and DOR were found in 15% of non-PCOS patients. 
 In the control group (non-PCOS), it was established that AT produces more 
testosterone with weight gain (1.82 vs. 1.38 nmol/L). All PCOS patients, regardless of 
BMI, have statistically significantly higher T levels than non-PCOS patients 
(2.44 nmol/L vs. 1.66 nmol/L). Adipose tissue and obesity in PCOS patients 
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significantly reduce SHBG. Thus, significantly increased androgen activity was 
recorded in both study groups. HA is the fundamental characteristic of PCOS patients. 
FAI was used as a surrogate marker for free T. It was significantly higher and 
pathological in all PCOS patients, and it was the highest in the normal-weight group. 
 Increased androgen activity and HA in the participating patients are associated 
with a high incidence of oligoanovulation in the whole sample. Among causes of 
infertility in our study population, HA and insulin resistance are highlighted as the main 
disorders accompanying obesity and PCOS. 
 Biomarkers of ovarian reserve remain normal and unchanged with higher BMI in 
non-PCOS patients. AMH, AFC and ovarian volume are significantly higher in PCOS 
women. Positive or negative effects of BMI on ovarian reserve were not determined 
even in that study group. Since obesity does not lower AMH levels, a lower risk for 
OHSS cannot be expected, as claimed by some studies. Ovarian volume > 10 ml was 
found in 63% of PCOS patients. Anovulatory PCOS cycles are associated with the 
highest ovarian reserve (AMH 66.4 pmol/L) and the highest average BMI (32.4 kg/m2). 
 The characteristics of increasing obesity are accompanied by prolonged cycles, 
elevated androgen levels (probably IR as well) and anovulation. It seems that only 
morbid obesity slightly lowers OR markers. 
 The analysis of the prevalence of low ovarian reserve in non-PCOS patients, i.e. 
the effect of obesity alone, has identified a similar incidence of poor ovarian response 
(POR) in women with normal and abnormal body weight. The prevalence of POR (low 
AMH, AFC, OV) was similar (14.1% vs. 13.2%). An elevated basal estradiol as a 
possible sign of POR was found in 10.4% of participants, equally in lean and obese 
patients. 
 Obesity does not significantly affect ovarian reserve biomarkers, but it is 
undoubtedly associated with irregular cycles, anovulation and hyperandrogenism, 
especially if accompanied by PCOS, in which case a high incidence of insulin 
resistance should also be expected. 
 These findings contribute to an understanding of reproductive risks associated 
with obesity and PCOS. We believe that they will contribute to clinical decision-making 
about ovulation stimulation and IVF treatment and support an individualized approach 
to long-term infertile female patients suffering from these two syndromes. 
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 According to above findings the minimal workup for obese infertile patients could 
be: BMI, WC, serum concentration of FSH, T, AMH and US analysis of uterus and 
ovaries. With these basic findings we can get enough information’s needed for the 
personal approach. 
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8. SAŽETAK 
 
Debljina je najčešća kronična bolest. U zapadnom svijetu i ovim prostorima učestalost 
prekomjerne tjelesne težine i debljine je 50-60%. Paralelno s porastom debljine 
posljednjih 30 godina raste i učestalost neplodnosti. Debljina je često udružena s 
sindromom policističnih jajnika (engl. Polycystic ovary syndrome- PCOS), pa udružena 
patofiziologija može biti razlog za niz metaboličkih i reprodukcijskih poremećaja. 
Debljina je povezana sa subfertilitetom i infertilitetom u žena i muškaraca. Uz debljinu je 
produljen time-to-pregnancy, tri puta je viši rizik neplodnosti i povišen je rizik za rane 
spontane pobačaje. Sa navedenim reprodukcijskim poremećajima posebno se povezuje 
centralna (abdominalna) debljina. Te povezanosti se temelje na disbalansu hormona, 
adipokina, hiperandrogenizmu i inzulinskoj rezistenciji. Također se često opisuje 
negativni učinak debljine na ovarijsku rezervu. 
Cilj istraživanja: 
U ovom istraživanju željeli smo utvrditi učinke debljine i centralne debljine na ovarijsku 
rezervu. Također smo nastojali utvrditi povezanosti debljine s promjenama 
reprodukcijskih hormona koje mogu biti razlog za subfertilitet. Nastojali smo odvojeno 
istražiti utjecaje debljine i PCOS-a na reprodukcijski kapacitet. Markere ovarijske  
rezerve ( antimüllerov hormon AMH,antral follicularcount- AFC i volumen jajnika) istražili 
smo prema indeksu tjelesne mase (engl. body mass indeks- BMI) populacije na kojoj 
smo proveli istraživanje. Istražili smo kakav utjecaj imaju reprodukcijski hormoni i 
debljina na osobine menstrualnog ciklusa. Promjene ovarijske rezerve mogu bitno 
utjecati na odabir načina i uspjeha liječenja. 
Pacijentice i metode: 
U ovoj prospektnoj studiji na 182 žena grupiranih u 3 kategorije prema indeksu tjelesne 
mase (normalan, prekomjeran, debljina),a od toga je bilo 52 žene s PCOS. U tim BMI 
grupama bio je podjednak broj pacijentica- 64, 56, 62. Istražili smo i usporedili nalaze 
hormona i ovarijske rezerve u svakoj BMI grupi pacijentica. Također smo istražili utjecaj 
debljine i centralne debljine, te PCOS-a na karakteristike menstrualnog ciklusa i 
ovulacije. Istraživane pacijentice su bile primarno ili sekundarno neplodne prosječno 4 
godine, i prosječne dobi 32 godine. Iz studije su isključene pacijentice s uterinim 
anomalijama, tubarnom neplodnošću, teškom endometriozom i tumorima uterusa ili 
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jajnika, endokrinim bolestima ili azoospermijom partnera. U istraživanim skupinama 
odredili smo i usporedili biomarkere ovarijske rezerve- antimüllerov hormon (AMH) 
antral follicular count (AFC) i volumen jajnika (engl. ovarian volume - OV). Također smo 
usporedili nalaze hormona- folikulostimulirajući (FSH), luteinizirajući (LH), prolaktin 
(PRL) i androgena. 
Statistička analiza: 
Statističke analize koristile su paket SPSS 17.0., a nalazi su prikazani kao srednja 
vrijednost i standardna devijacija. Parametričke podatke smo usporedili student- 
ovim t testom /ANOVA, a neparametrijske KrusckalWallis- ovim testom. Vrijednost 
statističke značajnosti bila je na razini 5% (p ≤ 0.05). 
Rezultati:  
U istraživanom uzorku neplodnih pacijentica bilo je 35% normalnog BMI-a, a 65% žena 
bile su prekomjerne tjelesne težine ili debele (BMI ≥ 25 kg/m2). 
Od toga su 28,6% imale PCOS, a u toj grupi pacijentica prevalencija abnormalnog BMI-
a bila je 71%. Od sekundarno neplodnih pacijentica (56 žena-30,8%), ukupno smo 
zabilježili 91 trudnoću. Od toga je bilo 54,9% spontanih pobačaja. Većina pobačaja 
(88%) bila je u populacijama abnormalnog BMI-a. Centralnu debljinu utvrdili smo u 68% 
debelih ispitanica, i u  90% debelih PCOS pacijentica. Abdominalnu debljinu povezali 
smo s inzulinskom rezistencijom jer je takva udruženost opće prihvaćena. Centralna 
debljina je značajno češća u debelih non PCOS pacijentica (68,3% vs. 15%) nego onih 
nižeg BMI-a. 
U debelih žena ranije je nastupila menarha (11,6 godina), dok PCOS odgađa menarhu 
na 13,9 godina. Menstrualni ciklus produljuje debljina za 2,6 dana u prosjeku, a PCOS i 
debljina za više od 11 dana. Oligomenoreje (> 35 dana), iregularne cikluse, ili 
anovulacije imalo je više od 80% PCOS pacijentica i 40% pacijentica s debljinom. 
Debljina i PCOS razlozi su za subfertilitet uz produljenje vremena za postizanje 
trudnoće- time-to-pregnancy (TTP) za 10 do 15 mjeseci. U debelih PCOS pacijentica 
TTP je bio statistički značajno dulji od onog u non PCOS grupi (25,6 mj vs. 19,9 mj). 
Porastom BMI blago raste razina serumskog testosterona (1,82 vs. 1,38 nmol/L), koji je 
statistički značajno najviši u PCOS pacijentica (2,44 nmol/L vs. 1,66 nmol/L). 
Hiperandrogenizam je izražen u obje istraživane skupine pacijentica, značajno najviše u 
PCOS pacijentica (free androgen indeks – FAI 6,83 vs. 2,87). 
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U našem istraživanju utvrdili smo da debljina inhibira razinu cirkulacijskog sex hormone 
binding globulina (SHBG), a on je značajno najniži u PCOS pacijentica. To je dodatni 
doprinos androgenoj aktivnosti u obje skupine istraživanih žena, što pokazuju 
abnormalne, vrijednosti FAI. Razine FSH su niže u PCOS pacijentica (5,02 IU/L vs. 6,85 
IU/L),a LH je značajno viši u PCOS-u u odnosu na non PCOS pacijentice (8,27 IU/L vs. 
6,44 IU/L), Najizraženiju inverziju FSH/LH utvrdili smo u PCOS pacijentica normalne 
tjelesne težine. Serumski prolaktin (PRL) je viši u PCOS pacijentica (20,4 ng/ml vs. 
15,22 ng/ml), a u 11,5% tih pacijentica je imalo blago nenormalnu razinu PRL. 
 
Porastom debljine (BMI) u obje skupine istraživanih pacijentica nije zabilježena razlika u 
ovarijskoj rezervi unutar svake težinske skupine žena. Debljina ne snižava AMH, AFC i 
OV, dok PCOS statistički značajno povisuje ovarijsku rezervu (AMH 55,15 pmol/L vs. 
14,76 pmol/L). 
Antral follicular count i OV ne ovise o količini masnog tkiva i BMI-u pa se ne može ni 
očekivati da bi u ovoj populaciji debljina bila povezana s rezistencijom na gonadotropine 
u stimulaciji ovulacije. PCOS pacijentice imale su značajno viši AFC (24,3 vs. 9,02) i 
volumen jajnika (9,87 vs. 6,69 ml). Također nismo utvrdili povezanost povišenog BMI s 
niskom ovarijskom rezervom (engl. poor ovarian response/reserve- POR). Učestalost 
POR bila je podjednaka u sve 3 grupe ispitanica (8,1- 17,8%). 
Anovulacijski ciklusi u PCOS pacijentica bili su povezani s najvišom ovarijskom 
rezervom (AMH 66,4 pmol/L) i najvišim prosječnim BMI (32,4 kg/m2). Prevalencija poor 
ovarian reserve (POR) podjednaka je u pacijentica normalne tjelesne težine i debelih.. 
Zaključci: 
Porastom debljine i u PCOS pacijentica produljuje se menstrualni ciklus i značajno su 
češće oligomenoreje i anovulacije. Utvrđeno je da su ti poremećaji, kao i 
hiperandrogenizam najizraženiji uz centralnu debljinu. Kako je već ranije dokazana 
povezanost navedenih pokazatelja s inzulinskom rezistencijom.Na temelju naših 
rezultata možemo istaknuti visoku povezanost debljine, centralne debljine i PCOS-a sa 
subfertilitetom i dugotrajnim infertilitetom. Nismo utvrdili pozitivan ili negativan efekt 
suvišnih masnog tkiva na markere ovarijske rezerve. 
U ovom istraživanju našli smo visoku povezanost debljine i PCOS-a s produljenim TTP 
(19 do 25 mjeseci) i s trajanjem neplodnosti (primarne ili sekundarne) prosječno 4 
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godine. Iako su poznati učinci ta dva sindroma na plodnost, obrada i liječenje 
neplodnosti dakle kasni. Na subfertilitet istraživane populacije ukazuje i visoka 
učestalost ranih spontanih pobačaja u sekundarno neplodnih ispitanica (54,9% svih 
trudnoća). 
Za dijagnozu centralne debljine našli smo da su najpouzdanije mjere WC > 88 cm i 
WSR > 0,50. Na WHR je snažan utjecaj imala izraženost visokog hip circumference u 
našoj populaciji debelih pacijentica. Centralna debljina je snažno povezana s 
anovulacijama, hiperandrogenizmom (HA) i oligomenorejom. Te smo poremećaje 
shvatili kao glavne razloge za neplodnost, a ne udruženost debljine s poremećenom 
ovarijskom rezervom.  
Debljina minimalno, a PCOS snažno utječu na disbalans reprodukcijskih hormona 
(FSH, LH, E2, i povišenu androgenu aktivnost (testosteron, SHBG, FAI). Ispitanice s 
anovulacijama, HA i PCOS-om imale su značajno više pokazatelje ovarijske rezerve. 
Ovo istraživanje može unaprijediti postupke i obradu pacijentica koje su prekomjerne 
tjelesne težine ili debele. Minimum pretraga i racionalan pristup bio bi odrediti BMI, WC, 
testosteron, FSH i AMH, uz UZV analizu jajnika. 
Ovi nalazi doprinos su poimanju reprodukcijskih rizika uz debljinu i PCOS, a svakako 
mogu pomoći u kliničkom odlučivanju za opseg obrade i individualizirani načina liječenja 
dugotrajno neplodnih pacijentica 
 
Ključne riječi: Debljina, centralna debljina, sindrom policističnih jajnika, neplodnost, 
rezerva jajnika 
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9. SUMMARY- Abstract in English 
 
“Impact of obesity in vvariar reserve”,  Albert Lila,  2019 
Obesity is the most frequent chronic disease. In the Western world and in these areas 
the incidence of overweight and obesity is 50–60%. In parallel with an increase in 
obesity over the past 30 years, there is also an increase in infertility incidence. Obesity 
is often associated with PCOS and the combined pathophysiology can cause a variety 
of metabolic and reproductive disorders. Obesity is also associated with subfertility and 
infertility in men and women.. 
 
Aim of the study: 
The aim of this study was to identify the effects of obesity and central obesity on ovarian 
reserve. We also tried to identify the correlation of obesity with changes in reproductive 
hormones, which could be a cause of subfertility. We separately investigated the effects 
of obesity and PCOS on reproductive capacity. Ovarian reserve markers (AMH, AFC 
and ovarian volume) were investigated according to the body mass index of 
participating patients.  
 
Methodology and methods: 
In this prospective cross-sectional cohort study on 182 women grouped in 3 categories 
according to body mass index (normal weight, overweight and obese), 52 had PCOS. 
We determined and compared hormone and ovarian reserve results in each BMI patient 
group.  
Statistical analysis:  
Statistical analysis was performed by using the statistical package SPSS 17.0. Data is 
reported as mean ± standard deviation. Student’s t test/ANOVA was used to compare 
the means of parametric data and the Man-Whitney test / the Krusckal Wallis test to 
compare non-parametric data. The Chi square test were used to analyze categorical 
outcomes. For statistical significance the value of the factor alpha is ≤ 0.05. 
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Results: 
In the investigated sample of infertile patients, 35% were normal-weight women, and 
65% were overweight or obese. Of that number, 28.6% had PCOS, while the 
prevalence of abnormal BMI in that patient group was 71%. Central obesity was 
identified in 68% of obese patients and in 90% of obese PCOS patients.  
Prolongs of the menstrual cycle, oligomenorrheae, anovulation, hyperandrogenism are 
more presente in obesity and PCOS patients than in obese respectivly control group. 
Obesity does not lower AMH, AFC and OV levels. 
 
Conclusion 
Since the relationship between the indicators and insulin resistance has already been 
proven, our results emphasize a high correlation of obesity, central obesity and PCOS 
with subfertility and long-term infertility. Positive or negative effects of excessive 
adipose tissue on ovarian reserve markers were not identified. 
 
Key words: Obesity, central obesity, polycystic ovary syndrome (PCOS), infertility, 
ovarian reserve 
 
 
 
 
 
 
 
 
 
 
 
 
149
 
 
 
 
10. REFERENCES: 
 
1. Fritz MA i L. Speroff: Clinical Gynaecologic endocrinology and infertility, W. 
Kluwer, Philadelphia, 2011. 
2. World Health Organization, Obesity and overweight, October 2017. 
3. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled 
analysis of 1698 population-based measurement studies with 19·2 million participants. 
Lancet. 2016 Apr 2;387(10026):1377-1396.  
4. Hrvatskizavod za javnozdravstvo; Odjel za prehranu, 
tjelesnuaktivnostiprevencijudebljine; Debljina, November 2017. 
5. Gallus S1, Lugo A, Murisic B, Bosetti C, Boffetta P, et al., Overweight and 
obesity in 16 European countries. Eur J Nutr. 2015 Aug;54(5):679-89.  
6. Medically reviewed by Daniel Bubnis, MS, NASM-CPT, NASE Level II-CSS on 
April 26, 2017 — What Is the Waist-to-Hip Ratio? 
7. Yen and Jaffe's: Reproductive endocrinology, Saunders, Philadelphia, 2009. 
8. Šimunić V. et al. Ginekologija, Ljevak, Zagreb, 2002. 
9. Goh LG, Dhaliwal SS, Welborn TA, Lee AH, Della PR. Anthropometric 
measurements of general and central obesity and the prediction of cardiovascular 
disease risk in women: a cross-sectional study. BMJ Open. 2014 Feb 6;4(2). 
10. Koren D1, Marcus CL, Kim C, Gallagher PR, Schwab R et al., Anthropometric 
predictors of visceral adiposity in normal-weight and obese adolescents. Pediatr 
Diabetes. 2013 Dec;14(8):575-84. 
11. Camhi SM1, Bray GA, Bouchard C, Greenway FL, Johnson WD et al., The 
relationship of waist circumference and BMI to visceral, subcutaneous, and total body 
fat: sex and race differences. Obesity (Silver Spring). 2011 Feb;19(2):402-8.  
12. St-Onge MP1, Gallagher D. Body composition changes with aging: the cause or 
the result of alterations in metabolic rate and macronutrient oxidation? Nutrition. 2010 
Feb;26(2):152-5.  
13. Saely CH1, Geiger K, Drexel H. Brown versus white adipose tissue: a mini-
review. Gerontology. 2012;58(1):15-23.  
14. Practice Committee of the American Society for Reproductive Medicine. Obesity 
and reproduction: a committee opinion. FertilSteril. 2015 Nov;104(5):1116-26.  
150
 
 
 
 
15. Tang QQ, Lane MD. Adipogenesis: from stem cell to adipocyte. Annu Rev 
Biochem. 2012; 81:715-36. 
16. Cohen P1, Spiegelman BM2. Cell biology of fat storage. Mol Biol Cell. 2016 Aug 
15;27(16):2523-7.  
17. Karpe F1, Pinnick KE2. Biology of upper-body and lower-body adipose tissue--
link to whole-body phenotypes. Nat Rev Endocrinol. 2015 Feb;11(2):90-100.  
18. Cui XB1, Chen SY1. White adipose tissue browning and obesity. J Biomed Res. 
2016 Oct 17;31(1):1-2. doi: 10.7555/JBR.31.20160101. 
19. Lapid K#1, Lim A#1, Clegg DJ2, Zeve D1, Graff JM1,3. Oestrogen signalling in 
white adipose progenitor cells inhibits differentiation into brown adipose and smooth 
muscle cells. Nat Commun. 2014 Oct 21; 5:5196.  
20. Frayn KN1, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integrative 
physiology of human adipose tissue. Int J ObesRelatMetabDisord. 2003 
Aug;27(8):875-88. 
21. Saito M1. Brown adipose tissue as a regulator of energy expenditure and body 
fat in humans. Diabetes Metab J. 2013 Feb;37(1):22-9.  
22. Cao L1, Choi EY, Liu X, Martin A, Wang C, et al., White to brown fat phenotypic 
switch induced by genetic and environmental activation of a hypothalamic-adipocyte 
axis. Cell Metab. 2011 Sep 7;14(3):324-38.  
23. Adipose Tissue. Not Just Fat. Introduction to Adipose tissue. Medical 
Biochemistry, December 2017. 
24. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white 
adipose tissue. Br J Nutr. 2004 Sep;92(3):347-55.  
25. Ibrahim MM1. Subcutaneous and visceral adipose tissue: structural and 
functional differences. Obes Rev. 2010 Jan;11(1):11-8.  
26. Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E et al., Obesity 
Pathogenesis: An Endocrine Society Scientific Statement. Endocr Rev. 2017 Aug 
1;38(4):267-296. 
27. Lass A1, Zimmermann R, Oberer M, Zechner R. Lipolysis - a highly regulated 
multi-enzyme complex mediates the catabolism of cellular fat stores. Prog Lipid Res. 
2011 Jan;50(1):14-27.  
151
 
 
 
 
28. Pasquali R. Obesity and androgens: facts and perspectives. FertilSteril. 2006 
May;85(5):1319-40. 
29. Leeners B1,2, Geary N3, Tobler PN2,4, Asarian L2,5. Ovarian hormones and 
obesity. Hum Reprod Update. 2017 May 1;23(3):300-321.  
30. Tersigni C1, Di Nicuolo F, D'Ippolito S, Veglia M, et al., Adipokines: new 
emerging roles in fertility and reproduction. ObstetGynecolSurv. 2011 Jan;66(1):47-63.  
31. Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying 
obesity? CurrOpin Endocrinol Diabetes Obes. 2012 Apr;19(2):81-7. 
32. Halawaty S1, ElKattan E, Azab H, ElGhamry N, Al-Inany H. Effect of obesity on 
parameters of ovarian reserve in premenopausal women. J ObstetGynaecol Can. 2010 
Jul;32(7):687-90. 
33. Lee EB, Mattson MP. The neuropathology of obesity: insights from human 
disease. Acta Neuropathol. 2014 Jan;127(1):3-28.  
34. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous 
system control of food intake. Nature. 2000 Apr 6;404(6778):661-71.  
35. Donato J Jr, Cravo RM, Frazão R, Elias CF. Hypothalamic sites of leptin action 
linking metabolism and reproduction. Neuroendocrinology. 2011;93(1):9-18.  
36. Chen X, Mo Y, Li L, Chen Y, Li Y et al., Increased plasma metastin levels in 
adolescent women with polycystic ovary syndrome. Eur J ObstetGynecolReprod Biol. 
2010 Mar;149(1):72-6. 
37. Comninos AN1, Jayasena CN, Dhillo WS. The relationship between gut and 
adipose hormones, and reproduction. Hum Reprod Update. 2014 Mar-Apr;20(2):153-
74 
38. Quennell JH1, Howell CS, Roa J, Augustine RA, Grattan DR, Anderson Leptin 
deficiency and diet-induced obesity reduce hypothalamic kisspeptin expression in 
mice. Endocrinology. 2011 Apr;152(4):1541-50. 
39. Tolson KP, Garcia C, Yen S, Simonds S, Stefanidis A et al., Impaired kisspeptin 
signaling decreases metabolism and promotes glucose intolerance and obesity. J Clin 
Invest. 2014 Jul;124(7):3075-9.  
40. Šimunić V. et al. Reprodukcijskaendokrinologija; Neplodnost- IVF, Školskaknjiga, 
Zagreb, 2012. 
152
 
 
 
 
41. Li MD. Leptin and beyond: an odyssey to the central control of body weight. Yale 
J Biol Med. 2011 Mar;84(1):1-7.  
42. Wei Y1, Schatten H2, Sun QY3. Environmental epigenetic inheritance through 
gametes and implications for human reproduction. Hum Reprod Update. 2015 Mar-
Apr;21(2):194-208.  
43. Lefebvre T, Dumont A, Pigny P, Dewailly D. Effect of obesity and its related 
metabolic factors on serum anti-Müllerian hormone concentrations in women with and 
without polycystic ovaries. Reprod Biomed Online. 2017 Sep;35(3):325-330.  
44. Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD et al., Why visceral fat is 
bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring). 2006 Feb;14 
Suppl 1:16S-19S. 
45. Lash MM, Armstrong A. Impact of obesity on women's health. FertilSteril. 2009 
May;91(5):1712-6. 
46. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 
2006 Dec 14;444(7121):881-7.  
47. Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC, Goulis DG. The complex 
interaction between obesity, metabolic syndrome and reproductive axis: a narrative 
review. Metabolism. 2013 Apr;62(4):457-78.  
48. Elia EM1, Bazzano MV1, Quintana R2 and Paz DA1,3. Reproductive disorders in 
obesity. Integrative Obesity Diabetes, 2015. 
49. Norman JE. The adverse effects of obesity on reproduction. Reproduction. 2010 
Sep;140(3):343-5. 
50. Ramlau-Hansen CH, Thulstrup AM, Nohr EA, Bonde JP, Sørensen TI et al., 
Subfecundity in overweight and obese couples. Hum Reprod. 2007 Jun;22(6):1634-7.  
51. Ly C1, Yockell-Lelièvre J2, Ferraro ZM3, Arnason JT4, Ferrier J5, Gruslin A6. 
The effects of dietary polyphenols on reproductive health and early development. Hum 
Reprod Update. 2015 Mar-Apr;21(2):228-48. doi: 10.1093/humupd/dmu058. Epub 
2014 Nov 5. 
52. Crujeiras AB1, Casanueva FF2. Obesity and the reproductive system disorders: 
epigenetics as a potential bridge. Hum Reprod Update. 2015 Mar-Apr;21(2):249-61.  
53. Aiken CE, Ozanne SE. Transgenerational developmental programming. Hum 
Reprod Update. 2014 Jan-Feb;20(1):63-75.  
153
 
 
 
 
54. Ohlstein JF1, Strong AL1, McLachlan JA1, Gimble JM1, Burow ME1, Bunnell 
BA2. Bisphenol A enhances adipogenic differentiation of human adipose stromal/stem 
cells. J Mol Endocrinol. 2014 Dec;53(3):345 
55. Escobar-Morreale HF, Santacruz E, Luque-Ramírez M, BotellaCarretero JI. 
Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and 
women and its resolution after bariatric surgery: a systematic review and meta-
analysis. Hum Reprod Update. 2017 Jul 1;23(4):390-408.  
56. Malhotra N1, Bahadur A, Singh N, Kalaivani M, Mittal S. Does obesity 
compromise ovarian reserve markers? A clinician's perspective. Arch Gynecol Obstet. 
2013 Jan;287(1):161-6. 
57. Šimunić V. PCOS Sindrom policističnih jajnika. Fotosoft, 2006. 
58. Joham AE, Palomba S, Hart R. Polycystic Ovary Syndrome, Obesity, and 
Pregnancy. SeminReprod Med. 2016 Mar;34(2):93-101. doi: 10.1055/s-0035-1571195. 
Epub 2016 Feb 8. Review. 
59. McCartney ChR, Marshall JC. Polycystic Ovary Syndrome. N Engl J Med. 2016 
Oct 6;375(14):1398-1399. 
60. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J et al., Definition and 
significance of polycystic ovarian morphology: a task force report from the Androgen 
Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014 May-
Jun;20(3):334-52.  
61. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005 Mar 
24;352(12):1223-36. 
62. Escobar-Morreale HF1, Carmina E, Dewailly D, Gambineri A, Kelestimur F, et al., 
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the 
Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012 
Mar-Apr;18(2):146-70.  
63. Ezeh U1, Yildiz BO, Azziz R. Referral bias in defining the phenotype and 
prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab. 2013 
Jun;98(6): E1088-96.  
64. Filippou P1, Homburg R. Is foetal hyperexposure to androgens a cause of 
PCOS? Hum Reprod Update. 2017 Jul 1;23(4):421-432.  
154
 
 
 
 
65. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary 
syndrome. Hum Reprod Update. 2008 Jul-Aug;14(4):367-78.  
66. Homburg R, Crawford G. The role of AMH in anovulation associated with PCOS: 
a hypothesis. Hum Reprod. 2014 Jun;29(6):1117-21.  
67. Indran IR, Huang Z, Khin LW, Chan JKY, Viardot-Foucault V et al., Simplified 4-
item criteria for polycystic ovary syndrome: A bridge too far? Clin Endocrinol (Oxf). 
2018 May 30 
68. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH et al., Endocrine 
Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society 
clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec;98(12):4565-92.  
69. Merkin SS1, Phy JL2, Sites CK3, Yang D4. Environmental determinants of 
polycystic ovary syndrome. FertilSteril. 2016 Jul;106(1):16-24. 
70. Diamanti-Kandarakis E1. Role of obesity and adiposity in polycystic ovary 
syndrome. Int J Obes (Lond). 2007 Nov;31 Suppl 2: S8-13; discussion S31-2. 
71. Barber TM1, Golding SJ, Alvey C, Wass JA, Karpe F et al., Global adiposity 
rather than abnormal regional fat distribution characterizes women with polycystic 
ovary syndrome. J Clin Endocrinol Metab. 2008 Mar;93(3):999-1004.  
72. Escobar-Morreale HF, San Millán JL. Abdominal adiposity and the polycystic 
ovary syndrome. Trends Endocrinol Metab. 2007 Sep;18(7):266-72.  
73. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic 
ovary syndrome. J Clin Endocrinol Metab. 2008 Jan;93(1):162-8.  
74. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P et al., Abdominal 
fat quantity and distribution in women with polycystic ovary syndrome and extent of its 
relation to insulin resistance. J Clin Endocrinol Metab. 2007 Jul;92(7):2500-5.  
75. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central 
obesity in women with polycystic ovary syndrome: a systematic review and meta-
analysis. Hum Reprod Update. 2012 Nov-Dec;18(6):618-37.  
76. Lujan ME1, Jarrett BY, Brooks ED, Reines JK, Peppin AK et al., Updated 
ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated 
follicle population and ovarian volume. Hum Reprod. 2013 May;28(5):1361-8. 
77. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. 
Lancet. 2007 Aug 25;370(9588):685-97.  
155
 
 
 
 
78. Palomba S, Santagni S, Falbo A, La Sala GB Complications and challenges 
associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 
2015 Jul 31; 7:745-63.  
79. Pasquali R1. Contemporary approaches to the management of polycystic ovary 
syndrome. Ther Adv Endocrinol Metab. 2018 Apr;9(4):123-134.  
80. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH et al., Consensus on 
women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam 
SHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. FertilSteril. 2012 
Jan;97(1):28-38. e25.   
81. Practice Committee of the American Society for Reproductive Medicine. Testing 
and interpreting measures of ovarian reserve: a committee opinion. FertilSteril. 2015 
Mar;103(3): e9-e17.  
82. Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE et al., Serum 
antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic 
ovaries and the polycystic ovarian syndrome (PCOS). FertilSteril. 2010 
Aug;94(3):1118-21.  
83. Skałba P, Cygal A, Madej P, Dąbkowska-Huć A, Sikora J et al., Is the plasma 
anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and 
hormonal disturbances in women with and without polycystic ovary syndrome? Eur J 
ObstetGynecolReprod Biol. 2011 Oct;158(2):254-9.  
84. Ahmad AK1, Kao CN2, Quinn M2, Lenhart N2, Rosen M2, et al., Differential rate 
in decline in ovarian reserve markers in women with polycystic ovary syndrome 
compared with control subjects: results of a longitudinal study. FertilSteril. 2018 
Mar;109(3):526-531. 
85. Alebić MŠ, Stojanović N, Duhamel A, Dewailly D. The phenotypic diversity in per-
follicle anti-Müllerian hormone production in polycystic ovary syndrome. 4Hum Reprod. 
2015 Aug;30(8):1927-33. 
86. Bhide P, Dilgil M, Gudi A, Shah A, Akwaa C et al., Each small antral follicle in 
ovaries of women with polycystic ovary syndrome produces more antimüllerian 
hormone than its counterpart in a normal ovary: an observational cross-sectional study. 
FertilSteril. 2015 Feb;103(2):537-41. 
156
 
 
 
 
87. Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary 
syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. 
FertilSteril. 2008 May;89(5):1039-48. 
88. Brodin T1, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Antimüllerian 
hormone levels are strongly associated with live-birth rates after assisted reproduction. 
J Clin Endocrinol Metab. 2013 Mar;98(3):1107-14. 
89. Carmina E, Campagna AM, Fruzzetti F, Lobo RA. Amh measurement versus 
ovarian ultrasound in the diagnosis of polycystic ovary syndrome in different 
phenotypes. EndocrPract. 2016 Mar;22(3):287-93. 
90. de Ziegler D1, Pirtea P1, Fanchin R1, Ayoubi JM1. Ovarian reserve in polycystic 
ovary syndrome: more, but for how long? FertilSteril. 2018 Mar;109(3):448-449. 
91. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N et al., The 
physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod 
Update. 2014 May-Jun;20(3):370-85. 
92. Pellatt L1, Rice S, Mason HD. Anti-Müllerian hormone and polycystic ovary 
syndrome: a mountain too high? Reproduction. 2010 May;139(5):825-33. 
93. Pellatt L1, Rice S, Dilaver N, Heshri A, Galea R et al., Mason HD Anti-Müllerian 
hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa 
cells. FertilSteril. 2011 Nov;96(5):1246-51. 
94. Smith U, Kahn BB. Adipose tissue regulates insulin sensitivity: role of 
adipogenesis, de novo lipogenesis and novel lipids. J Intern Med. 2016 
Nov;280(5):465-475. 
95. Piouka A1, Farmakiotis D, Katsikis I, Macut D, Gerou S et al., Anti-Mullerian 
hormone levels reflect severity of PCOS but are negatively influenced by obesity: 
relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 
2009 Feb;296(2): E238-43.  
96. Lefebvre T, Dumont A, Pigny P, Dewailly D. Effect of obesity and its related 
metabolic factors on serum anti-Müllerian hormone concentrations in women with and 
without polycystic ovaries. Reprod Biomed Online. 2017 Sep;35(3):325-330.  
97. Kriseman M1, Mills C2, Kovanci E2, Sangi-Haghpeykar H2, Gibbons W2. 
Antimullerian hormone levels are inversely associated with body mass index (BMI) in 
157
 
 
 
 
women with polycystic ovary syndrome. J Assist Reprod Genet. 2015 Sep;32(9):1313-
6.  
98. La Marca A, Spada E, Grisendi V, Argento C, Papaleo E et al., Normal serum 
anti-Müllerian hormone levels in the general female population and the relationship 
with reproductive history. Eur J ObstetGynecolReprod Biol. 2012 Aug;163(2):180-4. 
99. Merhi Z1, Buyuk E, Berger DS, Zapantis A, Israel DD et al., Leptin suppresses 
anti-Mullerian hormone gene expression through the JAK2/STAT3 pathway in 
luteinized granulosa cells of women undergoing IVF. Hum Reprod. 2013 
Jun;28(6):1661-9. 
100. Garg D1, Tal R2. The role of AMH in the pathophysiology of polycystic ovarian 
syndrome. Reprod Biomed Online. 2016 Jul;33(1):15-28.  
101. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS et al., American 
Association of Clinical Endocrinologists (AACE); American College of Endocrinology 
(ACE); Androgen Excess and PCOS Society (AES). American association of clinical 
endocrinologists, american college of endocrinology, and androgen excess and pcos 
society disease state clinical review: guide to the best practices in the evaluation and 
treatment of polycystic ovary syndrome--part 1. EndocrPract. 2015 Nov;21(11):1291-
300.  
102. Sigala J1, Sifer C2, Dewailly D3, Robin G3, Bruyneel A3 et al., Is polycystic 
ovarian morphology related to a poor oocyte quality after controlled ovarian 
hyperstimulation for intracytoplasmic sperm injection? Results from a prospective, 
comparative study. FertilSteril. 2015 Jan;103(1):112-8.  
103. Sjaarda LA1, Mumford SL2, Kuhr DL2, Holland TL2, Silver RM3 et al., 
Association of testosterone and antimüllerian hormone with time to pregnancy and 
pregnancy loss in fecund women attempting pregnancy. FertilSteril. 2018 
Mar;109(3):540-548. 
104. Carmina E, Chu MC, Moran C, Tortoriello D, Vardhana P et al., Subcutaneous 
and omental fat expression of adiponectin and leptin in women with polycystic ovary 
syndrome. FertilSteril. 2008 Mar;89(3):642-8.  
105. McKinnon CJ, Hatch EE, Rothman KJ, Mikkelsen EM, Wesselink AK et al., Body 
mass index, physical activity and fecundability in a North American preconception 
cohort study. FertilSteril. 2016 Aug;106(2):451-9.  
158
 
 
 
 
106. Meldrum DR. Introduction: Obesity and reproduction. FertilSteril. 2017 
Apr;107(4):831-832.  
107. Hudecova M, Holte J, Olovsson M, SundströmPoromaa I. Long-term follow-up of 
patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. 
Hum Reprod. 2009 May;24(5):1176-83. 
108. Kalra SK1, Ratcliffe SJ, Dokras A. Is the fertile window extended in women with 
polycystic ovary syndrome? Utilizing the Society for Assisted Reproductive Technology 
registry to assess the impact of reproductive aging on live-birth rate. FertilSteril. 2013 
Jul;100(1):208-13.  
109. Broughton DE, Moley KH. Obesity and female infertility: potential mediators of 
obesity's impact. FertilSteril. 2017 Apr;107(4):840-847.  
110. Brewer CJ1, Balen AH. The adverse effects of obesity on conception and 
implantation. Reproduction. 2010 Sep;140(3):347-64.  
111. Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in 
spontaneous conception: a systematic review. SeminReprod Med. 2011 
Nov;29(6):507-13.  
112. Brodin T1, Bergh T, Berglund L, Hadziosmanovic N, Holte J. Menstrual cycle 
length is an age-independent marker of female fertility: results from 6271 treatment 
cycles of in vitro fertilization. FertilSteril. 2008 Nov;90(5):1656-61.  
113. Cela V, Obino MER, Alberga Y, Pinelli S, Sergiampietri C et al., Ovarian 
response to controlled ovarian stimulation in women with different polycystic ovary 
syndrome phenotypes. Gynecol Endocrinol. 2018 Jun;34(6):518-523.  
114. Holte J1, Brodin T, Berglund L, Hadziosmanovic N, Olovsson M et al., Antral 
follicle counts are strongly associated with live-birth rates after assisted reproduction, 
with superior treatment outcome in women with polycystic ovaries. FertilSteril. 2011 
Sep;96(3):594-9.  
115. Bellver J, Melo MA, Bosch E, Serra V, Remohí J et al., Obesity and poor 
reproductive outcome: the potential role of the endometrium. FertilSteril. 2007 
Aug;88(2):446-51.  
116. Provost MP, Acharya KS, Acharya CR, Yeh JS, Steward RG et al., Pregnancy 
outcomes decline with increasing recipient body mass index: an analysis of 22,317 
fresh donor/recipient cycles from the 2008-2010 Society for Assisted Reproductive 
159
 
 
 
 
Technology Clinic Outcome Reporting System registry. FertilSteril. 2016 
Feb;105(2):364-8.  
117. Metwally M, Ong KJ, Ledger WL, Li TC Does high body mass index increase the 
risk of miscarriage after spontaneous and assisted conception? A meta-analysis of the 
evidence. FertilSteril. 2008 Sep;90(3):714-26.  
118. Bellver J1, Pellicer A, García-Velasco JA, Ballesteros A, Remohí J et al., Obesity 
reduces uterine receptivity: clinical experience from 9,587 first cycles of ovum donation 
with normal weight donors. FertilSteril. 2013 Oct;100(4):1050-8. 
119. José Bellver, M.D. Obesity and poor reproductive outcome: female and male 
body weight matter FertilSteril. May 2013Volume 99, Issue 6, Pages 1558–1559 
120. Rittenberg V, Seshadri S, Sunkara SK, Sobaleva S, Oteng-Ntim E et al., Effect of 
body mass index on IVF treatment outcome: an updated systematic review and meta-
analysis. Reprod Biomed Online. 2011 Oct;23(4):421-39.  
121. Tal R1, Tal O2, Seifer BJ3, Seifer DB4 Antimüllerian hormone as predictor of 
implantation and clinical pregnancy after assisted conception: a systematic review and 
meta-analysis. FertilSteril. 2015 Jan;103(1):119-30. 
122. Tian L1, Shen H, Lu Q, Norman RJ, Wang J Insulin resistance increases the risk 
of spontaneous abortion after assisted reproduction technology treatment. J Clin 
Endocrinol Metab. 2007 Apr;92(4):1430-3.  
123. Goldman KN, Hodes-Wertz B, McCulloh DH, Flom JD, Grifo JA. Association of 
body mass index with embryonic aneuploidy. FertilSteril. 2015 Mar;103(3):744-8. doi: 
10.1016/j.fertnstert.2014.11.029.  
124. Broughton DE, Moley KH. Obesity and female infertility: potential mediators of 
obesity's impact. FertilSteril. 2017 Apr;107(4):840-847. 
125. Mulders AG, Laven JS, Eijkemans MJ, Hughes EG, Fauser BC 
Patient predictors for outcome of gonadotrophin ovulation induction in women with 
normogonadotrophic anovulatory infertility: a meta-analysis.HumReprod Update. 2003 
Sep-Oct;9(5):429-49. 
126. Moragianni VA, Jones SM, Ryley DA. The effect of body mass index on the 
outcomes of first assisted reproductive technology cycles. FertilSteril. 2012 
Jul;98(1):102-8. 
160
 
 
 
 
127. Norman RJ, Chura LR, Robker RL. Effects of obesity on assisted reproductive 
technology outcomes. FertilSteril. 2008 Jun;89(6):1611-2.  
128. Bellver J, Ayllón Y, Ferrando M, Melo M, Goyri E et al., Female obesity impairs in 
vitro fertilization outcome without affecting embryo quality. FertilSteril. 2010 
Feb;93(2):447-54.  
129. Kaye L, Sueldo C, Engmann L, Nulsen J, Benadiva C. Survey assessing obesity 
policies for assisted reproductive technology in the United States. FertilSteril. 2016 
Mar;105(3):703-706. 
130. Wang JX, Warnes GW, Davies MJ, Norman RJ. Overweight infertile patients 
have a higher fecundity than normal-weight women undergoing controlled ovarian 
hyperstimulation with intrauterine insemination. FertilSteril. 2004 Jun;81(6):1710-2. 
131. Onalan R, Onalan G, Tonguc E, Ozdener T, Dogan M, et al., Body mass index is 
an independent risk factor for the development of endometrial polyps in patients 
undergoing in vitro fertilization. FertilSteril. 2009 Apr;91(4):1056-60.  
132. Luke B1, Brown MB, Stern JE, Missmer SA, Fujimoto VY et al., Female obesity 
adversely affects assisted reproductive technology (ART) pregnancy and live birth 
rates. Hum Reprod. 2011 Jan;26(1):245-52. 
133. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in 
women with polycystic ovary syndrome. BJOG. 2006 Oct;113(10):1148-59.  
134. Bailey AP1, Hawkins LK2, Missmer SA3, Correia KF4, Yanushpolsky EH2.Effect 
of body mass index on in vitro fertilization outcomes in women with polycystic ovary 
syndrome. Am J Obstet Gynecol. 2014 Aug;211(2): 163.e1-6.  
135. Legro RS. Effects of obesity treatment on female reproduction: results do not 
match expectations. FertilSteril. 2017 Apr;107(4):860-867. 
136. Jungheim ES1, Lanzendorf SE, Odem RR, Moley KH, Chang AS et al., Morbid 
obesity is associated with lower clinical pregnancy rates after in vitro fertilization in 
women with polycystic ovary syndrome. FertilSteril. 2009 Jul;92(1):256-61. 
137. Enrico Carmina, M.D., Salvo Bucchieri, M.D., Pasquale Mansueto, M.D., 
GiovamBattistaRini, M.D., Michel Ferin, M.D. et al., Circulating levels of adipose 
products and differences in fat distribution in the ovulatory and anovulatory phenotypes 
of polycystic ovary syndrome. Fertility Sterilty April 2009Volume 91, Issue 4, 
Supplement, Pages 1332–1335. 
161
 
 
 
 
138. Einarsson S, Bergh C, Friberg B, Pinborg A, Klajnbard A et al., Weight reduction 
intervention for obese infertile women prior to IVF: a randomized controlled trial. Hum 
Reprod. 2017 Aug 1;32(8):1621-1630.  
139. Palomba, Stefano Infertility in Women with Polycystic Ovary Syndrome, 
Springer 2018. 
140. Macut, D, Pfeifer, M, Yildiz, BO, Diamanti-Kandarakis, E Polycystic Ovary 
Syndrome, Karger, 2013. 
141. Dumesic DA1, Oberfield SE1, Stener-Victorin E1, Marshall JC1, Laven JS1 et al.,  
Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and 
Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015 Oct;36(5):487-
525.  
142. Lila A, Šimunić V, Kasum M Importance of obesity in women with polycystic 
ovary disease, Acta ClinCro, 57, 2018. In press 
143. Silvestris E, de Pergola G, Rosania R, Loverro GObesity as disruptor of 
the female fertility.ReprodBiol Endocrinol. 2018 Mar 9;16(1):16:22-35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
162
 
 
 
 
11. CURRICULUM VITAE 
 
 
 
Albert  Lila born on July  22, 1967 in Gjakova Kosovo, where he completed 
primary school and gymnasium. 
 
Education and professional training (graduation year): 
MD: School of Medicine, University of Prishtina, 1993 
Specialization in Gynecology and Obstetrics: Kosovo University Clinical Centre (KUCC), 
2004 
 
Postgraduate Training: 
CME postgraduate course on Gynecology and Obstetrics, Infertility in Salzburg, Austria, 
2010 
 
Publications: 12 papers in peer reviewed journals, including International Journal of 
Gynecology, FIGO, Gynecology Endocrinology, Acta medica-BIH, Acta Clinica Croatica 
and 1 original paper in Acta Clinica Croatica 
 
Author and co-author of comparative study of humane reproduction in Kosovo, Perinatal 
situation by years in Kosovo and manual for screening of best and cervical cancer. 
Oral Presenations and poster presentation in national conferecnes and congresses, 
also in Europian-EBCOG  and FIGO congress in 2009, 2012, 2015.   
 
Languages: Albanian, English and Croatian. 
 
More than 20 years working in Kosovo Occupational Health Institute as Chief of 
Gynecology Cabinet and leacturer at Faculty of Midwife and Nursing –University Fehmi 
Agani in Gjakova. 
Married and have two sons. 
 
 
163
 
 
 
 
 
164
